2(125)PROTOCOL SYNOPSIS
A Multicentre, Randomised, Double -blind, Placebo -controlled, Phase 3 
Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in 
Adult Subjects with Active Systemic Lupus Erythematosus
International Coordinating Investigator
Study site(s) and number of subjects planned
Approximately  450 subjects are planned at approximately  173 sites.
Study period Phase of development
Estimated date of first subject enrolled Q2 2015 3
Estimated date of last subject completed Q2 2018
Study design
This is a Phase 3, multicentre, multinational, randomised, double -blind, placebo -controlled 
study  to evaluate the efficacy  and safety  of an intravenous treatment regimen of anifrolumab 
(150 mg or 300 mg) versus placebo in subjects with moderatel y to severely active, 
autoantibody -positive systemic lupus ery thematosus (SL E) while receiving standard of care 
(SOC) treatment. The study  will be performed in adult subjects aged 18 to 70 y ears of age.
Approximately  450 subjects receiving SOC treatment will be randomised in a 1:2:2 ratio to 
receiv e a fixed intravenous dose of 150 mg anifrolumab, 300 mg anifrolumab, or placebo 
every  4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary  endpoint 
evaluated at the Week 52 visit. I nvestigational product will be administered as an i ntravenous 
(IV)
infusion via an infusion pump over a minimum of 30 minutes, Q4W. Subjects must be
taking either 1 or an y combination of the following: oral corticosteroids (OCS), antimalarial,
and/or immunosuppressants.
Randomisation will be stratified usi ng the following factors: SLE Disease Activity  Index 2000 
(SLEDAI -2K) score at screening (<10 points versus ≥10 points); Week 0 (Day  1) OCS dose 

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
3(125)(<10 mg/day versus 
≥10mg/day  prednisone or equivalent); and results of a ty pe 1 interferon 
(IFN) test (high ve rsus low).
This study  includes:
 A Screening Period : Up to 30 day s
 Treatment Period : A 52- week double -blind treatment period with investigational
product administration Q4W from Week 0 to Week 48 for a total of 13 doses
 At Week 52 , subjects will have 2 options:
If eligible, enrol into the long -term extension (L TE) study
OR
Continue in the current study  for another 8 weeks to complete a 12- week safety
follow -up after the last dose of investigational product (last dose of
investigational product will be g iven in Week 48)
Objectives
Primary Objective: Outcome Measures:
To evaluate the effect of anifrolumab 300 mg 
compared to placebo on disease activity as 
measured by the difference in the proportion of 
subjects who achieve an SLE Responder Index 
of ≥4 (SRI[4]) at Week 52Composite endpoint SRI(4), defined by the following 
criteria:
-Reduction from baseline of ≥4 points in the
SLEDAI -2K and
-No new organ system affected as defined by 1 or
more British Isles Lupus Assessment Group
(BILAG) -2004 A or 2 or mor e BILAG -2004 B
items compared to baseline using BILAG -2004
and
-No worsening from baseline in subjects’ lupus
disease activity defined by an increase
≥0.30 points on a 3- point Physician’s Global
Assessment (PGA) visual analogue scale (VAS)
and
-No discontinuation of investigational product or
use of restricted medications beyond the
protocol- allowed thresholdabefore assessment
Key Secondary Objectives: Outcome Measures:
To evaluate the effect of anifrolumab 300 mg compared to placebo on:
The proportion of subjects with SRI(4) at 
Week 52 in the IFN test -high sub- groupSRI(4) (see outcome measure for primary objective)
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
4(125)The proportion of subjects who achieve an 
OCS dose ≤7.5 mg/day at Week 40, which is 
maintained through Week 52 in the sub -group 
of subject s with baseline OCS 
≥10mg/dayMaintained OCS reduction defined by the following 
criteria: 
-Achieve an OCS dose of ≤7.5 mg/day
prednisone or equivalent by Week 40 and
-Maintain an OCS dose ≤7.5 mg/day prednisone
or equivalent from Week 40 to Week 52 and
-No discontinuation of investigational product or
use of restricted medications beyond the
protocol- allowed thresholdabefore assessment
The proportion of subjects with a ≥50% 
reduction in Cutaneous Lupus Erythematosus 
Disease Area and Severity Index (CLASI) 
activity score at Week 12 in the sub -group of 
subjects with baseline CLASI activity score 
≥1050% reduction in CLASI activity score compared to 
baseline defined by the following criteria:
-Achieve ≥50% reduction of CLASI activity
score at Week 12 compared to baseline and
-No discontinuation of investigational product or
use of restricted medications beyond the
protocol- allowed thresholdabefore assessment
The proportion of subjects with SRI(4) at 
Week 24SRI(4) (see outcome measure for primary objective)
The annualised flare rate through 52 weeks Annualised flare rate with flare defined as either 1 or 
more new BILAG -2004 A or 2 or more new 
BILAG -2004 B items compared to the previous visit
Other Secondary Objectives: Outcome Measures:
To evaluate the effect of anifrolumab 150 mg 
compared to placebo on disease activity as 
measured by the difference in the proportion of 
subjects who achieve SRI(4) at Week 52SRI(4) (see endpoint for primary objective)
To assess the difference between anifrolumab 
300 mg and placebo on measures of disease 
activity including levels of SRI response other 
than 4, British Isles Lupus Assessment Group -
based Composite Lupus Assessment (BICLA), 
the individual components of SRI, and the 
number of swollen and tender joints at 
Week 52,as well as SRI and BICLA over timeSRI(4), SRI(5), SRI(6), SRI(7), SRI(8), BICLA 
response, BILAG -2004, SLEDAI -2K, PGA, Major 
Clinical Response, Partial Clinical Response, and 
joint count
To assess the difference between anifrolumab 
300 mg and placebo on measures of organ 
damage, ie, Systemic Lupus International 
Collaborating Clinics/American College of 
Rheumatology Damage Index (SDI) at 
Week 52SDI
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
6(125)Investigational product , dosage and mode of administration
Approximately  450 subjects receiving SOC treatment will be randomised in a 1:2:2 ratio to 
receive a fixed IV dose of anifrolumab or placebo, as follows: 
 Anifrolumab (MEDI
-546) 150 mg IV administration Q4W OR
 Anifrolumab (MEDI- 546) 300 mg IV administration Q4W OR
 Placebo IV administration Q4W
Statistical methods
The primary  estimand of interest is the difference in change from baseline in disease activity  
between anifrolumab 300 mg and placebo, to reflect the effect of the initially  assigned and 
dosed investigational product. This is measured by  the primary  efficacy  endpoint, defined as 
the difference in the proportion of subjects achieving SRI(4) at Week 52. The full anal ysis set 
will be used as the primary  population for reporting efficacy  and safet y data. The full anal ysis 
set is defined as subjects who are randomised and received at least 1 dose of investigational 
product (modified Intention- To-Treat).
The sample size is primarily  driven b y the need to acquire an adequate safety  database size, as 
well as the ability  to assess key  secondary  endpoints. The primary  endpoint is the difference in 
proportions of subjects achieving SRI(4) at Week 52 com paring anifrolumab 300 mg to 
placebo. With assumed proportions of SRI (4) of 39% and 63% in the placebo and anifrolumab 
300mg groups, respectively  (based on the observed results in the interim analy ses of study  
CD-IA-MEDI -
546-1013), 180 subjects/arm y ields more than 99% power to reject the
hypothesis of no difference using a 2 -
sided alpha of 0.05. The minimal detectable difference
in SRI(4) between anifrolumab 300 mg versus placebo is approximately  10% with this sample
size. With half of the sample size (ie , 90 subjects) for the anifrolumab 150 mg treatment
group, a 12.5% difference in SRI (4) between anifrolumab 150 mg versus placebo would be
associated with a nominal p- value of 0.05.
A stratified Cochran -Mantel -Haenszel test with the same stratification fac tors as for the 
randomisation, ie, disease activity  at screening (SLEDAI -2K <10 points versus 
≥10points), 
Day 1 OCS dose (<10 mg/day versus ≥10 mg/day prednisone or equivalent), and results of the 
IFN test (high versus low) will be used for the assessment of the primary  objective. 
A non- responder imputation method will be used for the handling of missing data and is 
incorporated into the definition of the primary  endpoint. Subjects who discontinue from 
treatment and/or the study for an y reason, as well as subjects who require restricted 
medications bey ond the protocol -allowed threshold, will be imputed as failures. 
The key  secondary  endpoints will be analy sed similarly , with the exception of the effect on 
the annualised flare rate, which will be anal ysed using a negative binomial regression model. 
The model will include covariates of treatment group, and the stratification factors. The 
logarithm of the follow- up time will be used as an offset variable in the model to adjust for 
subjects having different ex posure times. The multiplicity  of the key  secondary  variables will 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
7(125)be controlled using a weighted procedure with pre -determined weights for each of the key  
secondary  variables.
All safet
y parameters will be anal ysed descriptively . 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
8(125)TABLE OF CONTENTS PAGE
TITLE PAGE ........................................................................................................... 1
PROTOCOL  SYNOPSIS ......................................................................................... 2
TABLE OF CONTENTS ......................................................................................... 8
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
.......................... 16
1. INTRODUCTION ................................................................................................. 20
1.1 Background ............................................................................................................ 20
1.2 Rationale for stud y design, doses and control groups ............................................ 22
1.2.1 Rationale for stud y design ..................................................................................... 22
1.2.2 Rationale for primary  endpoint selection ............................................................... 23
1.2.3 Rationale for dose selection ................................................................................... 23
1.2.4
Rationale for duration of infusion.......................................................................... 23
1.2.5 Interferon test background ..................................................................................... 23
1.3 Benefit/risk and ethical assessment
........................................................................ 24
1.4 Study  design ........................................................................................................... 29
1.4.1
Steroid burst ........................................................................................................... 29
1.4.2 Protocol -specif ied steroid tapering ........................................................................ 30
2. STUDY OBJECTIVES .......................................................................................... 32
2.1 Primary  objective ................................................................................................... 32
2.2 Secondary  objectives ............................................................................................. 32
2.3 Safety  objective ...................................................................................................... 34
2.4 Exploratory  objective ............................................................................................. 34
3. SUBJECT SEL ECTION, ENROL
MENT, RANDOMI SATION,
RESTRI CTIONS, DISCONT INUATION AND WI THDRAWAL ...................... 34
3.1 Inclusion criteria .................................................................................................... 34
3.2 Exclusion criteria ................................................................................................... 39
3.2.1 General exclusion criteria ...................................................................................... 39
3.2.2 Exclusion crite ria related to concomitant medications .......................................... 40
3.2.3 Exclusion criteria related to sy stemic lupus ery thematosus and other 
diseases .................................................................................................................. 42
3.2.4 Exclusion criteria related to infection and malignancy  risk factors .......................
43
3.3 Restrictions and concomitant medications ............................................................. 44
3.3.1 Excluded medications: Day  1 through the end of the study ................................ ..44
3.3.1.1 Medications that lead to immediate discontinuation of investigational 
product ................................................................................................................... 44
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
9(125)3.3.1.2 Restricted medications ........................................................................................... 45
3.3.1.3 Other concomitant medications ............................................................................. 46
3.3.2 Concomitant medications for Sy stemic Lupus Erythematosus standard of 
care during the study .............................................................................................. 46
3.3.2.1 Steroid burst and taper Week 0 (Day  1) to Week 12 ............................................. 49
3.3.2.2 Increase in corticosteroids from Week 12 to Week 40
.......................................... 49
3.3.2.3 Increase in oral corticosteroids after Week
40....................................................... 50
3.3.2.4 Increase in oral corticosteroids for intercurrent disease or to prevent 
adrenal insufficiency .............................................................................................. 50
3.3.2.5 Protocol -specified steroid tapering Week 8 to Week 40 ........................................ 50
3.3.3
Other restrictions.................................................................................................... 51
3.3.3.1
Fasting lipid profile................................................................................................ 51
3.3.3.2 Perioperative management of investigational product ........................................... 51
3.4 Subject enrolment and randomisation .................................................................... 51
3.5 Methods for ensuring 
blinding ............................................................................... 52
3.6 Unblinding ............................................................................................................. 53
3.6.1
Unblinding for Data and Safety  Monitoring Board ............................................... 53
3.7 Discontinuation of investigational product ............................................................ 53
3.7.1 Subject decision to discontinue investigational product ........................................ 55
3.7.2 Withdrawal of the informed consent ...................................................................... 55
3.7.3 Lost to follow -
up.................................................................................................... 55
3.7.4 Study  completion and end of study ........................................................................ 55
3.7.5
Procedures for discontinuation of a subject from investigational product ............ 55
3.8 Criteria fo r withdrawal ........................................................................................... 56
3.8.1 Screen failures ........................................................................................................ 56
3.9 Discontinuation of the study .................................................................................. 56
4. STUDY PL AN AND TIMI NG OF PROCEDURES ............................................. 57
4.1
Enrolment/Screening Period .................................................................................. 66
4.1.1
Other considerations for screening ........................................................................ 66
4.1.1.1
Oral examination.................................................................................................... 66
4.1.1.2 Mammograph y
....................................................................................................... 66
4.1.2 Re-screening subjects who screen fail ................................................................... 66
4.2 Treatment Period .................................................................................................... 67
4.2.1
Premature discontinuation of investigational product ........................................... 67
4.3 Unscheduled Visit .................................................................................................. 68
4.4 Follow -up Period ................................................................................................... 68
5. STUDY ASSESSMENTS ..................................................................................... 69
5.1 Description of stud y procedures ............................................................................ 69
5.2 Efficacy  assessments .............................................................................................. 69
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
10(125)5.2.1 Training and certification for Sy stemic Lupus Ery thematosus assessments ......... 69
5.2.2 Disease Act ivity Adjudication Group .................................................................... 70
5.2.3 Systemic Lupus Ery thematosus Disease Activity  Index 2000 ...............................
70
5.2.4 British Isles Lupus Assessment Group-2004......................................................... 71
5.2.4.1 Protocol -specific clarification and ext ension of BILAG -2004 definitions ............ 72
5.2.5 Physician Global Assessment ................................................................................ 72
5.2.6 Oral corticosteroid reduction ................................................................................. 73
5.2.7 Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology  Damage Index ................................................................................ 73
5.2.8 Cutaneous L upus Ery thematosus Disease Area and Severity  Index 
inflammatory  disease activity ................................................................................ 73
5.2.9 Skin photograph y
................................................................................................... 74
5.2.10 Joint count .............................................................................................................. 74
5.3 Safety  assessments ................................................................................................. 74
5.3.1 Adverse events ....................................................................................................... 74
5.3.2 Vital signs .............................................................................................................. 75
5.3.3 Physical examination ............................................................................................. 75
5.3.3.1 Complete phy sical examination ............................................................................. 75
5.3.3.2 Focused ph ysical examination ............................................................................... 75
5.3.3.3 Pap smear ............................................................................................................... 75
5.3.3.4 Assessment of Cushingoid features ....................................................................... 76
5.3.4 Assessment of cardiovascular risk ......................................................................... 76
5.3.5 Columbia Suicide Severity  Rating Scale ............................................................... 76
5.3.6 Personal Health Questionnaire Depression Scale -
8............................................... 77
5.3.7 Electrocard iogram .................................................................................................. 77
5.3.8 Tuberculosis screening and monitoring ................................................................. 77
5.3.8.1 Screening evaluation .............................................................................................. 77
5.3.8.2 Tuberculosis results from screening evaluations ................................................... 78
5.3.8.3 Tuberculosis monitoring during the stud y
............................................................. 78
5.3.9 Modified flare in dex.............................................................................................. 79
5.3.10 Clinical laboratory  tests ......................................................................................... 79
5.3.11 Laboratory  assessments for cardiovascular risk assessments ................................
82
5.3.11.1 Fasting lipid profil e................................................................................................ 82
5.3.11.2 Immunology  profile ............................................................................................... 82
5.4 Clinical pharmacology  assessm ents....................................................................... 83
5.4.1 Pharmacokinetics ................................................................................................... 83
5.4.2 Immunogenicit y
..................................................................................................... 83
5.4.2.1
Anti- drug antibodies .............................................................................................. 83
5.4.2.2 Neutralising antibodies .......................................................................................... 83
5.4.3 Pharmacod ynamics ................................................................................................ 83
5.4.4 Interferon test in whole blood ................................................................................ 84
5.4.5 Proteomics/biomarkers .......................................................................................... 84
5.4.6 Storage and destruction of biological samples ....................................................... 85
5.5 Quality  of life/pharmacoeconomic assessments
.................................................... 85
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C0000 5
Edition Number 5
Date 18 May 2016
11(125)5.5.1 Short Form 36 version 2 (acute recall) .................................................................. 85
5.5.2
Functional Assessment of Chronic Illness Therapy– FATIGUE ........................... 85
5.5.3 EuroQoL 5 dimensions .......................................................................................... 85
5.5.4 Lupus Quality  of Life ............................................................................................. 86
5.5.5 Patient Global Assessment ..................................................................................... 86
5.5.6 Work productivity  and Activity  Impairment ......................................................... 86
5.5.7
Medical Resource Use Questionnaire.................................................................... 86
5.5.8 Pain numerical rating scale .................................................................................... 86
6.
SAFETY REPORTING AND MEDICAL MANAGEMENT .............................. 87
6.1 Definition of adverse events .................................................................................. 87
6.2 Definition of serious adverse events ...................................................................... 87
6.3 Hy’s law ................................................................................................................. 87
6.4 Other events of special interest .............................................................................. 87
6.4.1 Overdose ................................................................................................................ 87
6.4.2 Pregnancy ............................................................................................................... 88
6.4.3 Maternal exposure .................................................................................................. 88
6.4.4 Paternal exposure ................................................................................................... 88
6.5 Adverse Events of Special I
nterest ........................................................................ 89
6.5.1 Non-opportunistic serious infection ....................................................................... 89
6.5.2 Opportunistic infection .......................................................................................... 89
6.5.3 Anaph ylaxis........................................................................................................... 90
6.5.4 Malignancy ............................................................................................................ 90
6.5.5 Herpes zoster .......................................................................................................... 90
6.5.6 Tuberculosis ........................................................................................................... 90
6.5.7 Influenza ................................................................................................................ 91
6.5.8 Vasculitis (non -Systemic L upus Ery thematosus) .................................................. 92
6.5.9 Major acute cardiovascular events ......................................................................... 92
6.6
Recording of adverse events .................................................................................. 92
6.6.1 Time period for collection of adverse events ......................................................... 92
6.6.2 Follow -
up of unresolved adver se events ................................................................ 92
6.6.3 Variables ................................................................................................................ 92
6.6.4 Causality  collection ................................................................................................ 94
6.6.5 Adverse events based on signs and s ymptoms
....................................................... 94
6.6.6 Adverse events based on examinations and tests................................................... 94
6.6.7 Disease progression/w orsening of s ystemic lupus ery thematosus .........................
94
6.7 Reporting of serious adverse events ....................................................................... 95
6.8 Reporting of adverse events of special interest ...................................................... 96
6.9 Management of investigational product -
related toxicities ..................................... 96
6.9.1 Anaph ylaxis, hy persensitivity , and infusion
-related reactions .............................. 96
6.9.2 Infections ................................................................................................................ 96
6.10 Study  governance and oversight ............................................................................ 97
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
12(125)6.10.1 Data and Safet y Monitoring Board ........................................................................ 97
7. INVESTIGAT IONAL PRODUCT AND OTHER TREATMENTS ....................
98
7.1 Identity  of investigational products ........................................................................ 98
7.2
Dose and treatment regimens................................................................................. 98
7.2.1 Dose preparation steps ........................................................................................... 98
7.2.2
Prior to administering the investigational product................................................. 98
7.2.3 Investigational product administr ation procedures ................................................ 99
7.2.4
Subject monitoring/procedures during and after the infusion................................ 99
7.2.5 Discharge ............................................................................................................. 100
7.2.6
Documentation of investigational product administration................................... 100
7.3 Labelling .............................................................................................................. 101
7.4 Storage ................................................................................................................. 101
7.5 Compliance .......................................................................................................... 101
7.6 Accountability ...................................................................................................... 101
7.7 Post study  access to study  treatment .................................................................... 102
8. STATI STICAL ANALYSES .............................................................................. 102
8.1
Statistical considerations...................................................................................... 102
8.2 Sample size estimate ............................................................................................ 102
8.3 Definitions of anal ysis sets .................................................................................. 103
8.3.1 All subjects anal ysis set
....................................................................................... 103
8.3.2 Full anal ysis set
.................................................................................................... 103
8.3.3 Pharmacokinetic anal ysis set
............................................................................... 103
8.4 Outcome measures for analy ses........................................................................... 104
8.4.1 Primary  outcome variable .................................................................................... 104
8.4.2 Key secondary  outcome variables ........................................................................ 104
8.4.2.1 Systemic Lupus Ery thematosus Responder Index of 
≥4 at Week 52 in 
interferon test -high subjects ................................................................................. 104
8.4.2.2 Oral corticosteroid management .......................................................................... 104
8.4.2.3 Skin lesions .......................................................................................................... 105
8.4.2.4 Systemic Lupus Ery thematosus Responder Index of 
≥4 at Week 24 .................. 105
8.4.2.5 Flares .................................................................................................................... 105
8.4.3 Other secondary  outcome variables ................................ ................................ .....105
8.4.3.1 Assessment of disease activity ............................................................................. 105
8.4.4 Subject reported outcome variables ..................................................................... 107
8.4.4.1
Short Form 36 version 2 (acute recall) ................................................................ 107
8.4.4.2
Pain Numerical Rating Scale ............................................................................... 107
8.4.4.3
Functional Assessment of Chronic Illness Therapy- FATIGUE .......................... 108
8.4.4.4 Patient Global Assessment ................................................................................... 108
8.4.4.5 LUPUS qualit y of life scale ................................................................................. 108
8.4.4.6 EuroQoL 5 dimensions ........................................................................................ 108
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
13(125)8.4.4.7 Work productivity  and Activity  Impairment -Lupus .......................................... 108
8.4.4.8
Medical Resource Use Questionnaire.................................................................. 108
8.4.5 Safety
 variables .................................................................................................... 108
8.4.5.1 Other significant adverse events .......................................................................... 109
8.4.6 Immunogenicit
y variables .................................................................................... 109
8.4.7
Pharmacokinetic variables ................................................................................... 109
8.4.8 Pharmacod ynamic outcome variables .................................................................. 109
8.5 Methods for statistical analy ses........................................................................... 109
8.5.1 Analy sis of the primary  variable .......................................................................... 111
8.5.2 Analy sis of the secondary  variables ..................................................................... 112
8.5.2.1 Analy sis methods for key  secondary  efficacy variables ...................................... 112
8.5.2.2 Analy sis methods for other secondary  efficacy  variables .................................... 112
8.5.2.3 Analy sis methods for safety  variables
................................................................. 113
8.5.2.4 Analy sis method for immunogenicit y variables .................................................. 114
8.5.2.5 Analy sis methods for pharmacokinetic variables ................................................ 114
8.5.2.6 Analy sis methods for pharmacody namic variables ............................................. 114
8.5.3 Subgroup anal ysis................................................................................................ 114
8.5.4 Interim anal ysi
s.................................................................................................... 114
8.5.5 Pooled analy sis..................................................................................................... 115
9. STUDY AND DATA MANAGEMENT ............................................................. 115
9.1 Monitoring of the stud y
....................................................................................... 115
9.1.1 Source data ........................................................................................................... 115
9.1.2 Study  agreements ................................................................................................. 115
9.1.3 Archiving of stud y documents ............................................................................. 116
9.2 Study  timetable and end of study ......................................................................... 116
9.3 Data management ................................................................................................. 116
10. ETHI CAL  AND REGULATORY REQUIREMENTS ....................................... 117
10.1 Ethical conduct of the study ................................................................................. 117
10.2 Subject data protection ......................................................................................... 117
10.3 Ethics and regulatory  review ................................................................................ 117
10.4 Informed consent ................................................................................................. 118
10.5
Changes to the protocol and informed consent form ........................................... 118
10.6
Audits and inspections ......................................................................................... 119
11. LIST OF REFERENCES ..................................................................................... 119
LIST OF TABLES
Table 1 Effective methods of birth control
............................................................ 37
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
14(125)Table 2 Study  plan detailing the procedures at screening ..................................... 57
Table 3 Study  plan detailing the procedures during the Treatment Period 
(double -
blind period)................................................................................ 59
Table 4 Study  plan detailing the procedures during Follow -
up ............................ 64
Table 5 Clini
cal laboratory  tests ............................................................................ 80
Table 6 Compatible materials of construction for IV bags .................................. 101
Table 7 Compatible materials of const
ruction for ancillaries (eg, infusion 
tubing) ..................................................................................................... 101
LIST OF FIGURES
Figure 1 Distribution of IFN transcript scores ........................................................ 24
Figure 2 Study  flow chart ....................................................................................... 31
Figure 3 Alpha recy cling ....................................................................................... 110
LIST OF APPENDICES
Appendix A Signatures (Not applicable )
Appendix B Additional Safety  Information
 
Appendix C Actions Required in Cases of Combined Increase of Aminotransferase and 
Total Bilirubin –Hy’s Law
Appendix D American College of Rheumatology  Classification Criteria
Appendix E Systemic Lupus Ery thema tosus Disease Activity  Index 2000
Appendix F British Isles Lupus Assessment Group-2004
Appendix G Physician Global Assessment
Appendix H Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology  Damage Index
Appendix I Cutaneous L upus Ery thematosus Disease Area and Severity  Index
Appendix J Columbia Suicide Severity  Rating Scale
Appendix K Personal Health Questionnaire Depression Scale -8
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
15(125)Appendix L Short Form 36 Version 2 (Acute Recall)
Appendix M Functional Assessment of Chroni c Illness Therapy -FATIGUE
Appendix N EuroQoL 5 Dimensions
Appendix O LupusQoL Questionnaire
Appendix P Patient Global Assessment
Appendix Q Work Productivity  and Activity  Impairment
Appendix R Pain Numeric Rating Scale
Appendix S Medical Resource Use Quest ionnaire
Appendix T Vasculitic Sy ndromes Excluded from the Study
Appendix U Restricted Medications
Appendix V Oral Corticosteroid Guidance
Appendix W General Guidance for Determination of Major Surgery
Appendix X Guidance for Abnormal Pap Smear Results
Appendix Y Anaph ylaxis
Appendix Z Modified Fla reIndex
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 M ay 2016
16(125)LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
The following abbreviations and special terms are used in this study  Clinical Study  Protocol.
Abbreviation or 
special termExplanation
ACR American Col lege of Rheumatology
ADA Anti- drug antibodies
ADL Activity of daily living
AE Adverse event
AESI Adverse event of special interest
AIS Adenocarcinoma in situ 
ALT Alanine aminotransferase
ANA Antinuclear antibody
Anti- Sm Anti- Smith 
Anti- RNP Anti- Ribonucleoprotein
Anti- SSA Anti- Sjogren’s Syndrome -related antigen A
Anti- SSB Anti- Sjogren’s Syndrome -related antigen B
AST Aspartate aminotransferase
β-hCG β-human chorionic gonadotropin
BCG Bacillus Calmette -Guerin
BICLA British Isles Lupus Assessment Group -based Composite Lupus Assessment
BILAG British Isles Lupus Assessment Group
BP Blood pressure
C3 Third component of complement
C4 Fourth component of complement
CH50 Total haemolytic complement
CHMP Committee for Medicinal Products for Human Use
CI Confidence interval
CIN III Cervical intraepithelial neoplasia grade III 
CIS Carcinoma in situ 
CLASI Cutaneous Lupus Erythematosus Disease Area and Severity Index
CLE Cutaneous Lupus Erythematosus
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
17(125)Abbreviation or 
special termExplanation
CNS Central nervous system
COPD Chronic obstructive pulmonary disease
CRF Case Report Form (electronic/paper)
CSA Clinical Study Agreement
C-SSRS Columbia Suicide Severity Rating Scale
CSR Clinical Study Report
CT Computed tomography
CV-EAC Cardiovascular Event Adjudication Committ ee 
dECG Digital electrocardiogram
DEHP Diethylhexyl phthalate
DSMB Data and Safety Monitoring Board
DNA Deoxyribonucleic acid 
dsDNA Double- stranded deoxyribonucleic acid
EC Ethics Committee, synonymous to Institutional Review Board (IRB) and 
Independent Ethics Committee (IEC)
ECG Electrocardiogram
EDC Electronic data capture 
EMA European Medicines Agency
EQ-5D-5L EuroQoL 5 dimensions
EudraCT European Clinical Trials Database
EULAR European League Against Rheumatism
FACIT -F Functional Assessment of Chronic Illness Therapy -FATI GUE
FDA Food and Drug Administration
FSH Follicle -stimulating hormone
GCP Good Clinical Practice
GMP Good Manufacturing Practice
HBcAb Hepatitis B core antibody
HBsAg Hepatitis B surface antigen
HBV DNA Hepatitis B virus DNA
HIPAA Health Insurance Portability and Accountability Act
HIV Human immunodeficiency virus
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
18(125)Abbreviation or 
special termExplanation
ICF Informed consent form
ICH International Conference on Harmonisation
ICU Intensive care unit
IFA Immunofluorescent assay
IFIGx Interferon- inducible gene expression
IFN Interferon
Ig Immunoglobulin
IGRA Interferon- gamma release assay
International 
Coordinating 
InvestigatorIf a study is conducted in several countries the International Coordinating 
Investigator is the Investigator coordinating the Investigators and/or 
activities internationally. 
IV Intravenous
IXRS Interactive voice/web response system
LLOQ Lower limit of quantitation
LTE Long- term extension
MACE Major adverse cardiovascular events 
MedDRA Medical Dictionary for Regulatory Activities
MI Myocardial infarction
MRI Magnetic resonance imaging
mRNA Messenger ribonucleic acid
nAb Neutralising antibodies 
NSAIDs Nonsteroidal anti -inflammatory drugs
OCS Oral corticosteroids
PD Pharmacodynamic
PGA Physician’s Global Assessment
PHQ -8 Personal Health Questionnaire Depression Scale -8
PI Principal Investigator 
PIP Proximal interphalangeal
PK Pharmacokinetic(s)
PtGA Patient Global Assessment
PVC Polyvinyl chloride
Q4W Every 4 weeks
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
19(125)Abbreviation or 
special termExplanation
QFT -G QuantiFERON -TB Gold
QoL Quality of life
RGQ Rotor -Gene Q
RNA Ribonucleic acid
RT-PCR Reverse transcriptase polymerase chain reaction
SAE Serious adverse event 
SAP Statistical analysis plan
SC Subcutaneous
SDI Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index
SF-36v2 (acute) Short Form 36 version 2 (acute recall)
SLE Systemic lupus erythematosus
SLEDAI -2K Systemic Lupus Erythematosus Disease Activity Index 2000
SMR Standardised mortality ratio
SOC Standard of care
SRI(4) Systemic Lupus Erythematosus Responder Index of ≥4 
TB Tuberculosis
ULN Upper limit of normal
VAS Visual analogue scale
WPAI Work productivity and Activity Impairment
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
20(125)1. INTRODUCTION
1.1 Back ground 
Systemic lupus ery thematosus (SL E) is a chronic, multisy stemic, disabling autoimmune 
rheumatic disease of unknown aetiology . Systemic lupus ery thematosus predominantly  affects 
women of childbearing years (
Cooper et al, 1998; Lahita, 1999 ) with a review reporting the 
female -to-male ratio in the childbearing y ears to be about 12:1 ( Ramsey -Goldman and Manzi, 
2000 ). There is substantial unmet medical need in the treatment of SLE, particularl y in 
subjects with moderate or severe disease. Although off -label therap y has improved 
management options in recent years, long -term prognosis remains poor for many  subjects. 
Compared to the general population, the overall mortality  in SL E is increased with a 
standardised mortalit y ratio (SMR; defined as the ratio of the number of deaths observed to 
deaths expected) of 2.4, (2.3 to 2.5 95% confidence interval [CI ]) in a large international 
cohort of 9,457 subjects followed for over 70000 subject -years ( Bernatsky  et al, 2006 ).
Clinical manifestations of SL E include, but are not limited to, constitutional sy mptoms, 
alopecia, rashes, serositis, arthritis, nephritis, vasculitis, ly mphadenopathy , splenomegaly , 
haemoly
tic anaemia, cognitive dy sfunction and other nervous s ystem involvement. These 
disease manifestations cau se a significant burden of illness and can lead to reduced ph ysical 
function, loss of employment, lower health -related quality  of life (QoL), and a lifespan 
shortened b y about 10 years (ACR ad hoc committee, September 1999 ). Increased 
hospitalisations and side effects of medications including chronic oral corticosteroids (OCS) 
and other immunosuppressive treatments add to disease burden in SL E (Doria and Briani, 
2008; Petri, 2001 ; Zonana -Nanach et al, 2000).
All of the therapies currently  used for the treatment of SL E have well known adverse effect 
profiles and there is a medical need to identify  new targeted therapies, particularly agents that 
may reduce the requirement for corticosteroids and cy totoxic agents.
There has been onl y 1 new treatment (belimumab) for SL E approved by  the US Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) in the approximately  
50years since h ydrox ychloroquine was approved for use in discoid lupus and SL E. However, 
belimumab is not approved every where, and the uptake has been modest. Many  agents 
currentl y used to treat SLE, such as azathioprine, cyclophosphamide, and mycophenolate 
mofetil/my cophenolic acid, have not been approved for the disease. Furthermore these drugs 
all have well -documented safet y issues and are no t effective in all patients for all 
manifestations of lupus. Antimalarial agents (eg, hy droxychloroquine) and corticosteroids 
may be used to control arthralgia, arthritis, and rashes. Other treatments include nonsteroidal 
anti-inflammatory  drugs (NSAIDs); analgesics for fever, arthralgia, and arthritis; and topical 
sunscreens to minimise photosensitivity . It is often difficult to taper subjects with moderate or 
severe disease completely  off corticosteroids, which cause long
-term morbidity  and may  
contribute to earl y cardiovascular mortalit y (Petri, 2001 ; Urowitz et al, 1976 ). Even small 
daily  doses of 5 to 10 mg prednisone used long -term carry  increased risks of side effects such 
as cataracts, osteoporosis, and coronary  artery  disease ( Petri, 2001).
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 201 6
21(125)Multiple lines of evidence indicate a role of t ype I interferons (IFNs) in the pathogenesis of 
SLE:
 Genetic pol ymorphisms associated with t ype I IFNs are associated with
susceptibility  to SLE ( Criswell, 2008 , Sigurdsson, Göring et al, 2008 ; Sigurdsson,
Nordmark et al, 2008 ).
 High IFN -α levels and type I IFN activity  have be en reported in SL E (Bengtsson et
al, 2000 , Dall’era et al, 2005).
 Increased levels of messenger ribonucleic acid (mRNA), whose transcription is
induced b y type I IFNs (ty pe I IFN signature), are prominent in peripheral blood
mononuclear cells and whole blood in approximately  60% of SLE subjects and a re
associated with greater disease activity  (Baechler et al, 2003 , Bennett et al, 2003 ,
Crow and Wohlgemuth, 2003
, Feng X et al, 2006 , Kirou et al, 2004 , Kirou et al,
2005). Transcripts induced by  type I IFN are the most overexpressed transcripts in
SLE (Yao et al, 2010).
 Proteins induced by  IFN are increased in subjects with SL E (Huang et al, 2008
,
Hylton et al, 1986, Okamoto et al, 2004).
 Overexpression of t ype I IFN, t ype I IFN signature, and proteins induced b y type I
IFNs have been associated with greater disease activity  and organ s ystem
involvement in SLE.
Subjects with high anti -double stranded deox yribonucleic acid (anti -
dsDNA) anti body  titres, 
lupus nephritis, and progressive skin rashes have high serum levels of t ype I  IFN (Bengtsson 
et al, 2000). In addition, subjects with acute skin involvement tend to have elevated IFN in 
blood and skin ( Dall’era et al, 2005). Skin biopsies from subjects with SL E also show 
increased ty pe IIFN signature ( Blomberg S et al, 2001, Farkas et al, 2001 , Yao et al, 2009 ). 
Proteins induced by  IFN are increased in subjects with active central nervous sy stem (CNS) 
symptoms ( Okamoto et al, 2004 ).
Immune complexes containing SLE autoantibodies, such as anti -dsDNA or 
antiribonucleoprotein (anti- RNP) antibodies, can activate ty pe I IFN produc tion ( Bengtsson et 
al, 2000 , Rönnblom and Alm, 2003 ). After internalisation through Fc receptors, 
autoantibody -containing immune complexes bind endosomal toll
-like receptor 7 (TL R7) and 
toll-like receptor 9 (TL R9), stimulating production of ty pe I IFN. T ypeI IFN stimulates 
monocy te derived dendritic cell maturation, which promotes loss of tolerance and generation 
of autoreactive T and B cells, autoantibody  production, immune complex formation, and 
further production of ty pe I IFN, creating a s elf-perpetuating cy cle of autoimmunity  
(Banchereau et al, 2004 , Pascual et al, 2006 , Rönnblom and Pascual, 2008 ).
With the growing evidence that t ype I IFNs play an important role in autoimmune d iseases 
such as SL E, inhibition of the biological activity  of ty pe I IFNs with anifrolumab may , 
therefore, be a novel efficacious therap y for the treatment of SLE and its significant unmet 
medical need.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
22(125)Anifrolumab (MEDI
-546) is a human immunoglobulin G1 k appa (IgG1κ) monoclonal 
antibody  (mAb) directed against subunit 1 of the ty pe I interferon receptor (IFNAR1). It is 
composed of 2 identical light chains and 2 identical heav y chains, with an overall molecular 
weight of approximately  148 kDa. Anifrolumab in hibits binding of ty pe I IFN to ty pe I 
interferon receptor (IFNAR) and inhibits the biologic activity  of all ty pe I IFNs. 
1.2 Rationale for study design, doses and control groups
1.2.1 Rationale for study design
This is a Phase 3, multicentre, multinational, randomised, double -blind, placebo -controlled 
study  to evaluate the efficacy  and safety  of an intravenous (IV) treatment regimen of 
anifrolumab (150 mg or 300 mg) versus placebo in adult subjects with moderatel y to severel y 
active, autoantibod y-positive SL E while receiving standard of care (SOC) treatment. 
It is thought that neutralisation of IFN signalling through the human ty pe I IFN receptor with 
anifrolumab will reduce the severit y of disease activity  in su bjects with chronic, 
moderatel y-to-severely  active SL E, and that anifrolumab will be well tolerated when given at 
the proposed doses for the duration of the stud y.
To ensure adequate treatment, all subjects will receive SOC treatment with at least 1 of the
following: OCS, antimalarial, or immunosuppressants, in addition to investigational product. 
This is consistent with the both the European League Against Rheumatism (EULAR) 
(Bertsias et al, 2008 ) and American College of Rheumatology  (ACR) ( ACR ad hoc 
committee, September 1999 ) management guidelines of moderate to severe SL E.
The study  will be randomised, placebo -controlled, and double -blind to ensure a robust design 
and minimise bias. This is the preferred design as outlined in the June 2010 FDA Guidance for 
Industry  Systemic Lupus Erythematosus- Deve loping Medical Products for Treatment and in 
the Committee for Medicinal Products for Human Use (CHMP) Guideline on clinical 
investigation of medicinal products for the treatment of SL E and lupus nephritis ( CHMP, 
February  2015).
Randomisation will be stratified b y Systemic Lupus Ery thematosus Disease Activity  Index 
2000 (SL EDAI 2K, see 
Appendix E) score at screening (<10 points versus ≥10 points), Day 1
OCS dose (<10 mg/day  versus ≥10 mg/day  of prednisone or equivalent), and the results of the 
IFN test (high versus low). Stratification is implemented in order to minimise the risk for 
baseline imbalance(s) across treatment arms on potentially  confounding variables. Baseline 
imbalances of these factors could impact efficacy  and/or safet y assessments of anifrolumab 
versus placebo.
A treatment period of 52 weeks is an appropriate study  duration to determine the 
investigational product’s long -term efficacy  and safety  profile.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
23(125)1.2.2
Rationale for primary endpoint selection
The primary  outcome measure is the proportion of subjects who achieve Systemic L upus 
Erythematosus Responder Index of ≥4 (SRI [4]) at Week 52. This endpoint was employ ed as 
the primary  endpoint in both pivotal studies of a large phase 3 program ( Furie et al, 2009 , 
Navarra et al, 2011 , Wallace et al, 2009 ) in SL E and provided the basis for regulatory  
approvals of belimumab. 
1.2.3 Rationale for dose selection
The selection of a dose of 300 mg anifrolumab every
 4 weeks (Q4W) for this study is based 
on safet y and efficacy results from the interim analysis of a Phase 2b study where 2 doses of 
anifrolumab (300 mg and 1000 mg) are evaluated relative to pl acebo as well as dose- response 
modelling and simulation. I n the interim anal ysis of the Phase 2b study , clinically  meaningful 
benefit was observed with the 300 mg dose, with no incremental benefit at 1000 mg, see 
Section 1.3 for details. In addition, a higher proportion of subjects reporting herpes zoster
reactivations was observed at 1000 mg compared to 300 mg. Given the comparable efficacy  
between t he 300 and 1000 mg anifrolumab doses and the increased frequency  of herpes zoster
events in the 1000 mg dose group relative to the 300 mg dose group, the benefit:risk profile 
appears to favour the 300 mg dose. Further, from the PK/efficacy  model, minimal 
improvement in efficacy  was predicted for doses higher than 300 mg, consistent with the 
observed Phase 2b stud y interim analy sis data. The model also predicted that doses lower than 
300 mg will result in lower efficacy  since trough concentrations (C trough) from doses lower 
than 300 mg will fall below the model -predicted concentrations corresponding to 80% of 
maximum SRI (4) efficacy . The non -linear PK properties of anifrolumab cause a large increase 
in C trough variability  at doses below 300 mg, so as anifrolumab dose is lowered, a large 
proportion of subjects are predicted to have very rapid clearance and negligible exposure to 
anifrolumab. A dose of 150 mg is evaluated in this study  to provide supportive evide nce that 
300 mg is the minimum effective dose of anifrolumab.
1.2.4 Rationale for duration of infusion
In a Phase 2b stud y where 2 doses of anifrolumab in combination with SOC (300 mg and 
1000 mg) were compared to placebo, combined with SOC, all doses were admi nistered over 
approximately  60 minutes. The frequency  of infusion -related reactions did not differ 
substantially  between the 300 mg (2.0%) and 1000 mg (3.8%) groups and both were lower 
than that observed in the placebo group (5.9%). Therefore, in this stud y the infusion time was 
reduced to a minimum of 30 minutes.
1.2.5 Interferon test background
Type I IFN has been considered to be important in SL E disease pathogenesis and inhibition of 
this pathway  is targeted by  anifrolumab. To understand the relationship betw een t ype I IFN 
expression and response to anti- IFN therap y, it is necessary to know if a subject’s disease is 
driven by  type I IFN activation. However, direct measurement of the target protein remains a 
challenge. As such, a transcript -based marker was developed to evaluate the effect of over 
expression of the target protein on a specific set of mRNA markers. The expression of these 
markers is easily  detected in whole blood and demonstrates a correlation with expression in 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
25(125) Study  CD-IA-MEDI -
546-1013 is an ongoing Phase 2b, randomised, double -blind, 
placebo controlled stud y of anifrolumab (300 and 1000 mg) in adult subjects with 
moderatel y to severel y active SL E (ongoing at the time of writing this protocol).
 Study CD-IA-MEDI -546-1145 is the ongoing open-label extension (OLE) for 
subjects completing Study  CD-IA-MEDI -546- 1013 (ongoing at the time of writing 
this protocol).
 Study  D3461C00002 is an ongoing study  in Japanese adult subjects with SLE 
(ongoing at the t ime of writing this protocol).
 Study  D3461C0000
1is an ongoing stud y in adult subjects with lupus nephritis 
(ongoing at the time of amending this protocol).
Study  CD-IA-MEDI -546-1013 is a Phase 2b, randomised, double- blind, placebo -controlled, 
parallel group study  to evaluate the efficacy  and safety  of anifrolumab in adult subjects with 
chronic, moderatel y to severel y active SL E with an inadequate response to SOC treatment for 
SLE. Subjects were randomised 1:1:1 to placebo, anifrolumab 300 mg or anifrolumab
1000 mg while continuing their SOC treatment. Enrolment in the study is complete. An 
interim analy sis (including the anal ysis of the primary  endpoint) was conducted after all 
subjects completed the Day  169 visit or discontinued from study  treatment earl y.As of the 
data cut -off date of August 15, 2014, a total of 305 subjects had been treated with 
investigational product (2 subjects discontinued from the study  prior to dosing). 
Efficacy in anifrolumab Phase 2b study
The primary  efficacy  endpoint of the Phase 2b study  was the proportion of subjects achieving 
response in Sy stemic Lupus Ery thematosus Responder Index ( 4) (SRI[ 4] ) with sustained 
reduction of OCS (<10 mg/day  and less than or equal to the dose received on Day  1 by  Day  85 
and maintained between Da ys 85 and 169) at Day  169. There were higher proportions of 
subjects in the 300 mg (34.3%) and 1000 mg (28.8%) anifrolumab groups than in the placebo 
(17.6%) group who met the primary  endpoint at Day  169. Similar results were also observed 
in the other co -primary  population, the IFN test- high subjects (representing approximately  
75% of the stud y population) but not in the IFN test -low subjects at Day  169 (it is important to 
note that the sample size is low in this subpopulation). Further, compared to the pl acebo 
group, numericall y higher proportions of subjects in the anifrolumab groups met the 
secondary  endpoints of SRI(4) with sustained reduction of OCS (<10 mg/day  and less than or 
equal to the dose received on Day  1 by  Day  281 and maintained between Day s 281 and 365)
at Day  365 (placebo [25.5%], 300 mg [51.5%] and 1000 mg [38.5%]) and reduction of 
background OCS dose to ≤7.5 mg/day  at Day  365 in those taking ≥10 mg/day  at baseline 
(placebo [26.6%], 300 mg [56.4%], and 1000 mg [31.7%]) . 
The efficacy  observ
ed with the primary  and secondary  endpoints was supported by  a wide 
range of evidence. A numericall y higher proportion of subjects receiving anifrolumab met SRI 
response criteria without the OCS taper requirement at Day  169 and Day  365 compared to 
placebo. Furthermore, compared to the placebo group numericall y higher proportions of 
anifrolumab treated subjects achieved SRI(5), SRI(6), SRI(7) , and SRI(8) response, as well as 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
26(125)a British Isles Lupus Assessment Group (BILAG) -
2004 based combined lupus assessment 
(BICLA) response.
Higher response rates were also observed in organ specific measures for anifrolumab-treated 
subjects compared with placebo. In subjects with moderate or severe skin disease (Cutaneous 
Lupus Ery thematosus Disease Area and Severit y Index [C LAS I] activity  score ≥10 ) at 
baseline, a numericall y higher proportion of subjects achieved at least 50% improvement from 
baseline in the CLASI activity  score following anifrolumab treatment compared to subjects 
receiving placebo. In subjects with moderate or severe arthritis (
≥8 swollen and tender joints) 
at baseline, a numericall y higher proportion of subjects treated with 300 mg anifrolumab 
achieved at least 50% improvement in swollen and tender joint counts compared to subjects 
treated with placebo.
Amongst subjects with a dose of ≥10mg/day  oral prednisone or equivalent at baseline, a 
numericall y higher proportion of subjects in the 300 mg anifrolumab group than in the 
placebo group were able to reduce OCS to ≤7.5 mg/day  prednisone or equivalent by  Day  169. 
Similar results were seen at Day  365. No apparent differences were seen when comparing the 
1000 mg anifrolumab and placebo groups.
Serum complement and anti
-dsDNA antibody  levels are often indicative of active disease in 
SLE. In subjects with detectab le anti- dsDNA autoantibody  levels at baseline, those treated 
with 300 mg anifrolumab demonstrated a numerically larger decrease from baseline in anti -
dsDNA antibod y levels at Day 365 than those who were treated with placebo. I n subjects with 
abnormal third component of complement (C3) levels at baseline, those treated with 
anifrolumab demonstrated a numericall y larger increase from baseline in C3 levels at Day 169 
and 365 than those who were treated with placebo. 
Expression of ty pe I IFN-inducible genes in whole blood using a 21 -gene panel 
(pharmacod ynamic [PD] marker) decreased following anifrolumab administration for all dose 
groups in subjects with a baseline positive ty pe I IFN signature in whole blood. Both the 
300mg and 1000 mg anifrolumab dose achie ved and maintained 82 to 90% neutralisation of 
the gene signature. In the placebo group no neutralisation of the gene signature (>6%) was 
observed at an y time point.
Safety experience in anifrolumab Phase 2b study through August 2014 
Although the safet y profile for anifrolumab is acceptable, an imbalance was seen in the rate of 
occurrence of uncomplicated herpes zoster reactivation .
The overall number of subjects with adverse events (AEs), serious adverse events (SAEs) and 
adverse events of special interes t (AESIs) (new or reactivated tuberculosis [TB], malignancy , 
infusion or hy persensitivity  or anaph ylactic reaction and non SL E-related vasculitis) were 
similar between the placebo and anifrolumab groups. Serious adverse events related to the 
investigationa l product were observed in 5.9% of the subjects in the placebo, 3.0% in the 
300mg and 1.0% in the 1000 mg anifrolumab group. Adverse events leading to 
discontinuation of the investigational product were observed in 7.9% in the placebo, 3.0% in 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
27(125)the 300 mg 
and 9.5% in the 1000 mg anifrolumab group. There was 1 death in the 1000 mg 
anifrolumab group ( ) and none in the other 2 treatment groups.
There was a higher number of subjects with infection -related AEs in both the 300 mg (63.6%) 
and 1000 mg (
61.9%) anifrolumab groups compared with the placebo group ( 51.5%). This 
was due primarily  to more reports of uncomplicated cases of herpes zoster in the anifrolumab 
treated subjects (300 mg: 5.1%; 1000 mg: 9.5%) compared to placebo (2.0 %). Importantl y, 
subjects with herpes zoster infection responded to standard antiviral treatment. One treatment -
emergent SAE of transverse my elitis with a positive varicella zoster virus poly merase chain 
reaction in cerebrospinal fluid was reported. The subject recovered fol lowing treatment with 
pulsed steroid and standard antiviral medication.
There was a higher number of subjects with infections reported as influenza in the 
anifrolumab groups (300 mg: 6.1%; 1000 mg: 7.6%) compared to placebo ( 2.0%); however, 
the protocol di d not require objective evidence confirming the aetiology  of these infections. 
Infusion- related reactions were observed in 5.9% of placebo treated subjects: 2.0% in the 
300mg anifrolumab group and 3.8% in the 1000 mg anifrolumab group. The characteristic s 
and severit y of these reactions were similar in all 3 treatment groups.
Overall benefit:risk assessment 
Anifrolumab demonstrated a clinicall y relevant benefit in subjects with moderate to severe 
SLE treated with SOC. The efficacy  was supported by a broad range of clinical measures of 
global (various levels of SRI  responses, BICLA) and organ specific disease activity  (CLASI, 
joint count). A clinically  relevant increase in the proportion of subjects achieving 
pre-specified corticosteroid reduction in t he 300 mg group was also observed compared with 
placebo, while no apparent difference was observed comparing the 1000 mg group and 
placebo. 
Anifrolumab was generally  well tolerated. A dose- related increase in the number of subjects 
with uncomplicated herpes zoster infections was observed in subjects receiving anifrolumab 
compared with placebo. To date, in clinical trials of anifrolumab, h ypersensitivity  events or 
anaph ylaxis/anaphy lactoid events have not occurred more frequently  in subjects who were 
treate d with anifrolumab as compared to placebo, although careful monitoring for such events 
will continue.
The administration of any  foreign protein may  be associated with acute allergic reactions that 
may be severe, and may  result in death. Acute allergic reac tions may  include hy potension, 
dyspnoea, cy anosis, respiratory  failure, urticaria, pruritus, angioedema, h ypotonia, and 
unresponsiveness. Reports of infusion- related reactions from clinical trials conducted to date 
suggest that the frequency , severit y and characteristics of these reactions are similar across all 
treatment groups.
Although anifrolumab is a human monoclonal antibody , subjects can develop anti -
anifrolumab antibodies that may  neutralise the activity  of the drug or may  be associated with 

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
28(125)acute o
r delay ed hypersensitivity  reactions including anaphy laxis. Subjects will be monitored 
for clinical manifestations that may  be associated with the formation of specific antibodies to 
anifrolumab generated during the stud y, as well as for the presence of su ch antibodies.
In this stud y, anifrolumab will be administered at a fixed IV dose of 150 mg or 300 mg Q4W 
for 52 weeks. The 300 mg dose is equivalent to the lower dose in the Phase 2 study  (CD- IA-
MEDI -546- 1013). Anifrolumab has been generally well tolerate d to date with no dose - related 
safet y signal observed with the exception of an imbalance in observed events of 
uncomplicated herpes zoster infections. 
In order to minimise the risk of treatment with anifrolumab, subjects with risk factors for 
serious infection, malignancy , or immune deficiency  disorders are specifically  excluded from 
participation.
Serious infections, including non -opportunistic serious infections, opportunistic infections, 
anaph ylaxis, malignancy , herpes zoster, TB (including latent TB), influenza, vasculitis (non 
SLE), and major adverse cardiovascular events (MACE) (including stroke, my ocardial 
infarction [MI ], or cardiovascular death) are designated as AESIs in this study . 
Major adverse cardiovascular events are also designated as AESIs. An external independent 
adjudication committee will assess all deaths and cardiovascular SAEs to determine if they  
meet criteria for MACE (stroke, MI, or cardiovascular death). Specific details will be 
addressed in a cardiovascular event adjudication charter. There have been no imbalances in 
reporting rates of MACE or other non -MACE cardiovascular events observed either with 
anifrolumab or other agents sharing a similar mechanism of action compared to 
controls/placebo to date. However, since accelerat ed coronary  artery  disease and 
cerebrovascular accidents are recognised complications of SL E, the adjudication process is 
put in place to support rigorous signal detection activity  across treatment arms.
Compared to the general population, subjects with S LE have a higher rate of depression and 
suicide. Therefore, subjects will be screened for suicidality  and those who are at high risk at 
baseline will be excluded from participation in the study .
In order to provide an independent periodic review of safety  throughout the trial, in addition to 
the ongoing, blinded review provided b y the Medical Monitor, an independent Data and 
Safety  Monitoring Board (DSMB) will review blinded and unblinded safety  data on a regular 
basis throughout the study  (see Section 6.10.1).
In conclusion, AstraZeneca believes that the available nonclinical and clinical data indicate an 
acceptable safet y profile for anifrolumab. The proposed dosing regimens for Protocol 
D3461C0005 are adequately  justified and the management plan for potential risks associated 
with anifrolumab is appropriate. The emerging safety  profile has not identified any  risks that 
would preclude continued invest igation of anifrolumab. AstraZeneca believes that 
anifrolumab continues to demonstrate an overall positive benefit -risk balance to support its 
further clinical evaluation in subjects with active SL E.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
29(125)1.4 Study design 
This is a Phase 3, multicentre, multinatio nal, randomised, double -blind, placebo -controlled 
study  to evaluate the efficacy  and safety  of an IV treatment regimen of anifrolumab (150 mg 
or 300 mg) versus placebo in adult subjects with moderatel y to severel y active, autoantibod y
-
positive SL E while receiving SOC treatment. The study  will be performed in adult subjects 
aged 18 to 70 years of age.
Approximately  450 subjects receiving SOC treatment will be randomised in a 1:2:2 ratio to 
receive a fixed IV dose of 150 mg anifrolumab, 300 mg anifrolumab, or placebo Q4W for a 
total of 13 doses (Week 0 to Week 48) with the primary  endpoint evaluated at the Week 52 
visit. I nvestigational product will be administered as an IV infusion via an infusion pump over 
a minimum of 30 minutes, Q4W. 
Subjects must be taki ng either 1 or an y combination of the following: OCS, antimalarial, or 
immunosuppressants. Specific medication restrictions are contained in the eligibility  criteria 
and Section 3.3. See Figure 2 for an outline of the study  design.
Randomisation will be stratified using the following factors: 
 SLEDAI -2K score at screening (<10 points versus 
≥10 points)
 Week 0 (Day  1) OCS dose (<10 mg/day versus ≥10 mg/day  prednisone or
equivalent)
 Results of the IFN test (high versus low)
This study  includes:
 A Screening Period : Up to 30 day s
 Treatment Period : A 52- week double - blind treatment period with investigational
product administration Q4W from Week 0 to Week 48 for a total of 13 doses
 At Week 52 , subjects will have 2 options:
If eligible, enrol into the long -term extension (L TE) study
OR
Continue in the current study  for another 8 weeks to complete a 12- week safety
follow -up after the last dose of investigational product (last dose of
investigational product will be given in Week 48)
The total study  duration could be up to approximately 64 weeks for subje cts who do not enrol 
into the L TE study  (including screening period) and up to approximately  56 weeks (including 
screening period) for those subjects who do enrol into the L TE study .
1.4.1 Steroid burst
Section 3.3.2 provides specific details on steroid burst and tapers. From Week 0 (Day  1) to 
Week 12, subjects may  receive 
only 1 burst of corticosteroids for an increase in SL E disease 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
30(125)activity  or to contr ol non -SLE related disease (eg, asthma or chronic obstructive pulmonary  
disease [COPD] exacerbation). Subjects receiving more than 1 burst during the first 12 weeks 
of treatment will be considered non -
responders for subsequent assessments of disease activi ty, 
regardless of the reason for the burst (SLE or non -SLE activity ). 
1.4.2 Protocol -specified steroid tapering
An important secondary  objective in this study  is assessing whether anifrolumab improves the 
ability  to reduce corti costeroid dose in patients to < 7.5 mg prednisone or equivalent per day . 
For this reason, steroid tapering to a target OCS dose of ≤7.5 mg/day  must be attempted in all 
subjects with a baseline OCS dose ≥10.0 mg/day . This will commence at Week 8 and continue 
stepwise until the target dose is reached, unless at least 1 of the following criteria is met:
 SLEDAI -2K activity  which is worsened compared to baseline in major organ
systems (renal, CNS, cardiopulmonary , vasculitis, fever, thrombocy topenia, or
haemoly tic anaemia, or gastrointestinal activity )
 Newl y-affected organ s ystem(s) based on the SLEDAI -2K, excluding serological
abnormalities (dsDNA antibodies, hy pocomplementemia)
 Moderate to severe skin disease as reflected by a CL ASI activity  score of ≥10
 Moderate to severe arthritis disease as reflected b y an active joint count of ≥8 tender
and/or swollen joints
A recommended steroid -tapering regimen is provided in Appendix V, but Investigators will 
have flexibility  in how the OCS dose is reduced at each visit. If steroid tapering is not 
attempted in an eligible subject, the Sponsor or Sponsor’s designee must be contacted 
immediately .
Investigators will not be required, but may  continue, to taper OCS dose bey ond the target of 
7.5mg/day  up to Week 40 based on disease activity . If a subject ha s an increase in disease 
activity  secondary  to OCS tapering, they  may  increase the dose up to a maximum of the 
baseline OCS therap y dose from Week 8 up to Week 40 without the subject being considered 
a non -responder for subsequent assessments of disease ac tivity . Subjects who require OCS 
dose above their baseline level may continue in the study  but will be considered 
non-responders for subsequent assessments of disease activity .
Steroid tapering will not be permitted after Week 40.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
31(125)Figure 2 Study flow chart
IFN = interferon; IV = intravenous; N = number of subjects; OCS = oral corticosteroid; SLEDAI = Systemic Lupus Erythematosus Disease Activity Index; 
Q4W = every 4 weeks; V = Visi t; W = Week
Revised Clinical Study Protocol
Drug Substance Anifro lumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
32(125)2. STUDY OBJECTIVES
2.1 Primary objective
Primary Objective: Outcome Measures:
To evaluate the effect of anifrolumab 300 mg 
compared to placebo on disease activity as 
measured by the difference in the proportion 
of subjects who achieve an SLE Responder 
Index of ≥4 (SRI[4]) at Week 52Composite endpoint SRI(4), defined by the following 
criteria:
-Reduction from baseline of ≥4 points in the 
SLEDAI -2K and
-No new organ system affected as defined by 1 or 
more BILAG -2004 A or 2 or m ore BILAG -2004 
B items compared to baseline using 
BILAG -2004 and
-No worsening from baseline in subjects’ lupus 
disease activity defined by an increase 
≥0.30 points on a 3- point Physician’s Global 
Assessment (PGA) visual analogue scale (VAS) 
and
-No discontinuation of investigational product or 
use of restricted medications beyond the 
protocol- allowed thresholdabefore assessment
aAllowed medication is described in Section 3.3. 
2.2 Secondary objectives
Key Secondary Objectives: Outcome Measures:
To evaluate the effect of anifrolumab 300 mg compared to placebo on:
The proportion of subjects with SRI(4) at 
Week 52 in the IFN test -high sub- groupSRI(4) (see outcome measure for primary objective)
The proportion of subjects who achieve an 
OCS dose ≤7.5 mg/day at Week 40, which is 
maintained through Week 52 in the sub- group 
of subjects with baseline OCS ≥10mg/dayMaintained OCS reduction defined by the following 
criteria: 
-Achieve an OCS dose of ≤7.5 mg/day 
prednisone or equivalent by Week 40 and
-Maintain an OCS dose ≤7.5 mg/day prednisone 
or equivalent from Week 40 to Week 52 and
-No discontinuation of investigatio nal product or 
use of restricted medications beyond the 
protocol- allowed thresholdabefore assessment
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
33(125)The proportion of subjects with a ≥50% 
reduction in CLASI activity score at Week 12 
in the sub
-group of subjects with baseline 
CLASI activity score ≥1050% reduction in CLASI activity score compared to 
baseline defined by the following criteria:
-Achieve 
≥50% reduction of CLASI activity
score at Week 12 compared to baseline and
-No discontinuation of investigational product or
use of restricted medications b eyond the
protocol- allowed thresholdabefore assessment
The proportion of subjects with SRI(4) at 
Week 24SRI(4) (see outcome measure for primary objective)
The annualised flare rate through 52 weeks Annualised flare rate with flare defined as either 1 or 
more new BILAG -2004 A or 2 or more new 
BILAG -2004 B items compared to the previous visit
Other Secondary Objectives: Outcome Measures:
To evaluate the effect of anifrolumab 150 mg 
compared to placebo on disease activity as 
measured by the difference in the proportion 
of subjects who achieve SRI(4) at Week 52SRI(4) (see endpoint for primary objective)
To assess the difference between anifrolumab 
300 mg and placebo on measures of disease 
activity including levels of SRI response other 
than 4, British Isles Lupus Assessment 
Group- based Composite Lupus Assessment 
(BICLA), the individual components of SRI, 
and the number of swollen and tender joints at 
Week 52, as well as SRI and BICLA over timeSRI(4), SRI(5), SRI(6), SRI(7), SRI(8), BICLA 
response, BILA G-2004, SLEDAI -2K, PGA, Major 
Clinical Response, Partial Clinical Response, and 
joint count
To assess the difference between anifrolumab 
300 mg and placebo on measures of organ 
damage, ie, Systemic Lupus International 
Collaborating Clinics/American Colleg e of 
Rheumatology Damage Index (SDI) at 
Week 52SDI
To assess the difference between anifrolumab 
300 mg and placebo on subject -reported health 
status, health -related QoL, and other 
subject- reported outcome measures of fatigue, 
pain, patient global assessm ent, and work 
productivity at Week 52Short Form 36 version 2 (acute recall) (SF -36v2 
[acute]), Pain numeric rating scale (NRS), Functional 
Assessment of Chronic Illness Therapy -FAT IGUE 
(FACIT -F), Patient Global Assessment (PtGA), 
Lupus QoL, EuroQoL 5 dime nsions (EQ -5D-5L), 
Work Productivity and Activity Impairment 
(WPAI) -Lupus, and Medical Resource Use 
Questionnaire 
To evaluate the pharmacokinetics, 
immunogenicity, and pharmacodynamics of 
anifrolumabAnifrolumab concentration and PK parameters, 
anti-drug antibodies (ADA), 21 -gene type I 
interferon (IFN) gene signature, anti -dsDNA 
antibodies, C3, fourth component (C4), and total 
haemolytic (CH50) complement levels
aAllowed medication is described in Section 3.3
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
35(125)6. Diagnosis of paediatric or adult SL E with a diagnosis of SL E according to the ACR
1982 revised 
criteria ( Tan et al, 1982 ) ≥24 weeks prior to signing the ICF
7. Currently  receiving at least 1 of the following *:
(a) Where prednisone is the single standard of care medication (ie, the
subject is not concurrently  receiving any  medication listed in inclusion
criterion 7(c)), a dose of oral prednisone ≥7.5 mg/day  but ≤40 mg/day
(or prednisone equivalent**) for a minimum of 8 weeks prior to Day  1.
In addition, t he dose of oral prednisone or prednisone equivalent the
subject is taking must be stable for a minimum of 2 weeks prior to
randomisation
(b) Where prednisone is not the single standard of care medication (ie, the
subject is concurrently  receiving at least one medication listed in
inclusion criterion 7(c)), a dose of oral prednisone ≤40mg/day  (or
prednisone equivalent**) for a minimum of 2 weeks prior to signing of
the ICF. In addition, the dose of oral prednisone or pred
nisone
equivalent the subject is taking must be stable for a minimum of 2 weeks
prior to randomisation
(c) Any of the following medications administered for a minimum of
12 weeks prior to signing the informed consent, and at a stable dose for
a minimum of 8 w eeks prior to signing the informed consent
through Day 1:
(i) Azathioprine ≤200 mg/day
(ii) Antimalarial (eg, chloroquine, hy droxy chloroquine,
quinacrine)
(iii) Mycophenolate mofetil ≤2 g/day  or my cophenolic acid
≤1.44 g/day
(iv) Oral, subcutaneous (SC), or intramuscular methotrexate
≤25mg/week
(v) Mizoribine ≤150 mg/day
*If receiving oral prednisone (or equivalent) and an additional agent, the dose duration
and maximum allowable dosages for both ( b) and ( c) must be met
**See Appendix V for examples of prednisone equivalency
8. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE (see
Appendix D
), at least 1 of which must be:
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
36(125)(a) Positive antinuclear antibody  (ANA) test at screening by
immunofluorescent assay (IFA) at the central labo ratory  with titre
≥1:80; OR
(b) Anti-dsDNA antibodies at screening elevated to above normal
(including indeterminate), as per the central laboratory ; OR
(c) Anti
-Smith (anti -Sm) antibody  at screening elevated to above normal as
per the central laboratory
9. At Screening, Disease Activity  Adjudication Group confirmation of:
(a) SLEDAI -2K Criteria: SLEDAI -2K score 
≥6 points and “Clinical”
SLEDAI -2K score ≥4 points. The “Clinical” SL EDAI -2K is the
SLEDAI -2K assessment score without the inclusion of points
attributable to an y urine or laboratory results including immunologic
measures:
(i) Includes points from the following clinical components:
arthritis, my ositis, rash, alopecia, mucosal ulcers, pleurisy ,
pericarditis, or vasculitis
(ii) Excludes points attributed to a fever, an SLE headache, and
organic brain sy ndrome
(b) BILAG -2004 Level Criteria: At least 1 of the following:
i) BILAG -2004 level A disease in ≥1 organ s ystem
ii) BILAG -2004 level B disease in ≥2 organ s ystems
(c) Physician’s Global Assessment (PGA) score ≥1.0 on a 0 to 3 VAS at
screening
10. Negative serum β- human chorionic gonadotropin (β -hCG) test at screening (females
of childbearing potential only ).
11. Females of childbearing potential must use 2 effective methods of avoiding
pregnancy , one of which isa barrier method, from Screening until 12 weeks after
the final dose of investigational product unless the subject is surgicall y sterile (ie,
bilateral tubal ligation, bilateral oophorectom y, or complete h ysterectomy ), has a
sterile male partner, is 1 y ear postmenopausal, o r practices abstinence. Cessation of
birth control after the 12 -week follow up period should be discussed with a
responsible ph ysician.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
37(125) Sustained abstinence is an acceptable practice; however, periodic 
abstinence, the rh ythm method, and the withdrawal method are not 
acceptable methods of contraception.
 Postmenopausal is defined as at least 1 year since last menses and the 
subject has an elevated follicle- stimulating hormone (FSH) level greater 
than the central laboratory value of post -menopausal at screeni ng.
Effective methods of birth control include those listed in Table 1. 
Table 1 Effective methods of birth control
Barrier Methods Intrauterine Device Methods Hormonal Methods
Male condom (with
spermicide *)Progesterone T Implants
Cap (with spermicide cream or 
jelly*) Copper T Hormone shot or injection
Diaphragm (with spermicide
cream or jelly*) Combined pill
Minipill
Patch
*where commercially available
12. Nonsterilised males who are sexually  active with a female partner of childbearing 
potential must use a condom (with spermicide where commercially  available) from 
Day 1 until at least 12 weeks after receipt of the final dose of investigational 
product
13. Femal es with an intact cervix must have documentation of a normal Pap smear with 
no documented malignancy  (eg, cervical intraepithelial neoplasia grade III [CI N 
III], carcinoma in situ [CIS], or adenocarcinoma in situ [AI S]) within 2 y ears prior 
to randomisatio n
(see Appendix X for guidance on abnormal Pap smear results)
*Any  abnormal Pap smear result documented within 2 y ears prior to randomisation 
must be repeated to confirm patient eligibility
14. Willing to forego other forms of experimental treatment during the study
15. Meets all of the following TB criteria:
(a) No history  of active TB prior to any Screening visit
(b) No history  of latent TB prior to initial Screening visit, with the 
exception of latent TB with documented completion of appropriate 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
38(125)treatment
Note: 
Subject s with no history  of latent TB prior to the initial Screening 
visit, but who are diagnosed with latent TB during screening, may  be 
considered eligible if appropriate treatment is initiated prior to 
randomisation. Such subject s may  be re -screened if necessa ry to allow 
for local guidelines on latent TB treatment initiation.
(c) No signs or s ymptoms suggestive of active TB from medical history  or
physical examination
(d) No recent contact with a person with active TB OR if there has been
such contact, referral to a physician specialising in TB to undergo
additional evaluation prior to randomisation (documented appropriatel y
in source), and, if warranted, receipt of appropriate treatment for latent
TB at or before the first administration of investigational product
(e) Must meet 1 of the following criteria:
(i) Negative QuantiFERON -TB Gold [QFT- G] test result for
TB obtained from the study  Central Laboratory  within
3 months prior to randomisation OR
(ii) Positive QFT -G test result for TB obtained during the
Screening Period from the study  Central Laboratory  for
which active TB has been ruled out and appropriate
treatment for latent TB has been initiated prior to the first
investigational product administration OR
(iii) Indeterminate (confirmed on retest) QFT- G test result for
TB obtained during the Screening Period from the study
Central Laboratory  with ongoing QFT -G testing for TB
according to the Stud y Plan
(f) A chest radiograph with no evidence of current active infection (eg, TB)
or old active TB, malignancy , or clinically  significant abnormalities
(unless due to SL E) obtained during the Screening Period or any time
within 12 weeks prior to signing of the informed consent
16. Day 1 “Clinical” SLEDAI -2K score ≥4 points
17. OCS dose stable for at least 2 weeks prior to randomisation
18. Stable SL E SOC treatment (see Section 3.3.2) at the time of randomisation
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
39(125)19. Women of child
-bearing potential must have a negative urine pregnancy  test at 
randomisation (Day  1), prior to administration of investigational product
20. In the opinion of the Investigator, must be able to comprehend the ICF and all 
protocol related assessments, such that the patient can complete all study  required 
documents, pro
cedures, and outcome measures.
3.2 Exclusion criteria
Any of the following would exclude the subject from participation in the study :
3.2.1 General exclusion criteria
1. Any condition that, in the opinion of the Investigator, would interfere with 
evaluation of the inve stigational product or interpretation of subject safet y or study  
results
2. Concurrent enrolment in another clinical stud y with an investigational product 
3. Individuals involved with the conduct of the study , their employ ees, or immediate 
family  members of suc h individuals
4. Lactating or pregnant females or females who intend to become pregnant any time 
from initiation of Screening until the 12- week safety  follow -up period following 
last dose of investigational product
5. Current alcohol, drug or chemical abuse, or a history  of such abuse within 1 y ear 
before Week 0 (Day  1)
6. Major surgery  within 8 weeks before signing the ICF or elective major surgery  
planned during the stud y period (see Appendix W)
7. Spontaneous or induced abortion, still or live birth, or pregnancy  ≤4 weeks prior to 
signing the ICF
8. At Screening (within 4 weeks before Week 0 [Day 1]), any  of the following:
(a) Aspartate aminotransferase (AST) >2.0 × upper limit of normal (ULN). 
(b) Alanine aminotransferase (ALT) >2.0 × ULN. 
(c) Total bilirubin >UL N (unless due to Gilbert's s yndrome)
(d) Serum creatinine >2.0 mg/dL (or >181 μmol/L )
(e) Urine protein/creatinine ratio >2.0 mg/mg (or >226.30 mg/mmol)
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
40(125)(f) Neutrophil count <1000/μL  (or <1.0 × 109/L)
(g) Platelet count <25000/μL (or <25 × 109/L)
(h) Haemoglobin <8 g/dL (or <80 g/L), or <7 g/dL (or <70 g/L) if related to
subject's SLE such as in active haemoly tic anaemia
(i) Glycosylated haemoglobin (HbA1c) >8% (or >0.08) at screening
(diabetic subjects onl y)
Note: Abnormal screening laboratory  tests may  be repeated ONCE on a separate sa mple 
before subject is declared a screen failure.
3.2.2 Exclusion criteria related to concomitant medications
9. Receipt of an y of the following:
(a) Where prednisone is the single standard of care medication (ie, the
subject is not concurrently  receiving any  medication listed in inclusion
criterion 7(c)), an y addition of a new oral prednisone therap y (or
equivalent) an y time in the 8 weeks prior to Day  1, OR any  change in/
discontinuation of current oral prednisone dose (or e quivalent) an ytime
within the 2 weeks prior to r andomisation (see Appendix V for examples
of prednisone equivalency)
(b) Where prednisone is not the single standard of care medication (ie, the
subject is concurrently  receiving at least one medication listed in
inclusion criterion 7(c)):
(i) Any addition of a new oral prednisone therapy  (or
equivalent) an y time from 2 weeks prior to signing of the
informed consent form through Day  1, OR an y change in/
discontinuation of current oral prednisone dose (or
equivalen t) anytime within the 2 weeks prior to
randomisation (see Appendix V for examples of prednisone
equivalency )
(ii) Any addition of a new dose of an y of the following an ytime
in the 12 weeks prior to signing of the informed consent
through Day  1, or change in/ discontinuation of current dose
anytime in the 8 weeks prior to signing of the informed
consent through Day  1: az athioprine; any  antimalarial (eg,
chloroquine, h ydrox ychloroquine, quinacrine);
mycophenolate mofetil/my cophenolic acid; oral ,SC,or
intramusc ular methotrexate; mizoribine
10. Receipt of an y of the following:
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
41(125)(a) Azathioprine >200 mg/day
(b) Mycophenolate mofetil >2 g/day  or my cophenolic acid >1.44 g/day
(c) Oral, SC, or intramuscular methotrexate >25 mg/week
(d) Mizoribine >150 mg/day
(e) Any change in route of 
administration of oral, SC, or intramuscular
methotrexate any time within the 8 weeks prior to signing of the
informed consent through Day  1
11. Receipt of an y investigational product (small molecule or biologic agent) within
4weeks or 5 half -lives prior to s igning of the ICF, whichever is greater (see
Appendix U)
12.
Prior receipt of anifrolumab
13. Receipt of an y commercially  available biologic agent within 5 half -lives (see
Appendix U) prior to signing of the ICF
14. Receipt of B cell -depleting therapy  (including but not limited to, ocrelizumab,
ofatumumab, atacicept, obinutuzumab, or rituximab)
<26 weeks prior to signing the ICF ; <40 weeks for atacicept
(see 
Appendix U)
or if therap y was administered ≥26 weeks ago (40 weeks for atacicept) ,
absolute B cell less than the lower limit of normal or baseline value prior to
receipt of B cell -depleting therapy  (whichever is lower)
15. Receipt of epratuzumab or tabalumab <26 weeks prior to signing the ICF , or
belimumab <12 weeks prior to signing the ICF
16. A known history  of allergy  or reaction to any  component of the investigational
product formulation or history  of anaph ylaxis to any  human gamma globulin
therap y
17. Regular use of >1 NSAID within 2 weeks prior to Week 0 (Day  1); OR receipt of
fluctuating doses of a NSAID within 2 weeks prior to Week 0 (Day  1)
18. Receipt of an y of the following:
(a) Intra -articular, intramuscular or IV glucocorticosteroids within 6 weeks
prior to Day 1
(b) Any live or attenuated vaccine within 8 weeks prior to signing the ICF
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
42(125)(administration of killed 
vaccines is acceptable, the Sponsor 
recommends Investigators ensure all subjects are up to date on required 
vaccinations, including influenza [inactivated/recombinant] vaccine 
prior to study  entry )
(c) Bacillus Calmette -Guerin (BCG) vaccine within 1 y ear of s igning the
ICF
(d) Any restricted medication listed in Appendix U if the washout period is
not met
(e) Blood transfusion within 4 weeks prior to signing the I CF
3.2.3
Exclusion criteria related to systemic lupus erythematosus and other diseases
19. History  of, or current diagnosis of, a clinically  significant non SL E-related
vasculitis sy ndrome (see Appendix T
). Vasculitis due to SL E is allowed in the study
20. History  or evidence of suicidal ideation (severity  of 4 [active: method and intent,
but no plan] or 5 [active: metho d, intent, and plan]) within the past 6 months; or any
suicidal behaviour within the past 12 months based on an assessment with the
C-SSRS at screening or at baseline
21. Active severe or unstable neurops ychiatric SLE including, but not limited to:
aseptic men ingitis; cerebral vasculitis; my elopathy ; dem yelination syndromes
(ascending, transverse, acute inflammatory  dem yelinating pol yradiculopathy ); acute
confusional state; impaired level of consciousness; psy chosis; acute stroke or stroke
syndrome; cranial neu ropathy ; status epilepticus; cerebellar ataxia; and
mononeuritis multiplex:
(a) That would make the subject unable to full y understand the I CF OR
(b) Where, in the opinion of the Principal Investigator (PI), protocol
specified SOC is insufficient and utilisation of a more aggressive
therapeutic approach, such as adding IV cy clophosphamide and/or high
dose IV pulse corticosteroid therap y or other treatments not permitted in
the protocol, is indicated
22. Active severe SLE -driven renal disease where, in the opinion of the PI , protocol
specified SOC is insufficient and utilisation of a more aggressive therapeutic
approach, such as adding IV cy clophosphamide and/or high dose IV pulse
corticosteroid therap y or other treatments not permitted in the protocol, is indicated
23. D iagnosis (within 1 y ear of signing the ICF) of mixed connective tissue disease or
any history  of overlap s yndromes of SLE and systemic sclerosis, as noted in A or B
below:
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
43(125)(a) An overlap s yndrome of SL E with my ositis or rheumatoid arthritis at
screening is pe rmitted provided the subject also meets the criteria for the
classification as SLE; or
(b) A past history  of mixed connective tissue disease, which over time has
developed into a diagnosis of SL E, is permitted provided diagnosis of
SLE has been present for at least 1 y ear
24. History  of or current diagnosis of catastrophic or severe anti
-phospholipid
syndrome within 1 y ear prior to signing the ICF. Antiphospholipid sy ndrome
adequatel y controlled b y anticoagulant therap y for at least 3 months is acceptable.
25. Histor y of, or current, inflammatory joint or skin disease other than SLE that, in the
opinion of the I nvestigator, could interfere with the inflammatory arthritis or skin
assessments and confound the disease activity  assessments
26. History  of any  non- SLE disease t hat has required treatment with oral or parenteral
corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to
signing the ICF
3.2.4 Exclusion criteria related to infection and malignancy risk factors
27. Known history  of a primary  immunodefic iency , splenectom y,or an yunderly ing
condition that predisposes the subject to infection, or a positive result for human
immunodeficiency  virus (HIV) infection 
confirmed by  central laboratory  at
screening . Subjects refusing HIV testing during the screenin g period will not be
eligible for study  participation
28. Confirmed positive test for hepatitis B serology  for:
(a) Hepatitis B surface antigen (HBsAg) , OR
(b) Hepatitis B core antibody  (HBcAb) AND hepatitis B virus (HBV) DNA
detected above the lower limit of quanti tation (LLOQ) by reflex testing
by the central laboratory  at screening
Note: Subjects who are HBcAb positiv
eat screening will be tested every  3months for HBV 
DNA. To remain eligible forthe study , the subject ’sHBV DNA levels must remain below the 
LLOQ as per the central laboratory .
29. Positive test for hepatitis C antibody  as confirmed by  central laboratory
30. Any severe herpes infection at any  time prior to Week 0 (Day  1), including, but not
limited to, disseminated herpes (ever), herpes encephalitis (ever ), recurrent herpes
zoster (defined as 2 episodes within 2 y ears) or ophthalmic herpes (ever)
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
44(125)31. Any herpes zoster , cytomegalovirus (CMV) or Epstein -Barr virus infection that has
not completely  resolved within 12 weeks prior to signing the ICF
32. Opportunistic infection requiring hospitalisation or intravenous antimicrobial
treatment within 3 y ears of randomisation
33. Any of the following:
(a) Clinically  significant chronic infection (ie, osteomy elitis, bronchiectasis,
etc) within 8 weeks prior to signing the ICF (chronic nail infections are
allowed)
(b) Any infection requiring hospitalisation or treatment with I V
anti-
infectives not completed at least 4 weeks prior to signing the ICF
34. Any infection requiring oral anti -infectives (including antivirals) within 2 weeks
prior to Day  1
35. History  of cancer, apart from:
(a) Squamous or basal cell carcinoma of the skin treated with documented
success of curative therapy  ≥3 months prior to Week 0 (Day  1)
(b) Cervical cancer in situ treated with apparent success with curative
therap y ≥1 year prior to Week 0 (Day  1)
3.3 Restrictions and concomitant medications
3.3.1 Excluded medications: Day 1 through the end of the study
Subjects must be instructed not to take an y medications, including over -the-counter products, 
without first consulting the Investigator.
3.3.1.1 Medications that lead to immediate discontinuation of investigational product
(a) Cyclophosphamide
(b) IFN therap y (alpha 2a and 2b, beta 1a and 1b, and pegy lated IFNs alpha 2a and 2b)
(c) Investigational agents
(d) Biologic immunomodulators (including, but not limited to, belimumab , abatacept,
or rituxumab )
(e) Live or attenuated vaccines (the Sponsor recommends that I nvestigators ensure all
subjects are up to date with required vaccinations prior to entry  into the study )
(f) Plasmapheresis
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
45(125)(g) BCG vaccine
(h) Any immunoglo bulin (Ig) therap y
(i) Intravenous corticosteroids >1 gm meth ylprednisolone or equivalent
(j) Any medications listed in 
Appendix U (please see the sulfasalazine, danazol, and
dapsone restrictions in Section 3.3.1.2), except restrictions below.
3.3.1.2 Restricted medications 
As anifrolumab is an investigative immunomodulatory  agent, non -protocol permitted changes 
to immune modifiers or immunosuppressants on study  arestrongl y discouraged.
If a subject receives 1 of the following, the Investigator must notify the  Medical Monitor 
immediately . The  Medical Monitor will determine with the Sponsor if the subject may  
continue to receive investigational product, however, the subject would be considered a 
non-responder.
(a) Sulfasalazine
(b) Danazol
(c) Dapsone
(d) Azathioprine >200 mg/day  or at a daily  dose greater than that at Week 0 (Day  1)
(e) Mycophenolate mofetil >2.0 g/day or my cophenolic acid >1.44 g/day  or at a daily
dose greater 
than that at Week 0 (Day  1)
(f) Oral, SC, or intramuscular methotrexate >25 mg/week or at a dail y dose greater
than that at Week 0 (Day 1)
(g) Mizoribine >150 mg/day or at a daily dose greater than that at Week 0 (Day 1)
(h) Any change in route of administration of oral, SC, or intramuscular methotrexate
(i) Intravenous corticosteroids >40 mg/day  but ≤1 gm/day  methy lprednisolone or
equivalent
(j) Intramuscular corticosteroids >80 mg/day  methy lprednisolone or equivalent
(k) Subcutaneous or intramuscular corticosteroid precursors
(l) Treatment with OCS >40 mg/day  prednisone or equivalent
(m) Treatment with OCS above Day 1 dose for a dosing period >14 day s

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
46(125)(n) Corticosteroids with a long biologic half -life (eg, dexamethasone, betamethasone)
(o) Other immunosuppressants including but not limited to calcineurin inhibitors (eg,
cyclosporine, tacrolimus [including topical] ) or leflunomide.
Note: Cy closporine ey e drops are acceptable for use in the study .
3.3.1.3 Other concomitant medications
Medication other than that described above, which is considered n ecessary for the subject’s 
safet y and wellbeing, may be given at the discretion of the Investigator and recorded in the 
appropriate sections of the Case Report form (CRF).
3.3.2 Concomitant medications for Systemic Lupus Erythematosus standard of care 
during the study
Permitted medications for SOC SL E are described below. Concomitant medications should 
only be administered after all visit assessments, including investigational product 
administration and post
-infusion PK blood draws (if applicable), with the exception of a 
subject with a previous infusion- related reaction who is to receive acetaminophen or 
equivalent. The acetaminophen or equivalent should be given after all visit assessments other 
than the infusion have been completed, and prior to starting the in fusion.
Permitted SOC SLE Limitations of Use
OCS-Oral prednisone or equivalent up to ≤40mg/day is permitted
from at least 2 weeks prior to signing the informed consent .
The dose of oral prednisone must remain stable at least 2 weeks
prior to randomisation
-Where prednisone is the single standard of care medication (ie,
the subject is not concurrently receiving any medication listed in
inclusion criterion 7(c)), a dose of oral prednisone ≥7.5 mg/day
but ≤40 mg/day (or prednisone equivalent) for a minimum of 8
weeks prior to Day 1 is required
-Subjects with increased SLE disease activity may receive 1
permitted burst and taper of OCS between Day 1 and Week 12.
Additional details on burst and taper for SLE and non -SLE (eg,
asthma or COPD exacerbati on) disease activity are provided in
Sections 3.3.2.1 to 3.3.2.4
Intramuscular corticosteroids-Subjects with increased SLE disease activity may receive 1
intramuscular injection of corticosteroids (methylprednisolone
≤80mg or equivalent) instead of a burst and taper of OCS
described above between Day 1 and Week 12.
-May only be administered after all assessments and
investigational product infusion have been completed at the visit
-Additional details on burst and taper for SLE and non SLE
disease activity are provided in Sections 3.3.2.1 to 3.3.2.4
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
47(125)Permitted SOC SLE Limitations of Use
Intra -articular/tendon 
sheath/ bursal corticosteroid 
injections-Intra -articular/tendon sheath/bursal injection should be 
minimized. Subjects may receive a maximum of 2 injections (for 
a total dose of ≤80 mg methylprednisolone or equivalent) instead 
of a burst and taper of OCS described above, between Day 1 and 
Week 12.
-An intra -articular/tendon sheath/bursal injection may be allowed 
for non- SLE related disorders up to Week 40 if the symptoms of 
the disorder do not interfere with the ability to assess 
SLE-related endpoints. The Investigat or must contact the 
medical monitor for permission to administer an 
intra-articular/tendon sheath/bursal corticosteroid injection prior 
to administration of corticosteroids for non -SLE related 
disorders
-If permission is given, the injection should not be a dministered 
until after the completion of all assessments, including 
investigational product administration and post -infusion PK 
blood draw (if applicable) 
Antimalarials and 
immunosuppressants 
(azathioprine, methotrexate, 
and mycophenolate 
mofetil/mycophenolic acid, 
and mizoribine)-Antimalarials and immunosuppressants (azathioprine, 
methotrexate, mycophenolate mofetil/mycophenolic acid, and 
mizoribine) are permitted, and at least 1 is required, as part of 
SLE therapy on Day 1 if the subject is not on OCS 
-Dose regimens must remain stable from Day 1 to the completion 
of Week 52 but may be decreased for toxicity or to optimise 
management of an AE, such as infection. The toxicity/event 
must be confirmed as a documented AE. The dose can be 
returned to the Day 1 level if the toxicity/event resolves and if 
clinically indicated.
-Antimalarials/immunosuppressants should not be changed if a 
subject has increased SLE disease activity during the OCS 
tapering period. 
Prescription NSAIDs-Prescription NSAIDs must remain stable from screening through 
Week 52 but can be reduced for reasons of toxicity but not 
efficacy. Prescription NSAIDs cannot be administered with 
other NSAIDs (including over -the-counter non- steroidals) 
except for low -dose aspirin
-On a given visit day, p rescription NSAIDs should not be taken 
until after all assessments have been completed and should be 
taken according to SOC
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
48(125)Permitted SOC SLE Limitations of Use
Non-prescription NSAIDS-NSAIDs should not be taken on the day of a scheduled visit until 
all assessments are complete.
-NSAIDs for a nalgesic purposes that never exceed 
label -approved doses of NSAIDs may be used for pain as 
required, based on Investigator judgment for up to 1 week at a 
time
-NSAIDs cannot be used in combination with another NSAID at 
any dose, except low -dose aspirin ( ≤325mg/day)
Acetaminophen or equivalent-Pain medications should not be used within a minimum of 6 to 
12hours (based on known duration of effect) of a scheduled visit 
-Normal release (not extended release) acetaminophen or 
equivalent (eg, paracetamol) may b e used for pain as required
-In a subject with a previous infusion -related reaction, 
acetaminophen or equivalent can be given after all visit 
assessments have been completed and prior to starting the 
infusion
Low-dose aspirin-Low-dose aspirin (maximum of 325mg/day) for cardiovascular 
disease is permitted
Topical therapy-Concurrent use of topical therapy for cutaneous lupus 
erythematosus (eg, corticosteroids) is permitted. Topical 
moisturisers are also permitted
-Topical therapy must be the same being used at signing of the 
informed consent and the dose and frequency of application 
must be stable during screening 
-During the study, topical therapy may be reduced or 
discontinued based on clinical manifestations and Investigator 
discretion. Should cutaneous s kin manifestations reoccur, the 
same topical therapy may be resumed up to the Day 1 dose.
-It is encouraged that no new dermatologic preparations be used 
for the duration of the study. It is also recommended that 
subjects use sunscreen (list as concomitant medication for SLE) 
and avoid sun exposure during the study
NSAIDs = nonsteroidal anti- inflammatory drugs; OCS = oral corticosteroids; SLE = systemic lupus 
erythematosus; SOC = standard of care 
All permitted SOC SL E therapies received from initiation of screening through the end of the 
study  will be recorded on the source document and CRF, and will include the specific 
indication for use (eg, general SLE activit y, skin involvement, nephritis, pleurisy) as well as 
the dose, start and stop dates, frequen cy, and route of administration. In addition, any  change 
in permitted SOC SL E therapy  and the reason for change must be documented.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
49(125)3.3.2.1
Steroid burst and taper Week 0 (Day 1) to Week 12
In order to allow adequate time for the investigational product to achieve significant clinical 
benefit, Investigators may administer 1burst and taper of corticosteroids between Week 0 
(Day  1) and Week 12 for increased SL E disease activity /non-SLE activit y.
A steroid burst as described below is defined as 1 of the following:
 OCS increase up to a maximum daily dose of 40 mg/day  prednisone (or equivalent) 
for up to a total of 14 days and that must be fully  administered and tapered to less 
than or equal to th e Day  1 dose by  the end of the 14th day . Any course of OCS 
above the Day  1 dose must not extend bey ond Week 12, regardless of when the 
course was started; 
OR
 Intramuscular methy lprednisone ( ≤80 mg) or equivalent administered as a single 
dose between Day  1and Week 12;
OR
 A maximum of 2 intra -articular/tendon sheath/bursal injections (for a total 
methy lprednisolone ≤80 mg or equivalent) can be given. Subjects who receive any  
intra-articular/tendon sheath/bursal injections should not receive OCS or 
intramusc ular burst between Day  1 and Week 12.
Subjects who receive more than 1 steroid burst and taper from Week 0 (Day 1) to Week 12, or 
who violate an y of the criteria above, may continue in the study, but will be considered 
non-responders for subsequent assessm ents of disease activity , regardless of whether the OCS 
burst was administered for increased SLE activit y or non -SLE causes.
3.3.2.2
Increase in corticosteroids from Week 12 to Week 40
Between Week 12 and Week 40, an increase in corticosteroid dose for increased S LE activity  
is not allowed. A subject receiving a steroid dose above his or her Week 0 (Day  1) dose may  
continue in the study , but will be considered a non -responder for subsequent assessments of 
disease activity .
An increase in OCS for non -SLE causes (eg, asthma or COPD exacerbation) is allowed 
ONCE with medical monitor approval between Week 12 and Week 40. This might include a 
non-SLE OCS up to ≤20mg/day  of prednisone (or equivalent) for up to a total of 14 day s and 
must be fully  administered and tapered to less than or equal to the Day  1 dose by  the end of 
the 14th day  and by  the Week 40 visit day . This will be captured as burst and taper not 
attributable to SL E. The non- SLE indication must be clearly  indicated in the source 
documents.
Subjects who rece ive non -SLE prednisone (or equivalent) at a total dose >20 mg/day  but 
≤40mg/day  for a dosing period of greater than 14 day s may  continue in the study  but will be 
considered non -responders for subsequent assessments of disease activity . If a subject receiv es 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
50(125)>40mg prednisone or equivalent) or a dose above baseline level for more than 14 days, it 
must be reported to the
 Medical Monitor. The  Medical Monitor will determine with 
the Sponsor if the subject may  continue to receive investigational product.
3.3.2.3 Increase in oral corticosteroids after Week 40
No increase in OCS is allowed after Week 40 (except for the management of AEs or as a 
prophy laxis for adrenal insufficiency  as described below). Subjects who receive an increase in 
their OCS after Week 40 will be considered non-responders for subsequent assessments of 
disease activity .
3.3.2.4 Increase in oral corticosteroids for intercurrent disease or to prevent adrenal 
insufficiency
In addition to the burst and tapers described above, subjects who are taking ≤7.5 mg/day 
prednisone or equivalent will be allowed to receive up to an additional 7.5 mg/day  to a total of 
15 mg/day  prednisone or equivalent for a total of up to 14 day s or a single dose of IV 
hydrocortisone ( ≤100 mg hy drocortisone followed by  half that dose for 2 day s before 
returning to their usual dose) for severe illness, surgery , or s ymptoms of adrenal insufficiency  
or corticosteroid withdrawal if clinicall y warranted from Day 1 to Week 40. 
3.3.2.5 Protocol -specified steroid tapering Week 8 to Week 40
On treatment day s, tapering will start after all assessments have been completed and 
investigational product has been administered . Tapering can be started on the scheduled stud y 
visit day  (eg, Week 8 Visit) based on clinical manifestations and the laboratory values from 
the previous visit. I f laboratory  values of the current visit show SL E activity  consistent with 
exception rule No. 1 or No. 2 below, the tapering can be reversed.
Beginning at Week 8 and continuing through Week 40, steroid tapering to an OCS d ose of 
≤7.5 mg/day  MUST be attempted in all subjects with OCS dose ≥10.0 mg/day  at Baseline, 
unless at least 1 of the following criteria is met:
 SLEDAI -2K activity  which is worsened compared to baseline in major organ 
systems (renal, CNS, cardiopulmonary , vasculitis, fever, thrombocy topenia, or 
haemoly tic anaemia, or gastrointestinal activity )
 Newl y
-affected organ s ystem(s) based on the SLEDAI -2K, excluding serological 
abnormalities (dsDNA antibodies, hy pocomplementemia) 
 Moderate to severe skin disease as reflected by  a CL ASI activity  score of ≥10 
 Moderate to severe arthritis disease as reflected b y an active joint count of ≥8 tender 
and/or swollen joints
Steroid tapering must be started within 14 day s of the visit. I f steroid tapering is not attempted 
in an eligible subject, the Sponsor or Sponsor’s designee must be contacted immediately . The 
recommended steroid -tapering regimen is provided in Appendix V, but due to variability  in 
subject responses to steroid treatment and tolerability of taper Investigato rs will have 
flexibility  in how the OCS dose is reduced at each visit.

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
51(125)Investigators will not be required, but may  continue, to taper OCS dose bey ond the target of 
7.5mg/day  up to Week 40 based on disease activity . Steroid tapering will not be permitted 
after Week 40. 
A subject experiencing an increase in disease activity  secondary  to OCS tapering may  increase 
the dose up to a maximum of the baseline OCS therap y dose from Week 8 up to Week 40 
without the subject being considered a non -responder for subseq uent assessments of disease 
activity . Subjects who require OCS dose above their baseline level may  continue in the study  
but will be considered non- responders for subsequent assessments of disease activity .
3.3.3 Other restrictions
3.3.3.1 Fasting lipid profile
Subjects will be required to fast for at least 8 hours prior to assessment of lipid profile at the 
visits described in the Treatment Period Study  Plan ( Table 
3). If the subject has not fasted, 
they should fast before the next visit, and the test can be done at that visit.
3.3.3.2 Perioperative management of investigational product
Elective surgery  should be avoided during the study  if clinically  feasible.
Major surgery
Pre-operative management of investigational product: if a non- urgent major surgical 
procedure becomes necessary  during the study , it should be scheduled at least 4 weeks after 
the last administration of investigational product, if clinically  feasible. 
Non-major surgery
The decision to withhold investigational product administration is at the I nvestigator’s 
discretion. 
Post-operative management of investigational product: investigational product administration 
can be resumed at the Investigator’s discretio n after all of the following criteria are met:
 External wound healing is complete, and 
 Any postoperative antibiotic course is completed, and
 All acute surgical complications have resolved
3.4 Subject enrolment and randomisation
Investigator(s) should keep a record of subjects considered for, and included in the study . The 
pre-screening/screening log will be evaluated periodically  during routine monitoring visits. 
The Investigator(s) will:
1. Obtain signed informed consent from the potential subject before an y study-specific 
procedures are performed . The subject is considered enrolled when the ICF is 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00 005
Edition Number 5
Date 18 May 2016
52(125)signed and the enrolment call is done in the interactive voice/web response sy stem 
(IXRS).
2. Assign potential subject a unique enrolment number, beginning with ‘ ’.
3. Determine subject eligibility .During screening, the Disease Activity  Adjudication 
Group (see Section 
5.2.2 ) will confirm eligibility  criteria based on the data captured 
in the electronic data capture (EDC) s ystem and from the Central Laboratory . Sites 
will be notified to either randomise or screen fail the subject. 
4. On Day  1, the Investigator will confirm that all eligibility  criteria still are fulfil led 
(including that the “Clinical” SLEDAI- 2K score is ≥4 points [see I nclusion 
Criterion No. 9for “Clinical SL EDAI -2K” definition], OCS dose has been stable 
for the last 2 weeks) and will then perform the randomisation transaction in the 
IXRS.
5. At randomisation the IXRS will assign eligible subjects a unique randomisation 
code and blinded investiga tional product kit number(s) to the subject.
Specific information concerning the use of the IXRS will be provided in the separate user 
manual. 
Block randomisation using an IXRS will be used to randomise subjects in a 1:2:2 ratio to 
receive a fixed IV dose of 150 mg anifrolumab, 300 mg anifrolumab, or placebo. AstraZeneca 
Biostatistics group is responsible for generating the randomisation scheme for this study  using 
the GRand sy stem. 
The randomisation will be stratified using the following factors: 
 SLEDAI -2K score at screening (<10 points versus ≥10 points)
 Week 0 (Day  1) OCS dose (<10 mg/day versus ≥10 mg/day  prednisone or 
equivalent)
 Results of the IFN test (high versus low)
Investigational product (anifrolumab or placebo) should, if possible, be adminis tered the same 
day the investigational product kit number is assigned.
3.5 Methods for ensuring blinding
This is a double -blind study  in which anifrolumab and placebo are distinguishable during the 
final preparation step of the investigational infusion bag. Al l packaging and labelling of 
investigational product is done in such way as to ensure blinding for all Sponsor and 
investigational site staff other than the unblinded investigational product manager. The kits on 
the shelf, and the infusion bags when prepar ed, look identical. Since anifrolumab and placebo 
can be distinguished at the preparation step, investigational product will be prepared by  an 
unblinded investigational product manager at the site, who will not be involved in the 
management of stud y subjec ts. 

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
53(125)Neither the subject nor any  of the Investigator or Sponsor staff/designee who are involved in 
the treatment or clinical evaluation and monitoring of the subjects will be aware of the 
treatment received. In the event that the treatment allocation for a subject becomes known to 
the Investigator or other study  staff involved in the management of study  subjects, the 
Sponsor, or designee must be notified immediately  by the Investigator.
3.6 Unblinding
In the event of a medical emergency , the Investigator may  unblind an individual subject’s 
investigational product allocation. Instructions for unblinding an individual subject’s 
investigational product allocation are contained in the IXRS manual. The investigator should 
promptly  document and explain any  premature u nblinding to the sponsor , without revealing 
the treatment given to patient to the sponsor. In general, unblinding should only  occur if 
management of the medical emergency  would be different based on the subject having 
received investigational product. In t he majorit y of cases, the management of a medical 
emergency  would be the same whether or not investigational product was received b y the 
subject. If this was the case, the investigational product allocation should not be unblinded.
AstraZeneca or its designee retains the right to break the code for SAEs that are unexpected 
and are suspected to be causally  related to an investigational product and that potentially  
require expedited reporting to regulatory  authorities. Treatment codes will not be broken for 
the planned analy ses of data until all decisions on the evaluability  of the data from each 
individual subject have been made and documented.
Subjects who have been unblinded by  AstraZeneca Patient Safet y or designee (and who have 
not been unblinded to the I nvestigator or Medical Monitor) will not, based on the unblinding 
alone, be discontinued from further receipt of investigational product.
3.6.1 Unblinding for Data and Safety Monitoring Board
An independent DSMB will review safety  data throughout the study . The DSMB will be 
provided with partiall y unblinded data (data that are summarised b y treatment group using 
masked treatment group labels). The DSMB may  choose to unblind the data for additional 
review as specified in the DSMB charter. The Sponsor and the stud yteam at  will remain 
blinded to all data transfers provided to the DSMB. Details about the DSMB will be included 
in the DSMB Charter. For further details on the DSMB, see Section 6.10.1.
3.7 Discontinuation of investigational product
Subjects may  be discontinued from investigational product in the following situations:
1.
Subject decision. The subject is at any time free to discontinue treatment, withou t 
prejudice to further treatment. The primary  reason should be documented as 1 of the 
following:
(a) Subject perceives the investigational product to be ineffective
(b) Subject is unable to comply  with protocol -specified visits and/or 

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
54(125)procedures due to conflicts 
not related to clinical trial
(c) Subject perceives logistics to be unacceptable
(d) Subject wishes to participate in another clinical trial 
(e) Subject wishes to take a treatment that is not allowed in this study
(f) An AE or laboratory  abnormality  is of concern to the subject, but not 
clinically  significant to phy sician
(g) Other, please specify  reason
2. Lost to follow -up: must be documented by time and date of telephone calls, emails, 
text messages, numbers called, individuals spoken to if not subject, and at least 2 
attempts to contact the subject via certified letter
3. AE that, in the opinion of the I nvestigator or the Sponsor/Sponsor’s delegate 
Medical Monitor, contraindicates further dosing with investigational product
4. Severe non -compliance with the study  protocol 
5. The Investigator or Sponsor/Sponsor’s delegate Medical Monitor deems withdrawal 
as being in the subject's best interest
6. Pregnancy , positive pregnancy  test, or subject expresses an interest to become 
pregnant 
7. Isolated HBc positivity with HBV DNA confirmed by the central laboratory
8. Receipt of an y medications identified in Section 3.3.1.1
9. The use of restricted medications listed in Section 3.3.1.2 if the  Medical 
Monitor, in consultation with the Sponsor, determines the subject must be 
discontinued 
10. A diagnosis of active TB, premature discontinuation of treatment for latent TB, or 
noncompliance with TB therap y. Note: duration of treatment for latent TB should 
follow the local practice. If local practice is not defined, then Centers for Disease 
Control guidance should be used.
Additional restrictions related to concomitant medications are discussed in Section 3.3.1.3.
Subjects who are permanently  discontinued from further receipt o
f investigational product, 
regardless of the reason (withdrawal of consent, due to an AE, other), will be identified as 
having permanentl y discontinued treatment, and will not be eligible for the LTE study.

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
55(125)3.7.1 Subject decision to discontinue investigational p roduct 
If the subject decides to discontinue investigational product for any  reason, including but not 
limited to those outlined in Section 3.7above, the subject will not receive any  further 
investigational product. The subject may  also refuse to continue any  further study  observation. 
3.7.2 Withdrawal of the informed consent
Subjects are free to withdraw from the study  at any  time (investigational produ ct and 
assessments), without prejudice to further treatment.
A subject who withdraws consent will alway s be asked about the reason(s) (see 
Section 3.7) 
and the presence of an y AEs. The Investigator will follow
-up AEs outside of the clinical 
study . 
If a subject withdraws from participation in the study , then his/her enrolment/randomisation 
code cannot be reused. Withdrawn subjects will not be replaced. 
3.7.3 Lost to follow- up
Subjects will be considered lost to follow -up only  if no contact has been established by  the 
time the study  is completed such that there is insufficient information to deter mine the 
subject’s status at Follow -up Visit 2. A subject is considered lost to follow up when the 
following attempts to contact the subject are unsuccessful: 
 Either phone calls, faxes or emails, and 
 Having sent 2 registered letters/certified mail, and
 One attempt to check the status of the subject using publicl y available sources, if 
allowed b y local regulations
“Lost to follow -up” as a reason for study  discontinuation must be documented by  time and 
date of telephone calls, emails, text messages, numbers called, individuals spoken to if not 
subject, and documentation that 2 certified/registered letters were sent.
3.7.4 Study completion and end of study
An individual subject will be considered to have completed the study  if the subject was 
followed up until the end of the study  (Week 60, or Week 52 for those enrolling in the LTE 
study ), regardless of the number of doses of investigational product that were received. The 
end of the stud y (“stud y completion”) is defined as the date of the last protocol- specified 
visit/assessment for the last subject in the study .
3.7.5 Procedures for discontinuation of a subject from investigational product
Discontinuation of investigational product does not necessaril y mean discontinuation of 
follow -up or termination of study  participati on. Compliant subjects who are discontinued from 
the investigational product should be encouraged to continue to undergo all study -related 
visits/procedures for the full treatment period ( Table 3) in order to support the final efficacy  
and safet y analysis for anifrolumab (see Section
8). The reason for premature discontinuation 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
56(125)of investigational product will be documented in the source documents and recorded in the 
CRF.
It is essential to collect as much data as possible for all subjects throughout the study  and 
especiall y all potential endpoint e vents. Complete withdrawal from the study (ie, withdrawal 
of consent) has a direct negative impact on the potential validity  of all study
 data and should 
be avoided wherever possible. I f the subject permanently  discontinues investigational product 
prior to their completion of the study  and wishes to continue with only selected study  
assessments; prioritized assessments are listed in Section 4.2.1.
For subjects who wish to withdraw from the stud y completely refer to Section 3.7.2.
3.8 Criteria for withdrawal 
3.8.1
Screen failures 
Screening failures are subjects who have provided informed consent and who subsequently  do 
not fulfil the eligibility  criteria for the study , and therefore must not be randomised. These 
subjects should have the reason for study  withdrawal recorded as “Eligibility  Criteria Not 
Fulfilled” (ie, subject does not meet the required inclusion/exclusion criteria). This reason for 
study  withdrawal is only  valid for screen failures (not randomised subjects). Rescreening of a 
subject will be permitted once.
3.9 Discontinuation of the study
The study  may  be stopped if, in the judgment of the Sponsor, trial subjects are placed at undue 
risk because of clinicall y significant findings that:
 Meet individual stopping criteria or are otherwise considered significant (see 
Section 3.7 for reasons for discontinuation of investigational product)
 Are assessed as causall y related to stud y drug 
 Are not considered to be consistent with continuation of the study
Regardless of the reason for termination, all data available for subjects at the time of 
discontinuation of follow -up must be recorded in the CRF. 
In terminating the study , the Sponsor will ensure that adequate consideration is given to the 
protec tion of the subjects’ interests.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
57(125)4. STUDY PLAN AND TIMIN G OF PROCEDURES 
Table 2 Study plan detailing the procedures at screening
Study Period Screening
Written informed consent /assignment of X
Medical history aX
Physical examination, weight and height X
Vital signs X
ECG X
Serum chemistry, haematology, and urinalysis X
Urine protein/creatinine ratio X
ANA, anti -dsDNA antibodies, anti -Sm antibody bX
B cell count cX
Chest x- ray (only in subjects who have not had a chest x -ray within 12 weeks 
prior to signing the ICF) d X e
FSH in postmenopausal females X
Serum pregnancy test in all females of childbearing potential X
Blood test for TB fX
Hepatitis B and C X
HIV testgX
IFN test bX
Pap smear (only in females with an intact cervix who have not had a normal 
Pap smear within 2 years prior to randomisation)X e
C3, C4, CH50 complement X 
BILAG -2004 associated laboratory tests ( anticardiolipin, lupus anticoagulant, 
haptoglobin, and Coombsh)X
C-SSRS X
BILAG -2004 X i
CLASI X i
Skin photography, if applicable jX i
SLEDAI -2K X i
PGA X i
Joint count X i
TB questionnaire X

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
58(125)Study Period Screening
Assessment of AESIs X
Assessment of AEs/SAEs X
ACR classification criteria X
Concomitant medications, including SLE medications X
Verify eligibility criteria X
ACR = American College of Rheumatology; AE = adverse event; AESI = adverse event of special interest; ANA 
= antinuclear antibody; BILAG = British Isles Lupus Assessment Group; C3 = third component of complement; 
C4 = fourth component of complement; CH50 = total haemolytic complement; CLASI = Cutaneous Lupus 
Erythematosus Disease Area and Severity Index; C -SSRS = Columbia Suicide Severity Rating Scale; dsDNA = 
Double stranded deoxyribonucleic acid; ECG = electrocardiogram; PGA = Physician’s Global Assessment; SAE 
= serious adverse event; SLEDAI -2K = Systemic Lupus Erythematosus Disease Activity Index 2000; TB = 
tuberculosis
aMedical History will include details for each body system contained in the BILAG -2004 assessment 
(BILAG Related History).
bRedraw  for ANA/anti -dsDNA, or IFN test can be done w ithin the 30 -day screening window, how ever, 
results needed to determine eligibility and stratification must be available w ithin the 30 -day screening 
window  for subjects to be randomise d.
cReceipt of B cell -depleting therapy (including but not limited to, ocrelizumab, ofatumumab, atacicept,
obinutuzumab, or rituximab) <26 w eeks prior to signing the ICF (<40 w eeks for atacicept [see Appendix 
U]) and if therapy was administered ≥26 w eeks ago (40 w eeks for atacicept) ,absolute B cell less than the 
lower limit of normal or baseline value prior to receipt of B cell -depleting therapy (whichever is low er).
dAnte rio-posterior and lateral images are required whenever possible, or per standard of care.
eAssessments are allowed anytime during the screening period as long as they are completed w ithin 30 days 
after signing the informed consent form.
fInterferon -gamma release assay (IGRAs) using QuantiFERON®-TB Gold In -Tube Test (QFT -GIT) .
gSubjects within the treatment or follow -up period at the time of amendment 4 approval w ill undergo HIV 
testing at the time of amendment 4 ICF signature.
hCoom bs will be performed as applicable per BILAG assessment requirements .
iThese assessments must all be completed at the same visit (SLEDAI -2K, BILAG -2004, joint count, PGA, 
CLASI, and skin photography [if applicable]).
jPhotography will be conducted at selected sites in subjects who sign an additional optional consent, and 
have a screening CLASI score of ≥10. If no baseline skin activity or photos can be captured at the patient’s 
Screening or Day 1 vis it, no further photo graphy will be done.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
59(125)Table 3 Study plan detailing the procedures during the Treatment Period (double -blind period)
Visit Number V1aV2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13V14 
(EDV)b
Study Week W0 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52
Procedure/Visit 
Window±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D
PtGA, FACIT -F, Pain 
NRSX X X X X X X X X X X X X X
PHQ -8 X X X X X
SF-36v2 (acute) X X X X X X X X
LupusQoL, EQ -5D-5L X X X X X
WPAI -Lupus X X X X X
Medical history X
Complete physical 
examinationX X X
Focused physical 
examinationX X X X X X X X X X X
Weight X X X X X X X X X X X X X X
Assessment of 
Cushingoid featuresX X X
ECG X X
Vital signs X X X X X X X X X X X X X X
Serum chemistry, 
haematology, and 
urinalysisX X X X X X X X X X X X X X
Pap smear Xc
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
60(125)Visit Number V1aV2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13V14 
(EDV)b
Study Week W0 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52
Procedure/Visit 
Window±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D
Urine pregnancy testdX X X X X X X X X X X X X X
TB blood test
(QFT-GIT)XeXeXeX
HBV DNA fX X X X
Immunology profile X X X
Lipid profilegX X X
Cardiovascular risk 
assessmentX X
IFN TesthX X
PK blood sample 
(predose)X X X X X X
PK blood sample 
(postdose)i X X
Immunogenicity blood 
sample (predose)j X X X X X X
Proteomics/ biomarker 
blood and urine sampleX X X X X
SLEDAI -2K associated 
laboratory tests k X X X X X X X X X X X X X X
Type I IFN signature 
with 21 -gene signature 
(PD marker)X X X X X
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
61(125)Visit Number V1aV2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13V14 
(EDV)b
Study Week W0 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52
Procedure/Visit 
Window±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D
C-SSRS X X X X X X X X X X X X X X
BILAG -2004 X X X X X X X X X X X X X X
BILAG -2004 
associated laboratory 
tests lX X X X X X X X X X X X X X
CLASI X X X X X X X X X X X X X X
Skin photography, if 
applicablem X X X X X X X
SLEDAI -2K X X X X X X X X X X X X X X
Modified flare index X X X X X
SDI X X X
PGA X X X X X X X X X X X X X X
Joint count X X X X X X X X X X X X X X
Protocol -specified 
steroid tapering (if 
indicated)X X X X X X X X X
Medical Resource Use 
QuestionnaireX X X X X X X X X X X X X X
TB questionnaire X X X X X X X X X X X X X X
Assessment of 
AEs/SAEs/AESIsX X X X X X X X X X X X X X
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
62(125)Visit Number V1aV2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13V14 
(EDV)b
Study Week W0 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52
Procedure/Visit 
Window±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D
Concomitant 
medicationsX X X X X X X X X X X X X X
Verify eligibility criteria X
Randomisation X
Investigational product 
administration n X X X X X X X X X X X X X
AE = adverse event; BILAG = British Isles Lupus Assessment Group; CLASI = Cutaneous Lupus Erythematosus Disease Area and Seve rity Index; C -SSRS 
= Columbia Suicide Severity Rating Scale (C -SSRS); dsDNA = double stranded deoxyribonucleic acid; ECG = electroc ardiogram; EDV = Early 
Discontinuation Visit; FACIT -F = Functional Assessment of Chronic Illness Therapy -FATIGUE; IFN = interferon; NRS = numeric rating scale; PD = 
pharmacodynamic; PGA = Physician’s Global Assessment; PHQ -8: Personal Health Questionnaire Depression Scale -8; PK = pharmacokinetic; SAE = 
serious adverse event; SDI = Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index ; SLEDAI -2K = 
Systemic Lupus Erythematosus Disease Activity Index 2000; TB = tuberc ulosis 
aOnce screening assessments are complete, all necessary laboratory results are reported, and adjudication is complete, a subject may be randomi sed. 
There does not need to be 30 days between screening and Week 0 (Day 1).
bSubjects continuing in the LTE study will have all assessments, then receive investigational product as part of the LTE protocol.
cSubjects should have a Pap smear betw een Week 48 and Week 52 to ensure that there is no evidence of ne w cervical dysplasia. S ince access to a Pap 
smear may vary by count ry, the Sponsor recommends that local guidelines for obtaining Pap smears in subjects who have received immunomodulators 
or immunosuppressive treatment be followed.
dUrine pregnancy test in females of childbearing potential.
eOnly d one if indeterminate at screening/previous visit using the IGRAs test that was used during screening (ie, QFT -GIT).
fSubjects who are HBcAb positiv eat screening will be tested every 3 months for HBV DNA. To remain eligible forthe study, the subject ’sHBV DNA 
levels must remain below  the LLOQ as per the central laboratory .
gLipid profile (cardiovascular assessment) -subjects w ill be required to fast for at least 8 hours prior to this assessment. If a subject has not fasted, the 
assessment should be perf ormed under fasted conditions at the next visit.
hWhole blood w ill be collected in PAXgene tubes to measure the overexpression of mRNA for certain types of type I IFN -inducible genes using a 4 -gene 
test. 
iPost-dose PK samples should be drawn 15 minutes ±5minutes after the completion of investigational product administration.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
63(125)jIn order to help understand the potential drug -relatedness of any hypersensitivity or anaphylaxis reaction, possible additional ADA testing (if not already 
scheduled for the vis it) may be done.
kSLEDAI -2K associated laboratory tests are C3, C4, CH50 complement, anti -dsDNA antibodies, urine protein/creatinine ratio.
lBILAG
-2004 laboratory tests to include anticardiolipin, lupus anticoagulant, haptoglobin, and Coom bs(Coom bs will be performed as applicable per 
BILAG assessment requirements ). Note: In order to avoid having to bring the subject back for a separate phlebotomy, the anticardiolipin, lupus 
anticoagulant, and haptoglobin blood specimen swill be collected at all specified visits, however the blood w ill be stored at the central laboratory and the 
analyses performed only if the Investigator indicates that these tests need to be completed because of clinical suspicion of haemolytic anaemia or 
antiphospholipid syndrome. Direct Coom bs test samples will only be collected per the investigator's opinion and applicable BILAG assessment 
requirements for determining haemolytic anaemia.
mPhotography will be conducted at selected sites in subjects who sign an additional optional consen t, and have a screening CLASI score of ≥10. If no 
baseline skin activity or photos can be captured at the patient’s Screening or Day 1 visit, no further photography will be done.
nInvestigational product will be administered as an IV infusion via an infus ion pump over a minimum of 30 minutes.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
64(125)Table 4
Study plan detailing the procedures during Follow- up
Visit Number Follow -up Visit 1 aFollow -up Visit 2 a
Study Week 8 weeks post final dose 12 weeks post final dose
Procedure/Visit Window
EQ-5D-5L, Pain NRS,SF -36v2 (acute), FACIT -F, WPAI X
PHQ -8 X
Physical examination, weight X
Vital signs X X
Serum chemistry, haematology, and urinalysis X X
Urine pregnancy test in females of childbearing potential X X
PK blood sample X X
Immunogenicity blood sample X
Proteomics/biomarkers blood and urine sample X
TB questionnaire X X
Type I IFN signature with 21- gene assay (PD marker) X
SLEDAI -2K associated laboratory tests bX X
BILAG -2004 associated laboratory tests cX X
C-SSRS X X
BILAG -2004 X X
CLASI X X
Skin photography, if applicabledX
SLEDAI -2K X X
PGA X X
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
65(125)Visit Number Follow -up Visit 1 aFollow -up Visit 2 a
Study Week 8 weeks post final dose 12 weeks post final dose
Procedure/Visit Window
Joint count X X
Medical Resource Use Questionnaire X X
Assessment of AESIs X X
Assessment of AEs/SAEs X X
Concomitant medications X X
AE = adverse event; AESI = Adverse Event of Special Interest; BILAG = British Isles Lupus Assessment Group; CLASI = Cutaneous Lupus Erythe matosus 
Disease Area and Severity Index; EQ- 5D-5L = EuroQoL 5 dimensions; FACIT -F = Functional Assessment of Chronic Illness Therap y-FATIGUE; IFN 
= interferon; NRS = numeric rating scale; PD = pharmacodynamic; PGA = Physician’s Global Assessment; PHQ -8 = Personal Health Questionnaire 
Depression Scale -8; PK = pharmacokinetic; SAE = serious adverse event; SF -36v2 (acute) = Short Form 36 version 2 (acute recall); SLEDAI -2K = 
Systemic Lupus Erythematosus Disease Activity Index 2000; TB = tuberculosis; VAS = visual analogue scale; WPAI = Work product ivity and Activity 
Impairm ent 
aFollow -up assessments are to be completed when subjects com plete the study (eg, early termination or after the treatment period) and are not going to 
participate in the LTE study. 
bSLEDAI -2K associated laboratory tests are C3, C4, CH50 complement, anti -ds DNA, urine protein/creatinine ratio. If central laborator y results are not 
available for SLEDAI -2K associated samples drawn on the date of visit, labs should be redraw n one time within 14 days of the SLEDAI assessment 
date.
cBILAG- 2004 laboratory tests to include anticardiolipin, lupus anticoagulant, haptoglobin, and Coombs (Coombs will be performed as applicable per 
BILAG assessment requirements). Note: In order to avoid having to bring the subject back for a separate phlebotomy, the antic ardiolipin, lupus 
anticoagulant, and haptoglobin blood specimen s will be collected at all specified visits, however the blood w ill be stored at the central laboratory and the 
analyses performed only if the Investigator indicates that these tests need to be completed because of clinical suspicion of haemolytic anaemia or 
antiphospholipid syndrome. Direct Coombs test samples will only be collected per the investigator's opinion and applicable BI LAG assessment 
requirements for determining haemolytic anaemia.
dPhotography will be conducted at selected sites in subjects wh o sign an additional optional consent , and have a screening CLASI score of ≥10. If no 
baseline skin activity or photos can be captured at the patient’s Screening or Day 1 visit, no further photography will be done.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
66(125)4.1 Enrolment/Screenin g Period
At Screening, subjects are assessed to ensure that they  meet eligibility  criteria. Once the 
subject signs the 
informed consent , they  are considered enrolled in the study . Subjects who do 
not meet these criteria must not be randomised into the stud y.
Screening procedures will be performed according to the Screening Study  Plan ( Table 2), 
from Day  -30 to Day  -1. 
Once screening assessments are com plete, all necessary  laboratory  results are reported, and 
adjudication is complete, a subject may  be randomised. There does not need to be 30 day s 
between screening and Week 0 (Day 1).
Chest x -rays and Pap smears may  be completed any time during the screeni ng period as long 
as all results have been reviewed b y the Investigator prior to randomi
sation. 
If a subject does not meet eligibility  criteria on the basis of a laboratory  value then the 
laboratory  value may  be repeated once within the screening period.
4.1.1 Other considerations for screening
4.1.1.1 Oral examination
In several biological programs there have been serious infections and/or death related to 
Ludwig’s angina. Although this has not been seen in the anifrolumab program, I nvestigators 
should check a subject’ s oral cavit y and review their dental health carefully during the 
screening process. While a dental examination is not required prior to enrolment in this study , 
Investigators are cautioned to consider carefully whether subjects have active caries or a 
dental infection that might impact on subject safety prior to enrolment.
4.1.1.2 Mammography
As subjects with SL E have impaired immune response, are treated with immunosuppressants, 
and are at potential risk for malignancy , it is recommended that patients enrolled in to the 
study  are compliant and up to date with local recommendations for mammography  or other 
screening procedures for breast cancer.
4.1.2 Re-screening subjects who screen fail
If a subject fails screening for inadequate disease activity , or other reason, whic h, in the 
opinion of the I nvestigator, may  change to make the subject eligible, the subject may  be 
re-screened 1 time. In this case, the subject will re- sign the informed consent document. If the 
subject fails screening twice, they  may  not undergo further screening for this study .Initial 
screening procedures completed within the 30 days prior to subject randomisation need not be 
repeated during the re -screen visit.
Revised Clinica l Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
67(125)4.2 Treatment Period
Procedures during the Treatment Period will be performed according to the T reatment Period 
Study  Plan ( Table 
3), from Week 0 (Day  1) to Week 52. The subject- reported outcome 
assessments should be completed by  the subject (unassisted by  spouse, family  members or 
friends) prior to all other evaluations, and prior to the infusion, as disease assessments/clinical 
evaluations may  confound the results. 
Before scheduling the Week 0 (Day  1) visit, ensure notification from the Disease Activity  
Adjudication Group has been received, confirming that subject meets adjudicated eligibility  
criteria (Inclusion Criterion No. 9). The Disease Activity  Adju dication Group will review all 
data necessary  to characterise subject SLE in relation to the SLEDAI -2K, BILAG -2004, and 
PGA assessments (including central laboratory  results).
On Day  1, ensure subject meets eligibility  criteria, including Day  1 assessments according to 
the Treatment Period Study  Plan ( Table 3). 
Subjects confirmed to be eligible will be randomised. 
Subjects will have scheduled visits 
at 4-week intervals to complete protocol- specified 
assessments and investigational product administration according to the Treatment Period 
Study  Plan ( Table 3). 
The last dose of investigational product will be administered on Week 48. At Week 52, 
subjects will have an End of Treatment (EOT) visit. For subjects who prematurel y discontinue 
investigational product and are not willing to continue to partic ipate in the study  refer to 
Section 3.7.
4.2.1 Premature discontinuation of investigational product
Subjects who discontinue investigational product will be asked to return for all regular ly 
scheduled clinic visits . If the subject is unwilling to complete all regularly  scheduled clinic 
visits, the subject should complete the EDV (Week 52) visit within 4 weeks of the last dose of 
investigational product, as well as Follow -up Visit 1 and Follow -up Visit 2 (8 and 12 weeks 
after the EDV visit) unless consent is withdrawn. If the subject is unwilling to continue with 
any study  visits, including EDV,
at a minimum, the following assessments should be 
completed: 
 SLEDA I-2K and the associated laboratory tests (anti -dsDNA antibodies, C3, C4, 
CH50)
 BILAG -2004 and the associated laboratory  tests ( anticardiolipin, lupus 
anticoagulant, haptoglobin, and Coombs [Coombs will be performed as applicable 
per BILAG assessment re quirements] ). Note: In order to avoid having to bring the 
subject back for a separate phlebotomy , the anticardiolipin, lupus anticoagulant, and 
haptoglobin blood specimen swill be collected at allspecified visits, however the 
blood will be stored at the c entral laboratory  and the anal yses performed only  if the 
Investigator indicates that these tests need to be completed because of clinical 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
68(125)suspicion of haemoly tic anaemia or antiphospholipid sy ndrome. Direct Coombs test 
samples will only  be collected per th e investigator's opinion and applicable BILAG 
assessment requirements for determining haemoly tic anaemia.
 CLASI
 PGA (phy sician global assessment)
 Skin photograph y, if indicated
 Joint count
The following safet y assessments will also be completed:
 Serum chem istry, haematology , urinal ysis
 Urine for protein, creatinine and urine
-protein -creatinine ratio
 Lipid Profile defined in Section 5.3.11.1
 Immunology  Profile define d in Section 5.3.11.2
 Vital signs
 Physical examination, weight
 Adverse events including AESI s
 Cardiovascular risk assessment
 TB questionnaire
 Concomitant medications
If the subject does not agree to do this, they  will be asked if they  can be followed on a 
monthly  basis via telephone calls. At these calls, they  will be asked about AEs/SAEs, lupus 
symptoms, and lupus medications. Steroid bursts will also be captured. 
Adverse events will be followed up per Section 6.6.2 .
4.3 Unscheduled Visit
There may  be times a subject needs to have an unscheduled visit. The Investigator should 
determine the assessments to be completed based on the reason for the unscheduled v isit and 
for subject safet y. Concomitant medications and AEs should be completed whenever a subject 
has an unscheduled visit. 
If a subject presents for an unscheduled visit in lieu of a regularl y scheduled visit (ie, the 
subject is seen for safet y and eff icacy  assessments when a regularl y scheduled dosing or 
follow -up visit is missed), the I nvestigator should complete all possible safety  and efficacy  
assessments applicable to the missed visit. Unscheduled efficacy  assessments should not be 
collected in bet ween completed regular study  visits. 
4.4 Follow -up Period
Procedures will be performed according to the Follow -up Period Study  Plan ( Table 4). 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
69(125)Subjects who complete the Week 52 visit may  be eligible to participate in a L TE study . 
Subjects who complete the double -
blind treatment period will have follow- up visits at 
Week 56 and We ek 60, unless they  enrol in the LTE study . Subjects who are withdrawn from 
the study , and do not agree to complete the 52- week study  period, should complete the earl y 
discontinuation visit (Week 52 procedures) within 4 weeks of the last dose of investigati onal 
product , and be followed 8 and 12 weeks after the EDV visit by completing the Follow -up 
Visit 1 and 2 assessments (see Section 3.7).
5. STUDY ASS ESSMENTS 
5.1 Description of study procedures
A Laboratory  Manual will be provided to the sites that specifies the procedures for collection, 
processing, storage, and shipment of samples, as well as laboratory  contact information, 
specific to this clinical res earch stud y.
5.2 Efficacy assessments
Efficacy  measurements will be made at the times indicated in the Study  Plan (see Table 2for 
assessments to be perfo rmed at Screening, Table 3for Treatment Period, and Table 4 for 
Follow -up).Subject -reported outcome assessments should be completed b y the subject, 
unassisted by  spouse, family  members or friends.
5.2.1 Training and certification for Systemic Lupus Erythematosus assessments
In order to maintain consiste nt evaluation of SL E disease activity  across study  sites, training 
and certification of Investigators and designated site personnel who will be completing the 
disease evaluations listed below will be conducted.
 SLEDAI -2K
 BILAG -2004 
 PGA
 CLASI
 Swollen and t ender joint count evaluation
The SL EDAI -2K, BILAG -2004, PGA, and CLASI  must be administered by  the Investigator 
or another qualified ph ysician, unless prior sponsor approval has been obtained for an y other 
clinically  trained site personne lwith documentation of adequate assessment experience per the 
study  central review plan . The joint count evaluation can be completed by  other site personnel 
who, as per Investigator discretion, are qualified to perform the assessments and have at least 
1 year of experience administering the joint count evaluation. Training will include printed 
training materials, digital video disks (DVDs) and formal presentations, as well as web -based 
training modules.
Revised Clinical Study Proto col
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
70(125)After attending stud y presentations (ie, Investigator Meeting) or after completion of online 
training modules, all Investigators and designated site phy sicians must pass an online 
examination in order to obtain certification for all disease evaluation assessments, with the 
exception of the joint count evaluat ion. Investigators and designated site personnel must be 
trained and certified prior to subjects entering screening at their respective sites. All 
assessments and certifications must be renewed via the study
 online training website prior to 
expiration and must remain current (not expire) throughout the course of the study. If there is 
a change in site personnel over the course of the study , new Investigators or phy sicians must 
be certified prior to performing the SLEDAI -2K, BILAG -2004, PGA, and CL ASI 
assess ments.
It is expected that the Investigator will ensure all joint count assessors have adequate 
experience (minimum of 1 y ear) and training qualifications to perform the swollen and tender 
joint count assessment. Assessors (including an y new Investigators or site personnel) must 
complete the online joint count training module and obtain certification prior to performing 
any joint assessment. 
Documentation of all training will be maintained in the site’s study  file.
Over the course of the study , Investigator assessments for a given subject should be completed 
by the same trained and/or certified Investigator, designated phy sician, or qualified site 
personnel (as described above) whenever possible.
5.2.2 Disease Activity Adjudication Group
has a Dise ase Activity  Adjudication Group who are medicall y-qualified individuals 
and/or support staff who assist in the ongoing management of this trial. The Disease Activity  
Adjudication Group will review all data necessary to characterise subject SLE in relation to 
the SL EDAI -2K, BILAG -2004, and PGA assessments (including central laboratory  results); 
however, the group will remain blinded for the duration of the study . Adjudication group 
members will have access to an independent expert on SL E disease activity  indices for 
unanticipated issues with regard to interpretation of these indices.
The Disease Activity  Adjudication Group will be utilised to confirm eligibility  during 
screening and will be utilised throughout the stud y to confirm SL EDAI -2K, BILAG -2004, and 
PGA scoring. The Adjudication Group will also ensure that the completion of efficacy  
assessments by  Investigators is of proper qualit y and consistency. 
If there is inconsistency  between assessments, additional clarification and training on these 
assessment s will be provided through the Disease Activity  Adjudication Group. 
5.2.3 Systemic Lupus Erythematosus Disease Activity Index 2000 
The SL EDAI -2K disease activity  index (see Appendix E) consists of a list of organ 
manifestations, each with a definition. A certi fied Investigator or designated phy sician will 
complete the SLEDAI- 2K assessment and decide whether each manifestation is “present” or 

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
71(125)“absent” in the last 4 weeks. The assessment also includes the collection of blood and urine 
for assessment of the labora tory categories of the SL EDAI -2K.
The SL EDAI -2K assessment consists of 24 lupus -
related items. It is a weighted instrument, in 
which descriptors are multiplied by  a particular organ’s “weight”. For example, renal 
descriptors are multiplied by  4 and central nervous descriptors b y 8 and these weighted organ 
manifestations are totalled into the final score. The SL EDAI -2K score range is 0 to 105 points 
with 0 indicating inactive disease. The SLEDAI- 2K scores are valid, reliable, and sensitive 
clinical assessmen ts of lupus disease activit y. The SL EDAI -2K calculated using a timeframe 
of 30 day s prior to a visit for clinical and laboratory values has been shown to be similar to the 
SLEDAI -2K with a 10 -day window ( Touma et al, 2010 ). A timeframe of 28 day s will be used 
in this study .
The “Clinical” SLEDAI- 2K score is the SLEDAI -2K assessment score without the inclusion 
of points attributable to any  urine or labora tory results including immunologic measures. Its 
use may  permit earlier clinical decisions to be made without waiting for immunologic 
measures (including anti- dsDNA antibodies and C3, C4, and CH50 complement levels). 
However, in an y circumstance where the “Clinical” SL EDAI -2K score is used, sites must 
subsequently  update the SL EDAI -2K assessment when laboratory  data become available so 
that the full SL EDAI -2K score is made available to the Sponsor.
A quick Reference Guide will be provided to all study  perso nnel, which contains detailed 
protocol -specific clarifications and extensions of SL EDAI -2K clinical parameter definitions 
and a guidance for correlating SLEDAI 2K and BILAG-2004 clinical parameters.
5.2.4 British Isles Lupus Assessment Group -2004 
The BILAG -2004 is a translational index with 9 organ s ystems (General, Mucocutaneous, 
Neurops ychiatric, Musculoskeletal, Cardiorespiratory, Gastrointestinal, Ophthalmic, Renal 
and Haematology ) that is able to capture changing severit y of clinical manifestations (see 
Appendix F). It has ordinal scales by  design and does not have a global score; rather it records 
disease activity  across the different organ s ystems at a glance by  comparing the immediate 
past 4 weeks to the 4 weeks preceding them. It is based on the principle of phy sicians’ 
intention to treat and categorises disease activity  into 5 different levels from A to E:
 Grade A represents very  active disease requiring immunosuppressive drugs and/or a 
prednisone dose of >20 mg/day  or equivalent
 Grade B represents moder ate disease activit y requiring a lower dose of 
corticosteroids, topical steroids, topical immunosuppressives, antimalarials, or 
NSAIDs
 Grade C indicates mild stable disease
 Grade D implies no disease activity  but the s ystem has previousl y been affected
 Grade E indicates no current or previous disease activity
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
72(125)Although the BILAG -
2004 was developed based on the principle of intention to treat, the 
treatment has no bearing on the scoring index. Only  the presence of active manifestations 
influences the scoring .
5.2.4.1 Protocol -specific clarification and extension of BILAG -2004 definitions
A quick Reference Guide will be provided to all study  personnel, which contains detailed 
protocol -specific clarifications and extensions of BILAG -2004 clinical parameter definitions 
and guidance for correlating SLEDAI 2K and BILAG -2004 clinical parameters. Please refer 
to this guide when completing disease activity  assessments. I mportant extensions of selected 
BILAG -2004 glossary  definitions are included as follows:
Protocol -specific extensions of BILAG -2004 and SL EDAI -2K clinical parameter definitions:
(i) BILAG -2004 A or B score in the musculoskeletal organ s ystem due to active 
polyarthritis, defined as follows:
“BILAG -2004 A”: severe arthritis (BILAG -2004 #41) manifested by  observed 
active s ynovitis in ≥2 joints with marked loss of functional range of movements 
and significant impairment of basic activities of daily  living (ADL), that has 
been present on several day s cumulatively  over the past 4 weeks, including at 
the time of the Screening visit. Basic ADL are defined as the following 
activities which require assistance or assistive devices (at least 1 must be present 
and documented in source): ambulation, toileting, grooming including bathing, 
dressin
g, feeding oneself (not responsive to steroids up to 10 mg/day , 
antimalarials, NSAIDs).
“BILAG -2004 B”: moderate arthritis or tendonitis or tenosy novitis 
(BILAG -2004 #42) defined as tendonitis/tenosy novitis or active synovitis in 
≥1joint (observed or thro ugh history ) with some loss of functional range of 
movements which leads to some loss of functional range of motion as 
manifested b y effects on instrumental ADL s (such as cooking, driving, using the 
telephone or computer, shopping, cleaning, etc), which ha s been present on 
several day s over the last 4 weeks and is present at the time of the Screening 
visit.
(ii) BILAG -2004 and SLEDAI -2K “lupus headache”: lupus headache is rare, migraine, 
tension or cluster headaches should not be recorded. L upus headache should only be 
recorded if it is disabling, lasts at least 3 day s, and does not respond to narcotics. I t 
is expected that its severity  would prompt formal testing (lumbar puncture, 
magnetic resonance imaging [MRI ], computed tomograph y [CT], etc) and require 
corticosteroids and/or immunosuppressants and potentially  hospitalisation for 
treatment. Lupus headache is considered a manifestation of lupus cerebritis.
5.2.5 Physician Global Assessment 
A trained and certified Investigator will complete the PGA (see 
Appendix G) . The PGA 
represents the ph ysician’s overall assessment of average SLE disease severity  on a VAS scale 
Revised Clinical Study Protocol
Drug Substance Anifroluma b (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
73(125)with 0 (no disease) to 3 (severe) disease activity
 over the last 4 weeks. The PGA for a given 
subject should be completed by  the same phy sician whenever possible.
The PGA is a modification of the classic analogue scale in that it is anchored with numbers 
from 0 to 3 demarcating no, mild, moderate and severe disease. The number 3 indicates severe 
disease and is at the end of the scale. This refers to the mo st severe possible disease, and does 
not reflect the most severe seen in a particular subject, but the most severe disease ever seen in 
all SL E subjects. Therefore, the line made b y the phy sician along this scale should virtually  
never get to this edge. An y disease rated greater than 2.5 is very  severe. The range of 
moderate disease covers approximately  1.5 to 2.4. Mild disease falls below 1.5. The 
instrument is similar to a logarithmic scale, with greater distances or demarcations possible 
among more mild
-moderate symptoms. 
When scoring the PGA, the score from the previous visit should be reviewed and the mark 
should be moved relative to the score from the previous visit. This is a global assessment, 
factoring in all aspects of the subject’s lupus disease activity . It should not reflect non -lupus 
medical conditions.
5.2.6 Oral corticosteroid reduction
Please refer to Section 3.3.2 for all information regarding steroid tapering. 
5.2.7 Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index 
The SDI has been developed to assess irreversible damage in SLE subjects independentl y of 
its cause (SLE activit y, therap y, comorbidities) but occurring after disease onset (see 
Appendix H). Damage, ie, irreversible impairment since onset of SL E is usually  defined as a 
clinical feature that has to be continuously present for at least 6 months to score. In addition 
some irreversible events such as MI or a cerebrovascular accident score as damage on their 
occurrence. Briefl y, damage is defined for 12 organ systems; peripheral vascular, ocular, 
neurops ychiatric, renal, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, s kin, 
endocrine (diabetes), gonadal, and malignancies. Damage over time can be stable or increase, 
to a maximum of 47 points, however there should be no decrease in the number of points 
(Schwartz et al, 2009 ).
5.2.8 Cutaneous Lupus Erythematosus Disease Area and Severity Index 
inflammatory disease activity 
The CL ASI is a validated index used for assessing the cutaneous lesions of SL E and consists 
of 2 separate scores: the first summarises the inflammatory  activity  of the disease; the second 
is a measure of the damage done b y the disease (see Appendix I). The activity  score takes into 
account ery thema, scale/hy pertrophy , mucous membrane lesions, recent hair loss, and non-
scarring alopecia. The damage score represents d yspigmentation, 
scarring/atroph y/panniculitis, and scarring of the scalp. Subjects are asked if their 
dyspigmentation lasted 12 months or longer, in which case the d yspigmentation score is 
doubled. Each of the above parameters is measured in 13 different anatomical locations, 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
74(125)included specifically  because they  are most often involved in cutaneous lupus ery thematosus 
(CLE). The most severe lesion in each area is measured.
5.2.9 Skin photography
Skin photograph y is an optional assessment. Subjects will sign an additional consent for 
photograph y if they agree to participate in these assessments. Photograph ywill be conducted 
at selected sites in subjects who sign an additional consent, and have a screening CLASI score 
of ≥10. 
Site staff will be trained to take photographs. The person who performs the CL ASI will 
identify  a single, active skin lesion (the tar get lesion) that is suitable for being photographed, 
and is considered to be the most significant inflammatory  lesion due to SL E. The same target 
lesion will be photographed throughout the study  at time points specified in the Study  Plan 
(Table 
2, Table 3, and Table 4). If no baseline skin activity or photos can be captured at the 
patient’s Screening or Day 1 visit, no further photography  will be done. In addition to the 
target lesion, photograph(s ) including the anatomic area (eg, arm, back, scalp) with the target 
lesion should also be taken. If feasible, photographs of other areas with active skin disease 
should also be taken to demonstrate changes in the overall burden of cutaneous disease 
activi ty. Additional details about photograph y are provided in the photography  manual. 
5.2.10 Joint count
The swollen and tender joint count is based on left and right shoulder, elbow, wrist, 
metacarpophalangeal (MCP) 1, MCP2, MCP3, MCP4, MCP5, proximal interphalangea l (PIP) 
1, PI P2, PI P3, PIP4, PI P5 joints of the upper extremities and left and right knee of the lower 
extremities. Conventionally , an active joint for the SL EDAI -
2K calculation is defined as a 
joint with pain and tenderness and at least 1 of the following (warmth, ery thema, swelling, or 
effusion) ( Merrill, 2014 ). However, in this study  an active joint for the joint count assessment 
is defined as a joint with tenderness and swelling only .
Each of 28 joints will be then be 
evaluated separately  for tenderness (by  palpating the joint) and swelling. Joints with intra -
articular injection within 4 weeks are not evaluable for the assessment.
The joint count asse ssment will include questions regarding limitation of range of movements 
and effects of joint symptoms on basic and functional ADLs.
5.3 Safety assessments
Key safety  assessments are AEs, AESIs, vital signs, phy sical examination, safet y laboratory 
tests, and E CGs. Safet y assessments will be made at the times indicated in the Study Plan (see 
Table 2 for assessments to be performed at Screening, Table 3 for Treatment Period, and 
Table 4 for Follow -up).Subject -reported outcome assessments should be completed b y the 
subject, unassisted by  spouse, family  members or friends.
5.3.1 Adverse events
Adverse events, SAEs, and AESI s are defined in Sections 6.1, 6.2, and 6.5, respectivel y.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
75(125)Record ing of AEs is described in Section 6.6and reporting of SAEs in Section
6.7.
5.3.2 Vital signs
Vital signs (oral temperature, blood pressure [BP], pulse rate, and respiratory  rate) will be 
obtained at each visit. Specific information on vital signs surrounding the infusion is included 
in Section 7.2.4
(Subject Monitoring/Procedures During and After Infusions).
5.3.3 Physical examination
Body height will be captured at scre ening onl y. Subjects will be weighed at each stud y visit. 
Medically  significant changes from the Screening phy sical examination will be recorded as 
AEs.
5.3.3.1 Complete physical examination
A complete ph ysical examination will be performed at the visits specified in the Study  Plan 
(Table 2, Table 3, and Table 4), and will include an assessment of the following: general 
appearance, head and neck, breast, respiratory , cardiovascular, abdomen, 
musculoskeletal /extremities, neurological, skin, lymph nodes, and thy roid.
5.3.3.2 Focused physical examination
The focused ph ysical examination will include an assessment of the organ sy stems required to 
complete protocol -specified assessment tools (SLEDAI -2K, BILAG -2004, join t count, and 
CLASI). Additional assessments should be done as clinically  indicated. Abnormal findings 
will be recorded as part of AE, SAE, AESI, or lupus activity , as appropriate. 
5.3.3.3 Pap smear
Most cases of cervical cancer appear to be related to infection w ith papilloma virus. Because 
of the potential for viral reactivation due to blockade of the interferon pathway , we are 
assessing cervical d ysplasia in this study , although to date there has been no signal in the 
anifrolumab studies. 
Abnormal Pap smear res ults received an ytime within the 2 y ears prior to randomisation must 
be repeated to ensure subject eligibility . If a Pap smear performed within 2 y ears prior to 
randomisation was normal with no documented malignancy  (eg, CIN III, CIS, or AI S), it does 
not need to be repeated. Subjects with abnormal Pap smear results of aty pical squamous cells 
of undetermined significance (ASC -US), atypical squamous cells where high -grade squamous 
intraepithelial lesion (HSIL) cannot be ruled out (ASC- H), at ypical glandular cells (AGC), or 
CIN grades I and II (CIN I  and II) will be allowed to enter the study ; please refer to Appendix 
X for guidance.
Subjects should have a Pap smear between Week 48 and Week 52 to ensure that there is no 
evidence of new cervical dy splasia. Since access to a Pap smear may  vary  by count ry, the 
Sponsor recommends that local guidelines for obtaining Pap smears in subjects who have 
received immunomodulators or immunosuppressive treatment be followed. If a Pap smear was 
performed between Week 48 a nd Week 52 and was not normal but show edno evidence of 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
76(125)malignancy  (eg, CIN III, CI S, or AIS), it should be repeated as per the patient’s 
gynaecologist’s recommendations. If the patient’s gynaecologist has recommended a repeat 
Pap smear be performed at a s
pecified interval, the Pap smear should be obtained as 
recommended and the report provided in the source document.
5.3.3.4 Assessment of Cushingoid features
Subjects will be assessed for Cushingoid features at the visits specified in the Treatment 
Period Study  Plan ( Table 3). Features, such as moon face, buffalo hump, purple or violaceous 
striae, central obesit y, hirsutism, acne, eas y bruising, and fragile sk in, will be captured 
separately  to evaluate whether resolution of same can occur overtime with OCS reduction.
5.3.4 Assessment of cardiovascular risk
To understand the contribution of the chronic inflammatory  response in SLE to dy slipidaemia 
(as a potential risk for accelerated subclinical arteriosclerotic cardiovascular disease) and the 
potential effects of anifrolumab treatment, both lipid (including LDL and HDL , trigl ycerides 
[see Section 5.3.11.1]) and inflammatory  profiles will be obtained during the study . Various 
risk factors for atherosclerosis will be assessed as part of the subject demographics at 
screening according to the Adult Treatment Panel (ATP) III Guidelin es. Current and previous 
concomitant medications received for cardiovascular indications should be collected and 
recorded.
5.3.5 Columbia Suicide Severity Rating Scale 
The C -
SSRS is a unique, simple, and short method of assessing both behaviour and ideation 
that tracks all suicidal events, and provides a summary  of suicidality  (Posner et al, 2007 ). It 
assesses the lethality of attempts and other features of i deation (frequency , duration, 
controllability , reasons for ideation, and deterrents), all of which are significantly  predictive of 
completed suicide (see Appendix J). 
The C -SSRS will be administered at all study  visits by  a trained rater. The trained rate r will 
record the clinical observation on the scale, which will be used as the source document. If at 
all possible, the same individual should perform the assessment at each visit to reduce scoring 
variability . In the event the primary  rater is not available, a designated back- up rater who 
meets the same qualifications may  perform the C -SSRS. An I nvestigator phy sician will review 
completed C -SSRS responses on the day  of assessment and document review within the 
source. 
If a subject indicates having a ratin g of t ype 4 or 5 suicidal ideation on the C -SSRS suicidal 
ideation scale at an y time since the previous visit when the C -SSRS was administered or 
indicates having had an y suicidal behaviour since the previous visit, the subject should be 
referred to a mental health professional immediately . If the C -SSRS is administered by  a rater 
other than the Primary  Investigator, it is recommended that the Primary  Investigator confirms 
suicidal ideation before making a referral to mental health services; however this sh ould not 
delay  the referral. 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
77(125)5.3.6
Personal Health Questionnaire Depression Scale-8
The PHQ -8 consists of 8 of the 9 criteria on which the DSM -IV diagnosis of depressive 
disorders is based ( American Psy chiatric Association, 1994, see Appendix K). It assesses 
symptoms of depression over the last 2 weeks. The PHQ -8 is completed b y the subject and 
scored b y the Investigator at visits specified in the Treatment a nd Follow -up Study  Plans 
(Table 3 and Table 4). In addition to the 8 questions on depression, there is also a non -score d 
question to assess how the depressive s ymptoms affect the subject’s level of functioning.
5.3.7 Electrocardiogram 
Digital ECGs (dECG) for all subjects at all centres will be conducted at the centre using a 
machine provided b y the central ECG vendor and will b e transmitted to the central ECG 
laboratory . Digital ECGs will be performed at Screening, Randomi sation, and at Visit 14 
(Week 52). Digital ECGs will be performed in triplicate at Randomisation and at Visit 14 
(Week 52) . Digital ECGs will be obtained after the subject has been resting in a supine 
position for at least 10 minutes. All dECGs will be documented b y recording the date, time, 
heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval. The 
corrected QT intervals will be calc ulated using the Fridericia formula.
The Investigator will judge the overall interpretation as normal or abnormal. I f abnormal, it 
will be decided as to whether or not the abnormality  is clinicall y significant or not clinically 
significant and the reason f or the abnormality  will be recorded on the eCRF, if the Investigator 
considers it clinically  significant. Abnormal values shall not be recorded as AEs unless 
deemed clinicall y significant.
Quality  assurance of the ECG waveform and subject demographics will be conducted b y a 
central ECG laboratory  operator at the central ECG laboratory . Electrocardiogram reports will 
be provided to the stud y sites once the analy sis is complete. It is the Investigator’s judgment 
whether the findings/results on the central ECG laboratory  report are clinically  relevant or not. 
5.3.8 Tuberculosis screening and monitoring
5.3.8.1
Screening evaluation
A blood test for TB will be done at screening using the interferon -gamma release assay  
(IGRAs) test (ie, QuantiFERON®-TB Gold In -Tube Test [QFT- GIT]). Evaluation of all 
subjects by  QFT -GIT test will be performed b y the central clinical laboratory, and chest x -rays 
will be completed at screening. If an adequate (anterio- posterior and lateral or per local 
standard of care) chest x -ray was performed within 12 weeks prior to signing the ICF, it does 
not need to be repeated at the Screening 
visit. 
Compared to culture confirmed TB, overall, 87.6% of subjects have a positive QFT -GIT result 
(Cellestis, 2005). The false negative rate in this setting appears to be over 12%. Further, the 
performance of the test in the setting of immunosuppressant drugs has not been evaluated. Nor 
has it been evaluated in i ndividuals with medical conditions other than, or in addition to, latent 
TB or tuberculosis disease. The guide also states that “Medical treatments or conditions that 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
78(125)impair immune functions can potentiall y reduce IFN -
γ responses and prevent detection of a
specific response to the (secretory  proteins) ESAT -6 and CFP -10 (the test stimulators)”.
Given the population to be enrolled in the SLE study , false negative tests are possible, so a 
chest x- ray is a relevant technique for detecting active pulmonary  disease and minimising 
potential risk to study  subjects. 
5.3.8.2 Tuberculosis results from screening evaluations
 If the screening QFT -G test is negative and there is no known history  of recent 
exposure t o individuals with active TB, and chest radiograph shows no evidence of 
active TB, the subject may be randomised without prophy laxis.
 If the screening QFT -G test is newly positive and chest radiograph shows no 
evidence of active TB, and the subject has no symptoms or medical history  
consistent with active TB, the subject must have a retest, and if retest is positive, the 
subject must start on prophylaxis prior to randomisation.
 If the screening QFT -G test is positive at the initial Screening visit, but the subject 
is not newly positive as of the initial Screening visit , the subject must have been 
diagnosed with latent TB and must have documentation confirming completion of 
appropriate treatment. Subject s with no history  of latent TB prior to the initial 
Screening visit, but who are diagnosed with latent TB during screening, may  be 
considered eligible if appropriate treatment is initiated prior to randomisation. Such 
subject s may  be re -screened if necessary  to allow for local guidelines on latent TB 
treatment 
initiation.
 If the screening QFT -G test is indeterminate, the test must be repeated at least 1 
time by  the central laboratory  as soon as possible. 
If the result remains indeterminate, the chest radiograph shows no evidence of 
active TB, there are no signs or s ymptoms of active TB, no recent contact with 
anyone with active TB, and there is no history  of latent (unless diagnosed with 
documentation of c ompletion of appropriate treatment) or active TB, the subject 
may be randomised and will have additional QFT -G testing performed 
according to the Stud y Plan (Table 2, Table 3, and Table 4). Additionall y, in the 
opinion of the I nvestigator and after discussion with the medical monitor, an 
expert specialising in TB may  be consulted prior to randomisation. 
5.3.8.3 Tuberculosis monitoring during the study
If, during the trial a subject who had an indeterminate TB result at screening is determined to 
have a:
 Positive QFT -G test result, the subject should be referred to a TB specialist. If a TB 
specialist is not available, the local country  guidelines should be followed for 
further diagnostic work up and anti- TB treatment regimens. If no local guidelines 
exist for immunocompromised individuals, then USA guidelines may  be followed. 
This should also be reported as an AESI.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
80(125)performed at the site using a dipstick. Abnormal safet y laboratory
 results should be repeated 
as clinically  indicat ed, as soon as possible (preferably  within 24 to 48 hours).
Additional safet y samples may be collected if clinically indicated at the discretion of the 
Investigator. 
Every  attempt should be made to redraw an y missing safet y laboratory  tests, even if the 
subject has received the investigational product. 
The Investigator should make an assessment of the available results with regard to clinicall y 
relevant abnormalities. The laboratory  results should be signed and dated and retained at the 
centre as source data for laboratory  variables. For information on how AEs based on 
laboratory  tests should be recorded and reported, see Section 6.6.6.
In case a subject shows an AST orALT ≥3xUL N ortotal bilirubin ≥2xULN please refer to 
Appendix C
, ‘Actions Required in Cases of Combined Increase of Aminotransferase and Total 
Bilirubin –Hy’s Law’, for further instructions.
The following laboratory variables will be measured:
Table 5 Clinical laboratory tests
Screening
ANA, anti -dsDNA antibodies, anti -Sm antibody, anti-RNP, anti -Sjogren’s Syndrome -related antigen A 
[SSA], and anti -Sjogren’s Syndrome -related antigen B [SSB] 
HbA1c in diabetic subjects only
Peripheral blood B lymphocyte count (only for subjects who received B cell -depleting therapy prior to 
signing the ICF, including but not limited to ocrelizumab, ofatumumab, atacicept, obinutuzumab, or 
rituximab)
BILAG -2004 associated laboratory tests analysed for all subjects at screening (anticardiolipin, lupus 
anticoagulant, haptoglobin, and Coombs [Coombs will be performed as applicable per BILAG 
assessment requirements])*
Hepatitis B surface antigen
Hepatitis B core antibody (reflex DNA testing if isolated HBc po sitive)
Hepatitis C antibody 
HIV test **
CK 
C3, C4, CH50 complement
Urine protein/creatinine ratio
QFT -G test
Haematology
Haematology/Haemostasis (whole blood)
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
81(125)WBC count with differential
RBC count
Haematocrit
Haemoglobin
Platelet count
MCV
MCHC
Serum Chemistry 
Calcium
Chloride
Potassium
Sodium
AST*
ALT*
ALP*
GGT
BUN
Creatinine
Total bilirubin* (reflexively fractionated if elevated)
Glucose
Albumin
CK 
*Note for serum chemistry: Tests for AST, ALT, ALP, and total bilirubin must be conducted concurrently and 
assessed concurrently.
Urinalysis
Colour
Appearance
Specific gravity
pH
Protein dipstick
Glucose
Ketones
Blood
Bilirubin
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
82(125)Microscopy including WBC/HPF, RBC/HPF, casts
Urine creatinine and protein, urine protein/creatinine ratio
Pregnancy Test 
Serum β -hCG (at screening  only)
Urine β -hCG (at every visit after screening, using a dipstick)
Serum FSH (at screening only) in postmenopausal females with menses absent for ≥1 year
Disease Evaluations
SLEDAI -2K-associated laboratory tests (C3, C4, CH50 complement, anti- ds DNA, urine 
protein/creatinine ratio)
Note: If central laboratory results are not available for SLEDAI -2K associated tests, samples should be 
redrawn one time within 14 days of the SLEDAI assessment date.
BILAG -2004 associated laboratory tests, including anticardiolipin, lupus anticoagulant, haptoglobin, 
and Coombs (as applicable). Coombs will be performed as applicable per BILAG assessment 
requirements.*
ALP = Alkaline phosphatase; ALT = alanine aminotransferase; ANA = antinuclear antibody; Anti -Sm = Anti -
Smith; AST = aspartate aminotransferase; β -hCG = β -human chorionic gonadotropin; BUN = blood urea 
nitrogen; BILAG = British Isles Lupus Assessment Group; C3 = third component of com plem ent; C4 = fourth 
component of complement; CH50 = total haemolytic complement; CK = creatine kinase; DNA = 
Deoxyribonucleic acid; GGT = gamma glutamyl transferase; HbA1c = Glycosylated haemoglobin; HBc = 
Hepatitis B core antibody; HPF = high power field ; MCHC = Mean corpuscular haemoglobin concentration; 
MCV = Mean corpuscular volume; QFT -G = QuantiFERON -TB Gold; RBC = red blood cell; SLEDAI -2K = 
Systemic Lupus Erythematosus Disease Activity Index 2000; WBC = w hite blood cell
*In order to avoid having t o bring the subject back for a separate phlebotomy, the anticardiolipin, lupus 
anticoagulant, and haptoglobin blood specimens will be collected at all specified visits, however the blood w ill 
be stored at the central laboratory and the analysis performed o nly if the investigator indicates that these tests 
need to be completed because of clinical suspicion of haemolytic anaemia or anti phospholipid syndrome. Direct 
Coom bs test samples will only be collected per the investigator's opinion and applicable BILAG assessment 
requirements for determining haemolytic anaemia.
**Subjects within the treatment or follow -up period at the time of amendment 4 approval will undergo HIV 
testing at the time of amendment 4 ICF signature.
5.3.11 Laboratory assessments for cardiovascular risk assessments
5.3.11.1 Fasting lipid profile
Subjects will have a fasting lipid profile (high density  lipoprotein cholesterol, low density  
lipoprotein cholesterol, and trigl ycerides) completed at times indicated in the Study Plan 
(Table 2, Table 3, and Table 4). Subjects will be required to fast for at least 8 hours prior to 
this as sessment (see Section
3.3.3).
5.3.11.2 Immunology profile
Subjects will have tests to determine immunology profile (ANA, anti -Sm, anti -RNP, 
anti-SSA, and an
ti-SSB), and quantitative immunoglobulins completed at times indicated in 
the Study  Plan (Table 2, Table 3, and Table 4). 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
83(125)5.4 Clinical pharmacology assessments
Clinical pharmacology  assessments will b
e made at the times indicated in the Study  Plan 
(Table 2, Table 3, and Table 4).
5.4.1 Pharmacokinetics 
For the PK anal ysis it is important that the date, start and stop time for the IV infusion, and the 
sample collection time are recorded. Instructions for sample collection, processing, storage, 
and shipment can be found in the separate laboratory manual provided to the centres. Serum 
will be collected according to the Study  Plan ( Table 3and Table 4 ). Post -dose samples should 
be collected 15 minutes ±5 minutes after completion of investigational product administration
after dosing on Week 0 (Day  1) and Week 48. Post -dose specimens should not be drawn 
through the IV line used to administer the investigational product.
Samples for determination of anifrolumab concentration in serum will be analy sed b y a central 
laboratory  on behalf of the Spon sor, using a validated bioanal ytical method. 
5.4.2 Immunogenicity
Instructions for immunogenicity  (anti -drug antibodies [ADA] and neutralising antibodies 
[nAb]) sample collection, processing, storage, and shipment can be found in the separate 
laboratory manual provided to the centre s.
5.4.2.1 Anti -drug antibodies 
The pre -dose serum samples to measure presence of ADA will be collected according to the 
Study  Plan (Table 3 and Table 4). The presence or absence of ADA will be determined in the 
serum samples using validated bioanal ytical methods. In order to help understand the potential 
drug-relatedness of any  hypersensitivity  or anaph ylaxis reaction, possible additional ADA 
testing (if not alread y scheduled for a visit) may be collected and anal ysed.
5.4.2.2 Neutral ising antibodies
Neutralising antibodies testing will only  occur on samples that are ADA positive. Samples 
that are ADA negative will not be tested for nAb. The presence or absence of neutralising 
ADA will be determined using a validated bioanalytical meth od. 
5.4.3 Pharmacodynamics 
Type I IFN inducible signature in whole blood will be assessed b y a 21 -gene assay  to be used 
as a PD marker to follow the biologic effect of anifrolumab on its target throughout the study . 
Whole blood will be collected for RNA isolat ion at the visits indicated in the Study  Plan 
(Table 
2, Table 3, and Table 4) in order to evaluate the mRNA expression levels of 21 t ype I 
IFN-inducib le genes. The remaining mRNA from the PD sample may  be utilised for 
additional biomarker work to further characterise the effects of anifrolumab on its target. 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
84(125)5.4.4 Interferon test in whole blood
Whole blood will be collected at screening in PAXgene tubes to m easure the overexpression 
of mRNA for certain t ypes of ty pe I IFN -inducible genes using a 4 -gene test. The IFN test and 
the data will be evaluated for development of a companion diagnostic. The IFN -
4-gene testing 
will be conducted at a designated central laboratory under a separate device test site protocol 
provided b y the device sponsor (QIAGEN). The QIAGEN therascreen®interferon -inducible 
gene expression (IFIGx) Rotor -Gene Q (RGQ) reverse transcriptase pol ymerase chain 
reaction (RT -PCR) Sy stem will be us ed, it comprises the following:
 PAXgene™Blood RNA Tubes (sample collection)
 PAXgene™Blood RNA Kit (RNA sample preparation)
 Therascreen IFIGx RGQ RT- PCR Kit used with the RGQ molecular diagnostic 
Platform with bespoke IFIGx software (sample testing)
The t herascreen IFIGx RGQ RT-PCR Kit will be labelled as per 21 CFR 809 .10 (c)(2)(ii), 
“For Investigational Use Only.” The performance characteristics of this product have not been 
established.
The primary  intent is to prospectivel y identify subjects as “test- high” or “test -low” for the 
purpose of randomisation. The results of this test will be used to stratify  subjects. The kit uses 
the expression of the genes IFI27, IFI44, IFI44L and RSAD2 compared with 3 reference 
genes; 18S, ACTB and GAPDH. The result is ex pressed as a score that is compared with a 
pre-established cut -off that classifies subjects into 2 groups with low or high levels of IFN 
inducible gene expression. The results of the test will not be used to determine eligibility  and 
will not be shared wit h the investigative site (ie, all site personnel will remain blinded to I FN 
test results). The assay  is not intended for prediction of response to anifrolumab in other 
diseases. 
5.4.5 Proteomics/biomarkers
Renal disease develops in more than half of SLE subject s. However, the onset of lupus 
nephritis is commonly  insidious and thus, early  diagnosis and treatment of lupus nephritis are 
difficult. Many  studies have shown the presence of inflammatory  proteins in the urine of lupus 
nephritis subjects and the correlat ion of such proteins with disease severit y/activity  and/or 
histological results. However, there are very  few studies that have evaluated the differences in 
urine proteomics between subjects with active lupus nephritis requiring treatment and subjects 
with either minimal or inactive renal disease. Understanding how anifrolumab impacts on 
urine proteomics should expand our insights regarding the effects of anifrolumab on the 
kidney  in subjects with SLE. 
Urine samples will be collected according to the time points outlined in the Study  Plan ( Table 
3and 
Table 4) . Approximately  30 to 40 mL of urine will be collected from each subject at the 
specified visits. Baseline urine samples will be used to assess differences in protein anal ytes 
from control health y donor samples b y a variet y of technical methodolog ies that may  include: 
immunoassay s, protein array s, and biochemical approaches. Longitudinal alterations in SL E 
dysregulated proteins will be assessed in association with clinical characteristics and/or 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
85(125)response to treatment. Additionally
, the results from the proteomic anal yses will be compared 
to those obtained from urine samples of lupus nephritis subjects. 
Plasma will be collected for correlative studies during visits specified in the Study  Plan (Table 
3and Table 4) . These studies will include proteins, peptides and immune complexes and will 
be conducted using immunoassay s, in vitro assays, and/or biochemical approaches. The data 
from these studies will be reported in separate research reports. 
5.4.6 Storage and destructi on of biological samples
Samples will be stored for up to 15 y ears or as per local regulation from the date of the Last 
Subject’s Last Visit, after which they  will be destroy ed.
5.5 Quality of life/pharmacoeconomic assessments
Quality  of life and pharmacoeconomic assessments will be made at the times indicated in the 
Study  Plan ( Table 2, Table 3, and Table 4 ) .Subject -reported outcome assessments should be 
completed b y the subject, unassisted by spouse , family  members or friends.
Subjects will be completing the following subject- reported questionnaires to assess treatment 
effects.
5.5.1 Short Form 36 version 2 (acute recall) 
The SF -36-v2 (acute) is a multipurpose, 36 -item survey  that measures 8 domains of health: 
physical functioning, role limitations due to phy sical health, bodil y pain, general health 
perceptions, vitality , social functioning, role limitations due to emotional problems, and 
mental health (see Appendix L). It yields scale scores for each of these 8 health domains, and 
2 summary  measures of phy sical and mental health: the Phy sical Component Summary  and 
Mental Component Summary .
5.5.2 Functional Assessment of Chronic Illness Therapy –FATIGUE 
The FACIT -F is a 13 -item subject -completed questionnaire t
o assess the impact of fatigue 
over the previous 7 day s (see Appendix M). The responses range from 0 (Not at All) to 4 
(Very  Much). Final scores are the sum of the responses and range from 0 to 52; higher scores 
indicate better Qo L (Yellen et al, 1997). Changes in scores >3 points are considered to be 
clinically  meaningful ( Cella et al, 2002 ).
5.5.3 EuroQoL 5 dimensions 
The EQ -
5D-5L is comprised of the following 5 dimensions: mobility , self -care, usual 
activities, pain/discomfort and anxiety /depression ( EuroQoL Group, 1990, see Appendix N). 
Each dimension has 5 response options (no problems, slight problems, moderate problems, 
severe problems and unable to/extreme problems) that reflect increasing levels of difficult y. 
EQ-5D- 5L health states will be converted into a single index value using values sets from the 
EQ-5D- 5L Crosswalk Project. The questionnaire also includes a VAS, where the subjects are 
asked to rate their health on a scale of 0 -100, wi th 0 being worst imaginable health state and 
100 being best imaginable health state.
Revised Clin ical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
86(125)5.5.4 Lupus Quality of Life
Lupus QoL is a 34 -item SL E
-specific health -related QoL measure (see Appendix O). I t was 
developed in the United Kingdom for use in adults with SLE ( McElhone et al, 2007) and was 
further validated in the USA ( Jolly  et al, 2010 ). The instrument consists of 8 domains 
(physical health [8 items], pain [3 items], planning [3 items], intimate relationships [2 items], 
burden to others [3 items], emotional health [6 items], body  image [5 items] and fatigue
[4items]). 
5.5.5 Patient Global Assessment 
Subjects will be asked to complete the PtGA (see Appendix P). The PtGA is a single -item 
question that takes into account all the way s in which illness and health conditions may affect 
the patient at this time. The p atient should consider the previous week when answering this 
question. Responses range from very  well to very  poor on a 100 mm VAS. The phy sician and 
subject must complete the PGA and PtGA, respectively , independently  of each other.
5.5.6 Work productivity and A ctivity Impairment 
The Work Productivity  and Activity  Impairment (WPAI ) is a validated, self -administered 
questionnaire consisting of 6 questions, assessing the impact of disease on productivity (see 
Appendix Q). The WPAI y ields 4 t ypes of scores: absente eism (work time missed), 
presenteeism (VAS [scored from 0 to 10] rating of impairment while working), work 
productivity  loss (overall work impairment /absenteeism plus presenteeism), and activit y 
impairment (VAS [scored from 0 to 10] rating of daily  activities, other than work at a job) 
(Reilly  et al, 1993 ).
5.5.7 Medical Resource Use Questionnaire
Medical resource use will be determined b y completing the Medical Resource Use 
Questionnaire Edition Number 3, which collects information on: 1) the number of 
unscheduled emergency  department visits; 2) unscheduled hospitalisations; 3) the length of 
stay for hospitalisations; 4) the number of intensive care unit (ICU ) stay s and the length of 
ICU stay s; 5) unscheduled medical provider visits; and 6) the cause(s) of hospitalisation over 
duration of the study  (see Appendix S). 
Site personnel will administer the questionnaire by interviewing the subject at every  visit. 
Further, site personnel are required to obtain source documentation (ie, medical records) for 
these visits and make the records available to the monitor. Appropriate SAE/AE forms need to 
be completed for hospitalisation and emergency  department visits.
5.5.8 Pain numerical rating scale 
Overall subject -reported pain will be captured with an 11- point NRS (0 no pain; worst 
imaginable) with a 1 week recall period (see Appendix R). 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
87(125)6. SAFETY REPORTING AND MEDICAL MANAGEMENT
The PI  is responsible for ensuring that all st aff involved in the study  are familiar with the 
content of this section.
6.1 Definition of adverse events
An AE is the development of an undesirable medical condition or the deterioration of a 
pre-existing medical condition following or during exposure to a ph armaceutical product, 
whether or not considered causall y related to the product. An undesirable medical condition 
can be s ymptoms (eg, nausea, chest pain), signs (eg, tachy cardia, enlarged liver) or the 
abnormal results of an investigation (eg, laboratory
 findings, ECG). In clinical studies, an AE 
can include an undesirable medical condition occurring at an y time, including run -in or 
washout periods, even if no study  treatment has been administered.
The term AE is used to include both serious and non- serious AEs.
6.2 Definition of serious adverse events
An SAE is an AE occurring during an y study phase (ie, run- in, treatment, washout, 
follow -up), that fulfils 1 or more of the following criteria:
 Results in death
 Is immediatel y life -threatening
 Requires in-patient hospitalisation or prolongation of existing hospitalisation 
 Results in persistent or significant disability /incapacity  or substantial disruption of 
the ability  to conduct normal life functions
 Is a congenital abnormality  or birth defec t
 Is an important medical event that may  jeopardise the subject or may  require 
medical intervention to prevent 1 of the outcomes listed above.
For further guidance on the definition of a SAE, see Appendix B.
6.3 Hy’s law
Cases where a subject shows elevations in liver biochemistry  may  require further evaluation 
and occurrences of AST or ALT ≥3xUL N together with total bilirubin ≥2xULN may  need to 
be reported as SAEs. Please refer to Appendix C for further instruction on cases of increases 
in liver biochemistry  and evaluation of Hy ’s Law.
6.4 Other events of special interest
6.4.1 Overdose
An overdose (ie, having been administered a greater dose of stud y drug than specified in this 
protocol) with associated AEs is recorded as the AE diagnosis/s ymptoms on the relevant AE 
modules in the CRF and in the Overdose Report.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
88(125)An overdose without associated s ymptoms is only reported in the Overdose Report.
If an overdose of investigational product occurs during the stud y, then the Investigator or 
other site personnel inform the appropr iate AstraZeneca representative or designee 
immediately  or no later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative or designee works with the Investigator to ensure 
that all relevant information is provided t o the Safet y Management data entry  site.
For overdoses associated with a SAE, the standard reporting timelines apply, see Section 6.7. 
For other overdoses, reporting must occur within 30 day s.
6.4.2 Pregnancy
All pregnancies and outcomes of pregnancy  should be reported to AstraZeneca.
6.4.3 Maternal exposure
If a subject becomes pregna nt during the course of the study , investigational product should be 
discontinued immediately.
Pregnancy  itself is not regarded as an AE unless there is a suspicion that the investigational 
product under stud y ma y have interfered with the effectiveness of a contraceptive medication. 
Congenital abnormalities/birth defects and spontaneous miscarriages should be reported and 
handled as SAEs. Elective abortions without complications should not be handled as AEs. The 
outcome of all pregnancies (spontaneous misca rriage, elective termination, ectopic pregnancy , 
normal birth or congenital abnormality ) should be followed up and documented even if the 
subject was discontinued from the study .
If any pregnancy occurs in the course of the study, then the Investigator or other site personnel 
informs the appropriate AstraZeneca representatives within 1 day , ie, immediatel y but no 
later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative or designee works with the Investigator to en sure 
that all relevant information is provided to 
Safety  Management and to AstraZeneca 
within 1 or 3 calendar days for SAEs (see Section 
6.6) and within 30 days for all other 
pregnancies.
The same timelines apply  when outcome information is available.
Any subject who becomes pregnant during the course of the study  will be followed so that 
pregnancy  outcome can be determined and reported to AstraZe neca and the regulatory  
authorities.
6.4.4 Paternal exposure 
Male subjects should refrain from fathering a child or donating sperm during the study  and for 
12 weeks following the last dose. 

Revised Clinical Study Pr otocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
89(125)Pregnancy  of the subject’s partner is not considered to be an AE. However, the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, 
or congenital abnormality) should if possible be followed up and docu mented. 
The outcome of an y conception occurring from the date of the first investigational product 
administration until 12 weeks after the last investigational product administration should be 
followed up and documented. Information on the pregnancy  of a subject’s partner must be 
obtained directl y from the subject’s partner. Therefore, prior to obtaining information about 
the pregnancy , the Investigator must obtain the consent of the subject’s partner.
6.5 Adverse Events of Special Interest 
An AESI  is an AE o
f scientific and medical concern specific to understanding biologics and 
requires close monitoring and rapid communication by  the Investigator to the 
Sponsor/Sponsor’s delegate. An AESI may  be serious or nonserious. 
Adverse Events of Special I nterest in t his protocol will be assessed at each visit in the CRF. 
The events of interest are serious infections, including non- opportunistic serious infections, 
opportunistic infections, anaph ylaxis, malignancy , herpes zoster , TB (including latent TB), 
influenza, va sculitis (non- SLE), and MACE (including stroke, MI, or cardiovascular death). 
Lupus nephritis (associated with SL E; WHO or ISN/RPS Classification Class III, IV or V) is 
defined not as an AESI but as a new BILAG -2004 A adjudicated AE.
An AESI  that meets 1 of the seriousness outcomes listed in Section 6.2 will be categorised as 
an SAE for the purposes of follow- up responsibility  and safet y reporting. A nonserious AESI 
will be categorised as an AE. For reporting of AESI s, see Section 6.8.
6.5.1 Non-
opportunistic serious infection
A serious non-opportunis tic infection is an y non-opportunistic infection that meets the SAE
criteria in Section 6.2.Serious non- opportunistic infection adverse events are reported as 
SAEs and AESI s. It is expected that culture results and all diagnostic or therapeutic procedure 
results performed on a subj ect experiencing a serious non -opportunistic infection will be 
provided as an SAE update. Non-serious non- opportunistic infections will not be captured as 
AESI s.
6.5.2 Opportunistic infection
An opportunistic infection is an invasive infection caused b y microorg anisms that are 
normally  non- pathogenic or rarely  pathogenic in individuals with normal immune function or 
cause an infection of a type or severity  not seen in the normal host. 
Examples of opportunistic infections that may  occur in SL E subjects include: 
herpes zoster
meningoencephalitis, Salmonella bacteremia, Pneumocystis jiroveci pneumonia or progressive 
multifocal leukoencephalopathy . It is expected that culture results and all diagnostic or 
therapeutic procedure results performed on a subject experienc ing a serious opportunistic 
infection will be provided as an SAE update. Since anifrolumab is an immunomodulatory  
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
90(125)agent and the sponsor needs to understand the safety  profile of this investigational product, 
including assessment of how anifrolumab may  affect resistance to different ty pes of 
infections, investigators are asked to undertake appropriate microbiologic identification 
including culture and report culture results for all patients who develop serious infections.
6.5.3 Anaphylaxis
Anaph ylaxis is a severe, potentially  fatal, sy stemic allergic reaction that occurs suddenl y after 
contact with an allergy -
causing substance, such as investigational product. For the purposes of 
this study , the definition detailed in Appendix Y is provided as a simple and rapid me ans to 
make the diagnosis of anaphy laxis during infusion with investigational product. This 
definition was a product of a s ymposium convened by  the National Institute of Allergy  and 
Infectious Diseases and Food Allergy  and Anaphy laxis Network ( Sampson et al, 2006). 
6.5.4 Malignancy
Malignancy  is a neoplasm characterised b y cells with abnormal features, uncontrolled rapid 
growth with invasive and/or metastatic tendencies diagnosed based on pathologic and clinical 
standards. Understanding risk of developing different malignancies is critical to establishing 
the benefit: risk profile for anifrolumab. Investigators are therefore requested to obtain biopsy  
results and pertinent biomarker and/or genetic testing results performed and to report these for 
any malignancies reported during the study .
6.5.5 Herpes zoster
Herpes zoster is a viral infection characterized by a cutaneous vesicular eruption on an 
erythematous base pr esenting along dermatome(s) and usuall y associated with prodromal 
pain. Herpes zoster results from the reactivation of varicella -zoster virus; multiple 
dermatomes may  be involved (>3 indicates disseminated disease) and organ or sy stemic 
infection may  occur (invasive; therefore an opportunistic infection). Poly merase chain 
reaction testing of samples from vesicles ,biops y,or other specimens (for example, 
cerebrospinal fluid ) may confirm the presence of varicella -zoster virus.
For additional information regarding Herpes zoster , refer to the Investigator Brochure. As this 
is an event of special interest, the Sponsor will collect information including whether or not 
subjects have received vaccination for Herpes zoster . The Herpes zoster vaccine will be 
captured in the appropriate sections of the CRF. 
6.5.6 Tuberculosis
Tuberculosis is a my cobacterial infectious disease generall y presenting as cough with 
systemic s ymptoms of infection diagnosed b y skin test (purified protein derivative), blood test 
(IFN -gamma release assay), radiographic imaging, body fluid and tissue sampling; 
presentation may  include disseminated or latent disease. An infection may  be new (at least 
conversion of a TB test to positive) or reactivation of dormant disease (new a ctive disease in a 
previously  TB test positive subject without prior evidence of active disease).
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
91(125) A bacteriologically confirmed TB case is a case where a biological specimen is 
positive by  smear microscopy , culture or rapid diagnostic such as PCR or nuclei c 
acid amplification test (Xpert MTB/RIF).
 A clinically diagnosed TB case is a case where the subject does not fulfil the 
criteria for bacteriological confirmation, but has been diagnosed with active TB b y 
a clinician or other medical practitioner who has decided to give the subject a full 
course of TB treatment. This definition includes cases diagnosed on the basis of 
x
-ray abnormalities or suggestive histology  and extra -pulmonary  cases without 
laboratory  confirmation. Clinically  diagnosed cases subsequent ly found to be 
bacteriologicall y positive (before or after starting treatment) should be reclassified 
as bacteriologically  confirmed.
Bacteriologicall y confirmed or clinicall y diagnosed cases of TB are also classified according 
to: anatomical site of disea se; history  of previous treatment; drug resistance; HIV status 
(World Health Organization, 2014). 
Latent TB is a my cobacterial infection without clini cal, bacteriological findings, or radiologic 
findings consistent with active TB and a TB blood test such as an IGRA (QuantiFERON 
Gold) or purified protein derivative skin test that is positive both at the time of provisional 
diagnosis and on repeat assessm ent. 
Subjects identified with latent TB will be assessed by  a local TB specialist to confirm the 
diagnosis and local SOC that will be used in treatment. Once latent TB is confirmed, treatment 
must be instituted immediately  and no investigational product m ay be administered until 
treatment of latent TB has begun. Additionally , subjects with newly  diagnosed latent TB must 
agree to complete a locally  recommended course of treatment for latent TB in order to 
continue receiv ingIP.
6.5.7 Influenza
Influenza is a severe viral infection that includes the following s ymptoms: temperature greater 
than 100.8°F (38.2°C), and malaise, headache, or my algia. It is often accompanied by  nausea, 
vomiting, and diarrhoea, and at least 1 of the following respiratory  symptoms: cou gh, sore 
throat, or shortness of breath.
Laboratory  criteria for influenza include at least 1 of the following: isolation of influenza virus 
from a clinical specimen, detection of influenza virus nucleic acid in a clinical specimen, 
identification of influ enza virus antigen b y direct fluorescent antibody test in a clinical 
specimen, OR influenza -specific antibod y response.
A confirmed case of influenza meets the clinical and laboratory  criteria for the viral illness. 
Laboratory  confirmation should be done u sing locally  available, rapid, commercial tests 
approved b y Regulatory Agencies and sampling respiratory specimens. 
Not all upper respiratory  viral infections or gastrointestinal viral infections are influenza. In 
the case where a subject reports a viral infection severe enough to be considered, in the 
opinion of the I nvestigator, influenza, a viral test should be performed (if possible) to confirm 
Revised Clinical Study Protocol
Drug Substance Anifrol umab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
92(125)the diagnosis. If, in the opinion of the I nvestigator, the subject has had influenza (the specific 
viral infe ction), this should be reported as an AESI , whether or not a test to confirm the 
diagnosis has been performed . 
Less severe viral infection should be reported as an AE onl y.
6.5.8 Vasculitis (non -Systemic Lupus Erythematosus)
Vasculitis (non -SLE) is defined as an inflammatory  disorder of blood vessels involving 
arteries and/or veins and characterized b y characteristic clinical signs/s ymptoms and 
diagnosed b y biopsy, imaging such as angiograph y or blood tests such as findings of 
antineutrophil cy toplasmic antibodie s consistent with the diagnosis. Underly ing causes should 
be identified, such as medications including stud y drug, infections or s ystemic inflammatory  
syndromes, wherever possible. See Appendix T for a list of vasculitic sy ndromes excluded 
from the study . 
6.5.9 Major acute cardiovascular events
As a measure of enhanced Pharmacovigilance, an independent Cardiovascular Event 
Adjudication Committee (CV -EAC) will review deaths (due to an y cause) and all SAEs in the 
cardiovascular SOC for evaluation as to whether to classify  as MACE events (stroke, MI, or 
cardiovascular death).
The CV -EAC will review cases of interest to determine if they  meet accepted diagnostic 
criteria. Causality  assessments will not be made by  the CV -EAC, nor will the committee 
possess governance authority . The CV -EAC will be blinded regarding an y information 
relating to the randomisation group.
6.6 Recording of adverse events
6.6.1 Time period for collection of adverse events
Adverse Events and SAEs will be collected from the time of signature of informed c onsent, 
throughout the treatment period and including the follow -up period until Follow -up Visit 2 
(12weeks post final dose) or Week 52 for the subjects who enrol in the LTE study .
6.6.2 Follow -up of unresolved adverse events
Any AEs that are unresolved at the subject’s last visit in the study  are followed up by  the 
study  staff for as long as medically  indicated. The Sponsor retains the right to request 
additional information for an y subject with ongoing AE(s)/SAE(s) at the end of the study, if 
judged necessary .
6.6.3 Variables 
The following variables will be collected for each AE;
 AE (verbatim)
 The date and time when the AE started and stopped
 Maximum intensity
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
93(125) Whether the AE is serious or not
 Investigator causality  rating against the investigational product (y es or no)
 Action taken with regard to investigational product
 Outcome of AE 
In addition, the following variables will be collected for SAEs:
 Onset Date (Date AE met criteria for serious AE)
 Detection Date (Date Investigator became aware of serious AE)
 AE is serious due to:
(a) Death
-Date of death
-Autopsy  performed
-Primary /secondary  cause of death
(b) Life threatening
(c) Inpatient hospitalisation or prolongation of existing hospitalisation
Date of hospitalisation
Date of discharge
(d) Congenital abnormality  or birth defect
(e) Important medical event
(f) Suspected transmission via a medicinal product of an infectious agent
 Description of AE
 Investigator causality  assessment to concomitant medications
 Investigator causality  assessment to study  procedures (y es or no)
It is important to distinguish between serious and severe AEs. Severit y is a measure of 
intensity , whereas seriousness is defined by  the criteria defined above. An AE of severe 
intensity  need not necessarily  be considered serious. For example, nausea that persists for 
several hours may  be considered severe nausea, but not a SAE. On the other hand, a stroke 
that results in only  a limited degree of disability  may  be considered a mild stroke but would be 
a SAE. The Investigator should provide an assessment of the se verity of each AE/SAE.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
94(125)6.6.4 Causality collection
The Investigator will assess causal relationship between investigational product and each AE, 
andanswer ‘y es’ or ‘no’ to the question ‘Do y ou consider that there is a reasonable possibility  
that the event may  have been caused by  the investigational product?’
For SAEs causal relationship will also be assessed for other medication and study  procedures 
andadditional study  drug (such as OCS, azathioprine, antimalarials, m ycophenolate 
mofetil/my cophenolic acid, methotrexate, and mizoribine)
. Note that for SAEs that could be 
associated with an y study procedure the causal relationship is implied as ‘yes’.
Aguide to the interpretation of the causalit y question is found in 
Appendix B.
6.6.5 Adverse events based on signs and symptoms
All AEs spontaneously  reported by  the subject or care provider or reported in response to the 
open question from the study  personnel: ‘Have you had any health problems since the 
previous visit/you were last asked?’ , or revealed by  observation will be collected and recorded 
in the CRF. When collecting AEs, the recording of diagnoses is preferred (when possible) to 
recording a list of sign s and sy mptoms. However, if a diagnosis is known and there are other 
signs or s ymptoms that are not generall y part of the diagnosis, the diagnosis and each sign or 
symptom will be recorded separately .
6.6.6 Adverse events based on examinations and tests
The resu lts from protocol mandated laboratory  tests and vital signs will be summarised in the 
clinical study  report (CSR). Deterioration as compared to baseline in protocol -mandated 
laboratory  values, vital signs, ECGs, and other safety  assessments should therefor e onl y be 
reported as AEs if they  fulfil any  of the SAE criteria or are the reason for discontinuation of 
treatment with the investigational product.
If deterioration in a laboratory  value/vital sign is associated with clinical signs and s ymptoms, 
the sign or symptom will be reported as an AE and the associated laboratory  result/vital sign 
will be considered as additional information. Wherever possible the reporting Investigator will 
use the clinical, rather than the laboratory  term (eg, anaemia versus low haemoglobin value). 
In the absence of clinical signs or s ymptoms, clinically  relevant deteriorations in 
non-mandated parameters should be reported as AE(s).
Deterioration of a laboratory  value, which is unequivocally  due to disease progression, should 
not be reported as an AE.
Any new or aggravated clinically  relevant abnormal medical finding at a phy sical examination 
as compared with the baseline assessment will be reported as an AE (or SAE, as appropriate).
6.6.7 Disease progression/worsening of systemic lupus erythematosus
Disease progression can be considered as a worsening of a subject’s condition attributable to 
SLE. It may  be an increase in the activity  or severity  of the existing manifestations of SL E or 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
96(125)is important that I nvestigators submit additional information requested by  AstraZeneca or 
 as soon as it becomes available.
The reference document for definition of expectedness/listedness is the IB.
6.8 Reporting of adverse events of special interest
Adverse Events of Special I nterest will be assessed by  the Investigator for severit y, 
relationship to the investigational product, possible aetiologies, and whether the event also 
meets criteria of an SAE. All AESI s (serious or nonserious) will be recorded on the AE CRF 
(using a reco gnized medical term or diagnosis that accuratel y reflects the event).
The reporting period for AESI s is the period immediatel y following the time that written 
informed consent is obtained through the end of subject participation in the study . Following 
detection of an AESI  (non -
serious), reporting is required within 72 hours of knowledge of the 
event, and for serious AESI s the standard 24- hour timeline for reporting to the appropriate 
AstraZeneca representative or designee applies.
6.9 Management of investig ational product- related toxicities 
6.9.1 Anaphylaxis, hypersensitivity, and infusion -related reactions
Infusion-related reactions have been reported with the administration of IV Ig and monoclonal 
antibodies. As with any  antibody , allergic reactions to dose adm inistration are possible. 
Therefore, appropriate drugs and medical equipment to treat acute anaph ylactic reactions must 
be immediately  available, and study  personnel must be trained to recognise and treat 
anaph ylaxis. For a definition of anaph ylaxis, hy persensitivity  reactions, and infusion
-related 
reactions, see Appendix Y.
Subjects should not be premedicated unless they  have had a prior infusion-related reaction to 
anifrolumab. However, if a prior infusion -related reaction has been documented, the 
Investi gator may  elect to administer prophy lactically  an antihistamine and/or 
acetaminophen/paracetamol for the comfort and safet y of the subject prior to subsequent 
infusions. Prophy lactic use of glucocorticosteroids prior to subsequent infusions is not 
permitte d.
6.9.2 Infections
When an infection is reported as an SAE or AESI, cultures should be obtained and culture 
results should be reported with the event. Other specific laboratory  or other investigations (eg, 
chest x -ray for pneumonia) that confirm or aid in the d iagnosis or treatment should be 
obtained when indicated and results should be reported with the SAE or AESI . 
Subjects who develop a new infection while undergoing treatment with investigational 
product should receive appropriate medical therapy , as determ ined b y local standards, and be 
monitored closely  until the condition resolves. Investigational product should not be 
administered to a subject with a clinically  significant, active infection as determined by  the 
Investigator (see Section 3.7). For an y active infection (eg, varicella zoster

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
97(125)infection/chickenpox) or significant exposure to any  infection (eg, varicella zoster infection in 
a naive subjec t, bacterial pneumonia), the Investigator should consider whether to interrupt 
investigational product administration and should notify  the medical monitor. 
Similarly , if a subject presents with signs or s ymptoms where opportunistic infections are 
conside red (eg, CNS sy mptoms consistent with progressive multifocal leukoencephalopathy  
or herpes encephalitis or aty pical pneumonia suggesting pneumocystis jiroveci pneumonia), 
investigational product should be interrupted until the I nvestigator confirms the sy mptoms and 
signs of infection have resolved or that no active infection has developed.
If dosing is resumed after resolution of a safety  concern (ie, infection or other AE) the 
investigational product must be administered within 14 day s of the scheduled tim e of the 
missed dose. If this is not possible, dosing should be resumed at the time of the next scheduled 
dose.
6.10 Study governance and oversight
The safet y of all AstraZeneca clinical studies is closely  monitored on an on -going basis b y 
AstraZeneca represent atives in consultation with  Safety Management . Issues identified 
will be addressed; for instance this could involve amendments to the study  protocol and letters 
to Investigators. 
6.10.1 Data and Safety Monitoring Board 
An independent DSMB will perform evalu ations of safet y data at specified regular intervals 
throughout the stud y and make recommendations to the Sponsor regarding further conduct of 
the study . The DSMB will be provided with data that are summarised by  treatment group 
using masked treatment grou p labels (eg, A, B, and C). After reviewing the data by  masked 
treatment group, the DSMB may  choose to unblind the treatment groups for additional review. 
The DSMB may  also ask for unblinded efficacy  data, if during the performance of a 
benefit/risk assess
ment the Board feels there is a potential safet y issue or concern. The DSMB 
will not routinely  review efficacy  data (blinded or unblinded). 
At any  time during the study , as well as on an ad hoc basis, the DSMB will also review any  
safet y data assessed b y the medical monitor as medically  relevant. Additional information, 
including frequency  of DSMB review, can be found in the DSMB charter.
If any event(s) occur that, in the opinion of the DSMB, contraindicates further dosing of 
additional subjects, the Sponsor will conduct a prompt cumulative review of safet y data and 
the circumstances of the event in question to determine whether dosing and study  
randomisation should be stopped, whether the protocol will be modified, or whether the stud y 
will be discontinu
ed permanently . Review by  the DSMB and Sponsor decision to resume 
(with or without modifications) is required for resumption of the study  in the event the stud y 
is interrupted. Where applicable, the regulatory authorities and Institutional Review 
Board/Independent Ethics Committee (I RBs/IECs) will be notified of any  actions taken with 
the study .

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
98(125)7. INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS
7.1 Identity of investigational products
Investigational product Dosage form and strength Manufacturer
Anifrolumab (MEDI -546) 150 mg/mL solution of 
anifrolumab (clear colourless to 
slightly yellow) intended for IV 
administration following 
dilution into 0.9% salineMedImmune, LLC
Placebo Solution (clear) intended for IV 
administration following 
dilution into 0.9% salineMedImmune, LLC
Excipients include 25 mM histidine/histidine -HCl, 50 mM ly sine-HC1, 130 mM trehalose 
dihydrate, 0.05% (w/v) plant -derived pol ysorbate 80, pH 5.9.
Each vial of investigational product or placebo contains 1.3 mL fill volume. I nvestiga tional 
product and placebo will be supplied to the site in cartons of 2 vials per kit. Each kit will have 
a unique number that will be printed on all labels within the kit (ie, the outer carton label and 
the label of each vial within the carton).
Preparati on of investigational product and placebo must be performed by  an unblinded 
qualified person (eg, pharmacist or study  nurse) at the site. When diluted as directed in the 
investigational product study  manual provided by  the Sponsor, placebo and investigatio nal 
drug appear identical. See Section 7.2below for diluent and infusion vessel and tubing 
specifications.
7.2 Dose and treatment regimens
The investig ational product, anifrolumab 150 mg, 300 mg or placebo, will be administered via 
controlled IV infusion pump into a peripheral vein over at least 30 minutes Q4W. Each dose 
must be at least 14 day s apart.
7.2.1 Dose preparation steps
From a 100 mL IV infusion bag of 0.9% normal saline, withdraw and discard a volume of 
saline equal to 2.0 mL. Then add 1.0 mL from each of the 2 vials in the kit into the infusion 
bag and mix by  gentle inversion. Due to approximately  10% overfill of normal saline, the final 
volume of the dilution will be greater than 100 mL. 
7.2.2 Prior to administering the investigational product
 Confirm subject was evaluated for signs and s ymptoms of TB
 Women of childbearing potential must have a negative urine pregnancy  test prior to 
receiving investigational product.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
99(125) Subjects should not have clinically  significant, active infection as determined by  the 
Investigator. 
 There should be at least 14 day s between doses. If the previous investigational 
product infusion was given within 14 day s, delay  visit until >14 day s has elapsed 
and contact the 
medical monitor. 
 Pre-dose blood samples will be collected
 Subjects should not be premedicated unless they  have had a prior infusion-related 
reaction to anifrolumab. However, if a prior infusion- related reaction has been 
documented, the Investigator may  elect to administer prophy lactically  an 
antihistamine or acetaminophen/paracetamol for the comfort and safet y of the 
subject prior to subsequent infusions. The medications should be given after visit 
asses sments have been completed. Prophy lactic use of glucocorticosteroids prior to 
subsequent infusions is not permitted.
7.2.3 Investigational product administration procedures
 Investigational product must be administered within 4 hours after preparation and 
may be stored at room temperature until administration. Total in- use storage time 
from dilution of anifrolumab to start of administration should not exceed 4 hours at 
room temperature. If refrigerated at 2 to 8°C (36 to 46°F ), storage time should not 
exceed 24 ho urs. If storage time exceeds these limits, a new dose must be prepared 
from new vials.
 Investigational product must be administered at room temperature b y controlled 
infusion via an infusion pump into a peripheral vein. A physician must be present at 
the site or immediately  available to respond to emergencies during all 
administrations of investigational product.
 Because compatibility  of anifrolumab with IV medications and solutions other than 
0.9% sodium chloride for injection, (United States Pharmacopeia), is not known, 
the investigational product solution should not be infused through an IV line in 
which other solutions or medications are being administered.
 Investigational product should be administered over a minimum of 30 minutes. 
 Immediately  followi ng the initial dosing, up to an additional 25mL of saline will 
be given via infusion pump at the same pump speed utilised at the completion of the 
initial dosing.
 An emergency  cart should be available in the infusion suite.
7.2.4 Subject monitoring/procedures d uring and after the infusion
Subjects will be monitored during the administration of the investigational product and for at 
least 2 hours after the first 4 infusions (Weeks 0, 4, 8, and 12). If there are no safet y concerns, 
for subsequent infusions subjects will be monitored during administration of the 
investigational product and for a minimum of 1 hour after completion of the IV infusion 
thereafter (Week 16 to Week 48). 

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
100(125)Monitoring will include vital signs (oral temperature, BP, pulse rate, respiratory  rate) in a 
sitting position at the following times:
 Shortly  before the IV infusion (within 15 ±5 minutes of the beginning of the 
investigational product infusion)
 Every  15 ±5 minutes during infusion
 Immediately  after completion of administration of investiga tional product, 
including post -dose saline flush (within 15 ±5 minutes after completion of 
investigational product administration)
 Every  30 ±5 minutes after completion of investigational product administration (not 
including saline flush) for at least 2 ho urs after the first 4 doses (Week 0 [Day 1] to 
Week 12) of investigational product are administered, and for at least 1 hour, 
thereafter (Week 16 to 48)
 Samples for PK laboratory assessments should be collected 15 ±5 minutes after 
completion of investigati onal product administration after dosing on Week 0 
(Day 1) and Week 48
Vital signs may  be taken more frequently , based on I nvestigator judgment. 
7.2.5 Discharge
The subject should only  be discharged from the site after the minimum monitoring period and 
when jud
ged stable in the opinion of the I nvestigator/designee. Blood pressure and pulse rate 
will be taken prior to discharge from the site.
7.2.6 Documentation of investigational product administration
Both the duration of the investigational product infusion and the duration of investigational 
product administration will be recorded. The duration of investigational product infusion and 
duration of investigational product administration will be calculated as follows:
 Duration of infusion: the amount of time elapsed from the infusion start time to the 
infusion stop time. I nfusion start time is defined as the time point where 
investigational product is first infused into the subject. Infusion stop time is defined 
as the time point where the infusion pump completes infu sion of the investigational 
product, not including the saline flush.
For example: an infusion with a start time of 12:00 PM would have a duration of 
infusion recorded as 30 minutes (a time between 12:00 PM and 12:30 PM).
 Duration of administration: the amo unt of time elapsed from the infusion pump start 
time to the infusion pump stop time PL US the time required to complete the 
additional flush of saline. The duration of administration will alway s be greater than 
the duration of infusion and will alway s incl ude the additional flush of saline.
Initial IV bag compatibility studies demonstrate that anifrolumab is compatible with I V bags 
composed of pol yolefin that is latex -free, pol yvinyl chloride (PVC) -free, and diethy lhexyl 
phthalate (DEHP) -free, and IV admini stration lines composed of PVC and poly ethylene that 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
101(125)are latex free and DEHP -
free. Additional studies demonstrate that anifrolumab is compatible 
with I V bags and ancillaries comprised of materials as described in Table 6and Table 7.
Table 6 Compatible materials of constr uction for IV bags
IV Bag Diluent Materials of Construction
0.9% saline Glass
0.9% saline Polyolefin copolymer, ethylene and propylene
0.9% saline PVC and DEHP
0.9% saline Polyethylene
0.9% saline Polypropylene
0.9% saline Ethylene polyvinyl acetate
Table 7 Compatible materials of construction for ancillaries (eg, infusion 
tubing)
Materials of Construction
Polyethylene
PVC with DEHP
PVC with 2 -ethylhexyltrimellitate
Polybutadiene
7.3 Labelling
Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and local 
regulatory  guidelines. The labels will fulfil GMP Annex 13 requirements for labelling. Label 
text will be translated into local language.
7.4 Storage
All study  drugs should be kept in a secure place under appropriate storage conditions. The 
investigational product should be stored at 2 to 8°C (36 to 46°F) and must not be frozen. 
7.5 Compliance
The administration of all study  drugs (including investigationa l product) should be recorded in 
the appropriate sections of the CRF. The investigational product will be administered by  study  
site personnel, who will monitor compliance.
7.6 Accountability
The study  drug provided for this study  will be used only  as directed in the study  protocol.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
102(125)The study  personnel will account for all study  drug administered to the subjects.
The Investigator’s or site’s designated investigational product manager is required to maintain 
accurate investigational product accountability  record s. Upon completion of the study , copies 
of investigational product accountability  records will be returned to AstraZeneca or designee. 
All unused investigational product will be returned to an AstraZeneca or designee -authorised 
depot or disposed of upon au thorisation by  AstraZeneca or designee or other written 
instructions provided by  AstraZeneca or designee (for contact information and specific 
shipping instructions).
Details regarding supplies, dose preparation, process for reporting product complaints, a nd 
accountability  for the investigational product will be provided to the sites.
7.7 Post study access to study treatment
Upon evaluation at Week 52, subjects will either be followed for a 12 -week Follow -up Period
,
or transition to an L TE study  (if eligible) that will continue for approximately  3 years after the 
completion of the Week 52 visit.
8. STATISTICAL ANALYSES 
8.1 Statistical considerations
All personnel involved with the analy sis of the study  will remain blinded until database lock 
and identification of prot ocol violations. Analy ses will be performed b y AstraZeneca or its 
representatives. 
A comprehensive Statistical Anal ysis Plan (SAP) will be prepared prior to the first subject in 
to the study . Any subsequent amendments to the SAP will be documented, with f inal 
amendments completed prior to unblinding of the data for the anal ysis. Details of all anal yses, 
including sensitivity  analy ses, will be fully  documented in the SAP.
8.2 Sample size estimate
A total of 450 subjects receiving SOC treatment will be randomise d 1:2:2 to treatment with 
150 mg anifrolumab, 300 mg anifrolumab, or placebo.
The sample size is primarily  driven b y the need to acquire an adequate safety  database size, as 
well as the ability  to assess key  secondary  endpoints. The primary  endpoint is the difference in 
proportions of subjects achieving SRI(4) at Week 52 comparing anifrolumab 300 mg to 
placebo. With assumed proportions of SRI (4) of 39% and 63% in the placebo and anifrolumab 
300mg groups, respectively , 180 subjects/arm y ields more than 99% power to reject the 
hypothesis of no difference using a 2 -
sided alpha of 0.05. The minimal detectable difference 
in SRI(4) between anifrolumab 300 mg versus placebo is approximately  10% with this sample 
size. 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
103(125)It is not straightforward to precisel y arrive at the power estimate for the assessments of key  
secondary  endpoints due to the multiplicity  procedure used to preserve the ty pe I error, as well 
as uncertainties of the size of sub -
groups in most assessments. Approximate estimates of 
power for 2 example e ndpoints are listed below. These calculations assume that the primary  
endpoint is met, and the testing of the key  secondary  endpoints is therefore allowed. Further, 
for these examples each endpoint is tested using a weighted Holm procedure, and the alpha 
given b y the assigned weight in the first step of the algorithm: 
 Difference in proportions of subjects achieving SRI(4) at Week 52 in the IFN test 
high sub group: Given 75% of subjects are IFN test- high; proportions of SRI(4) in 
the IFN test -high subgroup of 35% and 61% in the placebo and anifrolumab 
treatment groups, respectively ; a 2- sided alpha of 0.04 y ields 98% power.
 Difference in proportion of subjects who achieve an OCS dose ≤7.5 mg/day  at 
Week 40, which is maintained through Week 52 in the sub- group of subjects with 
baseline OCS ≥10mg/day : Given 60% of subjects have an OCS dose of at least 
10 mg at baseline; proportions of subjects tapering the OCS dose of 32% and 59% 
in the placebo and anifrolumab treatment groups, respectivel y; a 2-sided alpha of
0.004 y ields 87% power. 
The anifrolumab 150 mg treatment group will be subject to a secondary  analy sis to inform the 
benefit:risk profile for anifrolumab. With half of the sample size (ie, 90 subjects) for the 
anifrolumab 150 mg treatment group, a 12.5% difference in SRI(4) between anifrolumab 150 
mg versus placebo would be associated with a nominal p -value of 0.05. The evaluation of 
anifrolumab 150 mg is outside of the formal multiplicity  testing strategy .
The assumptions of the effect sizes and sizes of subgroups used for the calculations above are 
based on the observed results in the interim analyses of study  CD IA MEDI 546-1013. 
8.3 Definitions of analysis sets
8.3.1 All subjects analysis set
This analy sis set will comprise all subjects screened for the study  and will be used for 
reporting of disposition and screening failures.
8.3.2 Full analysis set
The full anal ysis set will be used as the primary  population for reporting efficacy  and safety  
data. This comprises all subjects randomised into the study  who receive at least 1 dose of 
investigational product and will be anal ysed according to randomised treatment (modified 
Intention- To-Treat). An y major deviations from randomised treatment will be listed and 
considered when interpreting the safet y data.
8.3.3 Pharmacokinetic a nalysis set
All subjects who received anifrolumab and who had at least 1 quantifiable serum PK 
observation post first dose, will be included in the PK analy sis dataset. All PK summaries will 
be based on this anal ysis set.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
104(125)8.4 Outcome measures for analyses
Base line is defined as the last measurement prior to randomisation and dose administration on 
Day 1. If the Day  1 value is missing or is invalid or is collected after administration of 
investigational product, the latest assessment prior to dose administration on Day  1 will serve 
as baseline.
When applicable, adjudicated values of BILAG -2004, SL EDAI -2K, CLASI, and PGA will be 
used for all assessments.
8.4.1 Primary outcome variable
The primary  endpoint used to evaluate the effect of anifrolumab 300 mg compared to pla cebo 
on disease activity  is the difference in proportion of subjects achieving SRI(4) at Week 52, 
where a subject achieves SRI (4) if all of the following criteria are met:
 Reduction from baseline of ≥4 points in the SL EDAI -2K;
 No new organ sy stem affected 
as defined b y 1 or more BILAG -2004 A or 2 or more 
BILAG -2004 B items compared to baseline using BILAG -2004;
 No worsening from baseline in the subjects’ lupus disease activity  defined by  an 
increase ≥0.30 points on a 3- point PGA VAS;
 No discontinuation of investigational product or use of restricted medications 
beyond the protocol -
allowed threshold before assessment. Allowed medication is 
defined in Section 3.3. 
8.4.2 Key secondary outcome variables
8.4.2.1 Systemic Lupus Erythematosus Responder Index of ≥4 at Week 52 in 
interferon test -high subjects
The key  secondary  endpoint used to evaluate the effect of anifrolumab 300 mg compared to 
placebo on disease activity  in the IFN test -high subgroup is the difference in proportions of 
subjects achieving SRI(4) at Week 52 in subjects classified as IFN test
-high. SRI (4) is defined 
in Section 8.4.1.
8.4.2.2
Oral corticosteroid management
The key  secondary  endpoint used to evaluate the effect of anifrolumab 300 m g versus placebo 
on the ability  to reduce the OCS dose in subjects with baseline OCS ≥10mg/day  prednisone 
or equivalent is the difference in proportions of subjects meeting all the following criteria: 
 Achieve an OCS dose of ≤7.5 mg/day  prednisone or equi valent b y Week 40; 
 Maintain an OCS dose ≤7.5 mg/day  prednisone or equivalent from Week 40 to 
Week 52; 
 No discontinuation of investigational product or use of restricted medications 
beyond the protocol -allowed threshold before assessment (see Section 3.3).
Revi sed Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
105(125)8.4.2.3 Skin lesions
The key  secondary  endpoint used to evaluate the effect of anifrolumab 300 mg versus placebo 
on inflammatory  cutaneous lupus lesions in subjects with baseline CL ASI activity  score ≥10 is 
the difference in proportions of subjects who meet the following criteria: 
 Achieve ≥50% reduction of CL ASI activity  score at Week 12 compared to baseline; 
 No discontinuation of investigational product or use of restricted medications 
beyond the protocol -allowed threshold before assessment (see Section 3.3).
8.4.2.4 Systemic 
Lupus Erythematosus Responder Index of ≥4 at Week 24
The key  secondary  endpoint used to evaluate the earl y effect of anifrolumab 300 mg 
compared to placebo on disease activity  is the difference in proportions of subjects achieving 
SRI(4) at Week 24. SRI(4) is defined in Section 8.4.1 . 
8.4.2.5 Flares 
The key  secondary  endpoint used to evaluate the effect of anifrolumab 300 mg versus placebo 
on flares is the annualised flare rate through Week 52. A flare is defined as either 1 or more 
new BILAG -2004 A or 2 or more new BILAG -2004 B items compared to the previous visit 
(ie, a worsening from an E, D, or C score to a B score in at least 2 organ s ystems or a 
worsen ing from an E, D, C, or B to an A score in any  1 organ s ystem compared to the 
previous visit).
8.4.3 Other secondary outcome variables
8.4.3.1 Assessment of disease activity
SRI(4) of anifrolumab 150 mg treatment group
The effect of anifrolumab 150 mg compared to placeb o on disease activity will be assessed by  
the difference in proportions of subjects achieving SRI (4) at Week 52. SRI(4) is defined in 
Section 8.4.1.
Supportive SRI endpoints
In addition to the endpoint described in Section 8.4.1 , the difference between anifrolumab 
300mg and placebo in SRI  at 
Week 52 will be assessed using levels other than 4, ie, SRI (5), 
SRI(6), SRI(7), and SRI(8), where SRI(X) (X=5, 6, 7, or 8) is defined by  the proportion of 
subjects who meet the following criteria:
 Reduction from baseline of ≥X points in the SL EDAI -2K;
 No n ew organ systems affected as defined by  1 or more BILAG -2004 A or 2 or 
more BILAG -2004 B items compared to baseline using BILAG-2004;
 No worsening from baseline in the subjects’ lupus disease activity  defined by  an 
increase ≥0.30 points on a 3- point PGA VA S;
 No discontinuation of investigational product or use of restricted medications 
beyond the protocol -allowed threshold before assessment (see Section 3.3).
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
106(125)The difference between anifrolumab and placebo in the proportion of subjects achieving 
SRI(X), X=4, 5, 6, 7, or 8 will also be assessed longitudinally  over time up to Week 52.
BICLA
The effect of anifrolumab 300 mg versus placebo on disease activi ty will also be assessed 
using the difference in proportion of subjects meeting the criteria for BI CLA response at 
Week 52, where a subject is a BICLA responder if the following criteria are met:
 Reduction of all baseline BILAG -
2004 A to B/C/D and baseline BILAG -2004 B to 
C/D, and no BILAG -2004 worsening in other organ sy stems, as defined by 1 new 
BILAG -2004 A or more than 1 new BILAG- 2004 B item; 
 No worsening from baseline in SL EDAI -2K as defined as an increase from baseline 
of >0 points in SL EDAI -2K;
 No worsening from baseline in the subjects’ lupus disease activity  defined by  an 
increase ≥0.30 points on a 3- point PGA VAS;
 No discontinuation of investigational product or use of restricted medications 
beyond the protocol -allowed threshold before assessment (see Section 3.3).
The difference between anifrolumab 300 mg and placebo in the proportion of subjects 
achieving BI CLA will also be assessed longi tudinally  over time up to Week 52.
Supportive outcome variables of the Individual components of SRI and BICLA
The individual components of the composite SRI  and BICLA endpoints as defined in Section 
8.4.1 and above will be assessed by
 treatment. 
Further, t he effect of anifrolumab 300 mg versus placebo on PGA will be evaluated using the 
difference in mean change in PGA from baseline longitudin ally over time to Week 52. I n 
addition, the effect of anifrolumab 300 mg versus placebo on Major Clinical Response and 
Partial Clinical Response will be evaluated where these endpoints are defined as: 
 Difference in proportion of subjects who achieve Major Clinical Response, ie, a 
subject with BILAG -2004 C scores or better at Week 24 with no new BILAG-2004 
A or BILAG -2004 B scores and maintenance of response with no new BILAG-2004 
A or B scores between Week 24 and Week 52.
 Difference in proportion of subjec ts who achieve Partial Clinical Response, ie, a 
subject with a maximum of 1 BILAG -2004 B score or better at Week 24 and 
maintenance of response without a new BILAG -2004 A or more than 1 new 
BILAG -2004 B item out to Week 52.
Active, swollen and tender join ts
The endpoints used to evaluate the effect of anifrolumab 300 mg versus placebo on active, 
swollen, and tender joints are: 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
107(125) Difference in change from baseline to Week 52 in the number of active, swollen, 
and tender joints; 
 Difference in proportion of su bjects with at least 8 swollen and at least 8 tender 
joints at baseline who achieve at least a 20% reduction from baseline in both the 
number of swollen and tender joints at Week 52;
 Difference in proportion of subjects with at least 8 swollen and at least 8 tender 
joints at baseline who achieve at least a 50% reduction from baseline in both the 
number of swollen and tender joints at Week 52.
Change in SDI
The endpoint used to evaluate the effect of anifrolumab 300 mg versus placebo on irreversible 
damage i n SLE subjects is the difference in mean change in SDI global score from baseline to 
Week 52.
Supportive outcome variables for the assessment of skin lesions
In addition to the endpoint described in Section 8.4.2.3 , the maintenance of effect in the 
CLASI activity  score will be evaluated using the proportion of subjects with a CL ASI activity  
score ≥10 at baseline who achieve at least a 50% reduction in CLASI activity  score at 
Week 12 and maintain response at Week 52.
The difference between anifrolumab 300 mg and placebo in the mean change from baseline in 
CLASI activity  as well as CL ASI damage score will be evaluated longitudinally  over time up 
to Week 52.
Supportive outcome variables for the assessment of flares
In addition to the endpoint in Section 
8.4.2.5, the annualised rate of flares will als o be 
evaluated where a flare is defined as either 1 or more new BILAG -
2004 A or 2 or more new 
BILAG -2004 B items compared to baseline . 
In addition, time to flare, ie, time from first exposure of investigational product to the first 
flare will be assessed. Both definitions of flares will be used for the assessment: either 1 or 
more new BILAG -2004 A or 2 or more new BILAG -2004 B items compared to previous visit
(as introduced in Section 8.4.2.5) ; and the definition described above comparing to baseline. 
8.4.4 Subject reported outcome variables
8.4.4.1 Short Form 36 version 2 (acute recall)
The difference between anifrolumab 300 mg and placebo in the mean change fro m baseline in 
SF-36v2 (acute) Ph ysical Component Score and Mental Component Score to Week 52 will be 
assessed. 
8.4.4.2 Pain Numerical Rating Scale 
The difference between anifrolumab 300 mg and placebo in the mean change from baseline in 
pain NRS to Week 52 will be assessed.
Revised Clinic al Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
108(125)8.4.4.3 Functional Assessment of Chronic Illness Therapy -FATIGUE 
The difference between anifrolumab 300 mg and placebo in the mean change from baseline in 
FACIT -
F total score to Week 52 will be assessed. 
8.4.4.4 Patient Global Assessment 
The difference between anifrolumab 300 mg and placebo in the mean change from baseline in 
PtGA (measured on a VAS ranging from 0 to 100mm) to Week 52 will be assessed.
8.4.4.5 LUPUS quality of life scale
The difference between anifrolumab 300 mg and placebo in the mean change from baseline in 
LUPUS QoL score to Week 52 will be assessed.
8.4.4.6 EuroQoL 5 dimensions
The proportion of subjects in each EQ -5D- 5L health state (no problems, slight problems, 
moderate problems, severe problems and unable to/extreme problems) , by dimension, as well as 
the VAS Score and single summary  utility  index, including changes from baseline, will be 
explored over time. 
8.4.4.7 Work productivity and Activity Impairment 
-Lupus
The WPAI  score levels (percentages) at baseline, Week 24, and Week 52 will be explored. 
8.4.4.8 Medical Resource Use Questionnaire
The following endpoints will be explored: 
 Number of subjects with unscheduled health care visits; 
 Number of unscheduled specialist visits;
 Number of unscheduled primary  care visits;
 Number of subjects with unscheduled emergency  department visits;
 Of subjects with visits, number of unscheduled emergency  department visits;
 Number of subjects with hospital stay s;
 Of subjects with visits, number of hospital visits;
 Length of hospital stay .
8.4.5 Safety variables
Thefollowing safet y data will be collected: vital signs, ph ysical examination, 12 -lead ECG, 
haematology , clinical chemistry , urinal ysis, C-SSRS, PHQ -8,flares as defined by a 
modification of the SELENA Flare Index using the SL EDAI 2K , and reported AEs (inclu ding 
AEs of special interest, see Section 6.5).
Change from baseline to each post -
treatment time point where scheduled assessments were 
made will b e calculated for relevant measurements. The number and proportion of subjects 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
109(125)with flares as defined b y a modification of the SELENA Flare Index using the SL EDAI 2K
and the number of 
such flares will be explored. Marked abnormal ECG values or changes 
from baseline will be identified based on pre -determined criteria. Occurrence of suicidal 
behaviour and ideation, based on the C -SSRS, from baseline up to Week 52 will be explored. 
AEs will be summarised by  means of descriptive statistics and qualitative summar ies. 
8.4.5.1 Other significant adverse events
During the evaluation of the AE data, a 
medically  qualified expert will review the list of 
AEs that were not reported as SAEs and discontinuations due to AEs.
Based on the expert’s judgment, significant AEs of particular clinical importance may , after 
consultation with the Astra Zeneca Global Patient Safety  Physician, be considered other 
significant AEs (OAEs) and reported as such in the CSR.
Examples of these are marked haematological and other laboratory  abnor malities, and certain 
events that lead to intervention (other than those alread y classified as serious), dose reduction, 
or significant additional treatment.
8.4.6 Immunogenicity variables
ADA assessments will be conducted utilising a tiered approach (screen, co nfirm, titre). The 
presence of nAb will be tested in all ADA -positive samples time points of week 12 and later 
using a ligand binding assay .
8.4.7 Pharmacokinetic variables
Due to the limited sampling schedule, the PK assessment will be primarily  based on the 
observed stead y -state serum trough (predose) concentrations, C trough. Maximum concentrations 
after the first and last dose will also be evaluated.
8.4.8 Pharmacodynamic outcome variables
The outcome variable for anti -dsDNA antibodies, C3, C4, and CH50 complement levels will 
be the mean change from baseline to Week 52 in subjects with abnormal complement level at 
baseline, or positive anti- dsDNA antibodies at baseline, defined as complement level below 
lower limit of normal. 
The outcome variable for the suppression of the IFN 21 gene PD signature is the percent 
suppression of fold change, relative to a pooled normal control, from baseline levels. 
8.5 Methods for statistical analyses
The anal ysis of the primary  and secondary  endpoints will include all data captured duri ng the 
52-week treatment period, regardless of whether study  treatment was prematurely  
discontinued, or delay ed, and/or irrespective of protocol adherence. 

Revised Clinical Study P rotocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
111(125) From Week 0 (Day
 1) to Week 12, the study  design allows for 1 burst and taper of 
OCS in order to allow adequate time for investigational product to achieve 
significant clinical benefit.
 One burst of OCS to ≤20 mg/day  between Week 12 and Week 40 is also all owed 
for non -SLE causes.
 Subjects who require additional bursts of OCS will still be encouraged to remain in 
the study , but will be considered a non -responder for subsequent assessments of 
disease activity
Subjects who discontinue investigational product will be asked to come to each visit for the 
scheduled assessments through the Week 52 end of treatment visit. The definition of the 
primary  endpoint includes a criterion that corresponds to a non- responder imputation for 
subjects who prematurely  discontinu e from investigational product, or who receive restricted 
medications bey ond the protocol -allowed threshold. Sensitivity  anal yses, excluding this 
criterion from the definition of SRI -response, where missing data is handled in a different 
way, (eg, a multiple imputations method) may  be carried out. Details will be pre -specified in 
the SAP. 
Presentation of Results
All data will be presented by  treatment group. Descriptive statistics (number, mean, standard 
deviation [SD], median, minimum, and maximum) will be provided for continuous variables, 
and counts and percentages will be presented for categorical variables.
95% CI s will be presented for treatment comparisons. If a model is used to estimate the 
treatment difference, the corresponding CI according to the model will be presented. 
Otherwise, the unadjusted CI  will be used. Nominal p -values may  be presented for secondary  
endpoints not included in the strategy  for preserving the t ype I error rate. Statistical 
significance cannot be interpreted from these p -values. 
Demograph y and baseline characteristics will be summarised by  treatment group for the full 
analysis set. 
8.5.1 Analysis of the primary variable 
The estimand of primary  interest in this study  is the difference in change from baseline in 
disease activity  between anifrolumab 300 mg and placebo, to reflect the effect of the initially  
assigned and dosed investigational product (full analy sis set). This is measured by  the primary  
efficacy  endpoint, defined as the difference in the proportion of subjects achieving SRI(4) at 
Week 52 comparing the anifrolumab 300 mg to the placebo group. The null hy pothesis is that 
the proportion of subjects achieving SRI(4 ) on anifrolumab 300 mg is equal to that of placebo. 
The alternative hy pothesis is that the proportion of subjects achieving SRI(4) on anifrolumab 
300 mg is not equal to that on placebo, ie,
H0: difference in proportion achieving SRI(4) (anifrolumab vs Pla cebo) = 0
H
a: difference in proportion achieving SRI(4) (anifrolumab vs Placebo) ≠ 0
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
112(125)The proportion of subjects achieving SRI(4) in the anifrolumab 300 mg treatment group will 
be compared to that in the placebo group using a Cochran
-Mantel -Haenszel (CMH) a pproach 
(Cochran, 1954) stratified by : 
 SLEDAI -2K score at screening (<10 points versus ≥10 points)
 Week 0 (Day  1) OCS dose (<10 mg/day versus ≥10 mg/day prednisone or 
equivalent)
 Results of a ty pe 1 IFN test (high versus low)
Strata with low counts will be collapsed prior to the anal ysis. Details for collapsing of strata 
will be pre -specified in the SAP.
The estimated treatment effect (ie, the differen ce in response rate for anifrolumab 300 mg 
versus placebo), corresponding 95% CI, and 2 -sided p -value for the difference at Week 52 
will be presented. In addition, the response rate and the corresponding 95% CI  within each 
treatment group will be presented .
Further , longitudinal presentations of results over time based on the same analy sis, with the 
corresponding 95% CI, will be created. In addition, the individual components of the 
composite SRI (4) endpoints will be summarised by  treatment group.
8.5.2 Analysis of the secondary variables
8.5.2.1 Analysis methods for key secondary efficacy variables
All key  secondary  endpoints, with the exception of the difference in annualised flare rate 
through Week 52 (which will be anal ysed using a negative binomial regression model), will 
be anal ysed and presented similarly  to the primary endpoint as described in Section 8.5.1. 
Details will be described in the SAP. Non
-responde r imputation will be used when applicable 
to handle missing data. 
The flare rate in the anifrolumab 300 mg treatment group will be compared to the flare rate in 
the placebo group using a negative binomial model. The response variable in the model will 
be the number of flares over the 52 -week treatment period. The model w ill include covariates 
of treatment group, and the stratification factors. The logarithm of the follow -up time will be 
used as an offset variable in the model to adjust for subjects having different exposure times. 
The estimated treatment effect and the corresponding 95% CI as well as the 2 -sided p- value 
will be presented. In addition, supportive analy ses only  including flares while on treatment 
will be carried out.
8.5.2.2 Analysis methods for other secondary efficacy variables
The difference between anifrolumab 150 mg and placebo in the proportion of subjects who 
achieve SRI(4) at Week 52 will be assessed and presented similarl yto the primary  endpoint as 
described in Section 8.5.1 .The difference between anifrolumab 300 mg and placebo in other 
secondary  binary  responder endpoints will be assessed in the same way . In addition, the 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
113(125)individual components of the composite SRI  and BICLA endpoints will be summar ised by  
treatment group.
The time to first flare will be anal ysed as a supportive anal ysis to the assessment of reduction 
of flares to explore the extent to which treatment with anifrolumab 300 mg delay s the time to 
first flare compared with placebo. A Cox proportional hazard model will be fitted to data 
including the covariates of treatment, and the stratification factors. Details will be presented in 
the SAP.
Continuous endpoints (including SLEDAI -2K, PGA, joint counts (active, swollen and tender), 
activi ty and damage CLASI  scores, FACIT -F, PtGA, and LUPUS QoL Scale) will be 
analysed using linear mixed effect models with fixed effects for treatment group, visit, and 
stratification factors and subject as random effect. Results will be presented in terms of the 
adjusted means for each treatment group, estimates of treatment differences, and associated 
CIs. Model assumptions will be checked and, if not met, appropriate data transformations may  
be applied or non -parametric approaches will be considered. Details will be presented in the 
SAP. 
The EQ -
5D-5L health states (no problems, slight problems, moderate problems, severe 
problems and unable to/extreme problems) will be summarised by  visit and treatment group 
for each dimension. The VAS Score and single summar y utility  index as well as their change 
from baseline will also be summarised b y visit and treatment group. The WPAI  scores will be 
summarised as percentages by  visit and treatment. Also, the improvements in these scores 
from baseline to Week 24 and Week 52 will be summarised. The medical resource use, as 
described in Section 8.4.4.8 , will be summarised by visit and treatment. 
8.5.2.3 Analysis methods for safety variables
AEs (including AESI s) will be summarised by  means of counts summaries by  Medical 
Dictionary  for Regulatory  Activities (MedDRA) Sy stem Organ Class and Preferred Term (PT) 
separately  for the study  periods (treatment period and follow -up perio d). All AEs will be 
listed. 
Laboratory  data for haematology  and clinical chemistry  will be summarised. The frequency  of 
changes with respect to normal ranges between baseline and each post -treatment time point 
will be tabulated. Frequencies of clinicall y noteworthy  values (defined in the SAP) occurring 
during the clinical study  will also be given. Shifts from normal to abnormal between baseline 
and each post -baseline time point will be evaluated for urinal ysis.
The incidence of markedly  abnormal values and changes from baseline in the ECG parameters 
will be summarized by  treatment group.
The proportion of subjects with suicidal behaviour and suicidal ideation throughout the study  
based on the C -SSRS will be presented for each treatment group. The proportion of subjects 
within each of the 4 suicidal behaviour categories and within each of the 5 suicidal ideation 
sub-categories will also be presented for each treatment group. Descriptive statistics on the 
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
114(125)total number of attempts, total number of interrupted a ttempts, and total number of aborted 
attempts will be summarized for each treatment group.
Other safety  variables will be summarised as appropriate. Further details will be provided in 
the SAP.
8.5.2.4 Analysis method for immunogenicity variables
Anti
-drug antibod ies to anifrolumab will be summarised using descriptive statistics at each 
visit by  treatment group. ADA titres -time profiles of anifrolumab b y treatment group will be 
generated. The impact of ADA on PK and PD will be assessed. The potential association of
ADA with safet y and efficacy will be explored. 
8.5.2.5 Analysis methods for pharmacokinetic variables
Anifrolumab serum concentrations will be summarised using descriptive statistics at each visit 
by treatment group. Serum concentration-time profiles of anifrolu mab b y treatment group will 
be generated. The potential influence of demographic covariates such as body weight, race, 
gender and age will be explored. I mpact of ADA on PK will also be explored. Serum 
concentrations of anifrolumab, summary  statistics, empi rical covariate analy sis results and PK 
profiles will be provided in the CSR or as an addendum to the CSR.
8.5.2.6 Analysis methods for pharmacodynamic variables
Pharmacod ynamic variables will be summarised as appropriate.
8.5.3 Subgroup analysis 
To explore the unifor mity of the detected overall treatment effect on the primary , and when 
applicable, key  secondary  efficacy  endpoints, subgroup anal yses may  be performed for the 
following factors: 
 SLEDAI -2K score at screening (<10 points versus ≥10 points) 
 OCS dose at bas eline (<10 mg/day  versus ≥10 mg/day  prednisone or equivalent) 
 IFN test (IFN test [high versus low]) 
 Gender 
 Age ( ≥18 to 65 and ≥65 y ears) 
 Geographic region 
 Onset of disease (adult versus paediatric onset) 
 BMI ( ≤35, >35 kg/m2) 
 Race 
Full details of the subgroup anal yses will be pre -specified in the SAP. 
8.5.4 Interim analysis
No interim anal ysis is planned.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
115(125)8.5.5
Pooled analysis
A pre -planned pooled analy sis of SRI(4) at Week 52 in the IFN test -low subjects, pooling data 
from this study  and its sister study , D3461C00004, will be carried out to characterise the 
disease activity  in this population. 
Similarly , pre-planned pooled anal yses will be carried out to further support the evaluation of 
the key  secondary  endpoints assessing the effect of ani frolumab 300 mg on skin lesions, 
ability  to reduce the OCS dose, and flares. 
Details of these anal yses will be presented in the SAP for the Integrated Summary  of Efficacy .
9. STUDY AND DATA MANAGEMENT
9.1 Monitoring of the study
During the study , an AstraZeneca or designee representative will have regular contacts with 
the study  site, including visits to:
 Provide information and support to the Investigator(s)
 Confirm that facilities remain acceptable
 Confirm that the investigational team is adhering to the protoc ol, that data are being 
accuratel y and timel y recorded in the CRFs, that biological samples are handled in 
accordance with the Laboratory  Manual and that study  drug accountabilit y checks 
are being performed
 Perform source data verification (a comparison of the data in the CRFs with the 
subject’s medical records at the hospital or practice, and other records relevant to 
the study ) including verification of informed consent of participating subjects. This 
will require direct access to all original records for each subject (eg, clinic charts)
 Ensure withdrawal of informed consent to the use of the subject’s biological 
samples is reported and biological samples are identified and disposed of/destroy ed 
accordingl y, and the action is documented, and reported to th e subject
The AstraZeneca representative will be available between visits if the Investigator(s) or other 
staff at the centre needs information and advice about the study  conduct.
9.1.1 Source data
Refer to the Clinical Study Agreement (CSA) for location of sour ce data.
9.1.2 Study agreements
The PI  at each/the centre should comply  with all the terms, conditions, and obligations of the 
CSA, or equivalent, for this study . In the event of any  inconsistency  between this Clinical 
Study  Protocol and the CSA, the terms of the Clinical Study  Protocol shall prevail with 
respect to the conduct of the study  and the treatment of subjects and in all other respects, not 
relating to stud y conduct or treatment of subjects, the terms of the CSA shall prevail.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
116(125)Agreements between 
 on behalf of AstraZeneca, and the PI must be in place before an y 
study -related procedures can take place, or subjects are enrolled.
9.1.3 Archiving of study documents
The Investigator follows the principles outlined in the CSA.
9.2 Study timetable and end of study
The end of the stud y is defined as ‘the last visit of the last subject undergoing the study ’.
The study  is expected to start in Quarter 2, 2015 and to end by  Quarter 2, 2018.
The study  may  be terminated at individual centres if the study  procedures are not being 
performed according to Good Clinical Practice (GCP), or if recruitment is slow. AstraZeneca 
may also terminate the entire study  prematurel y if concerns for safet y arise within this study  
or in any  other study  with anifrolumab.
9.3 Data management
Data ma nagement will be performed b y , according to the Clinical Informatics Plan . 
The system will be used for data collection and query  handling. The 
Investigator will ensure that data are recorded on the CRFs as specified in the study  protocol 
and in accordance with the instructions provided.
The Investigator ensures the accuracy , completeness, and timeliness of the data recorded and 
the provision of answers to data queries according to the CSA. The I nvestigator will sign the 
completed CRFs. A c opy of the completed CRFs will be archived at the study  site.
Adverse events and medical/surgical history will be classified according to the terminology  of 
the latest version of the MedDRA. Medications will be classified according to the 
AstraZeneca Drug Dictionary . All coding will be performed b y the coding group. Data 
queries will be raised for inconsistent, impossible or missing data. All entries to the study  
database will be available in an audit trail.
The data will be validated as defined in the Clinical I nformatics Plan and Edit Specifications 
Document. Qualit y control procedures will be applied to each stage of data handling to ensure 
that all data are reliable and have been processed correctl y. The Clinical Informatics Plan will 
also clarify  the roles and responsibilities of the various functions and personnel involved in 
the data management process.
When all data have been coded, validated, signed and locked, clean file will be declared. An y 
treatment revealing data may thereafter be added and the final database will be locked.

Revised Clinical Study Protocol
Drug Substance Anifrolumab ( MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
117(125)Serious adverse event reconciliation
Serious adverse event reconciliation reports are produced and reconciled with the subject 
safet y database and/or the investigational site. SAE reconciliation between safet y data and 
clinical data will be performed by  
 The frequency  depends on the expected volume of 
SAE reports and will be defined in the AE/SAE Reconciliation Plan. 
Management of external data
The data collected through third party  sources will be obtained and reconc iled against study  
data.
10. ETHICAL AND REGULATORY REQUIREMENTS
10.1 Ethical conduct of the study
The study  will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/GCP, applicable re gulatory  requirements 
and the AstraZeneca policy  on Bioethics and Human Biological Samples.
10.2 Subject data protection
The I CF will incorporate (or, in some cases, be accompanied by  a separate document 
incorporating) wording that complies with relevant data protection and privacy  legislation.
10.3 Ethics and regulatory review
An EC should approve the final study  protocol, including the final version of the I CF and any  
other written information and/or materials to be provided to the subjects. The Investigator will 
ensure the distribution of these documents to the applicable EC, and to the study  site staff.
The opinion of the EC should be given in writing. The Investigator should submit the written 
approval to AstraZeneca or designee before enrolment of an y subject i nto the study . 
The EC should approve all advertising used to recruit subjects for the study.
AstraZeneca or designee should approve an y modifications to the I CF that are needed to meet 
local requirements.
If required b y local regulations, the protocol sho uld be re -approved b y the EC annually.
Before enrolment of an y subject into the study , the final study  protocol, including the final 
version of the ICF, is approved b y the national regulatory authority or a notification to the 
national regulatory  authority is done, according to local regulations.
AstraZeneca or designee will handle the distribution of any of these documents to the national 
regulatory  authorities.

Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
118(125)AstraZeneca or designee will provide Regulatory  Authorities, ECs and PI s with safet y 
updates/re ports according to local requirements.
Each PI is responsible for providing the EC with reports of an y serious and unexpected 
adverse drug reactions from any  other study  conducted with the investigational product. 
AstraZeneca or designee will provide this information to the PI  so that he/she can meet these 
reporting requirements.
10.4 Informed consent
The PI(s) at each centre will:
 Ensure each subject is given full and adequate oral and written information about 
the nature, purpose, possible risk and benefit of the study
 Ensure each subject is notified that they  are free to discontinue from the study  at 
any time
 Ensure that each subject is given the opportunity  to ask questions and allowed time 
to consider the information provided
 Ensure each subject provides sig
ned and dated informed consent before conducting 
any procedure specifically  for the study
 Ensure the original, signed I CF(s) is/are stored in the Investigator’s Study  File
 Ensure a cop y of the signed I CF(s) is/are given to the subject
 Ensure that an y incen tives for subjects who participate in the study  as well as any  
provisions for subjects harmed as a consequence of study  participation are 
described in the ICF(s) that is/are approved b y an EC.
10.5 Changes to the protocol and informed consent form
Study  procedu res will not be changed without the mutual agreement of the International 
coordinating Investigator and AstraZeneca or designee.
If there are an y substantial changes to the stud y protocol, then these changes will be 
documented in a stud y protocol amendment and where required in a new version of the study  
protocol (Revised Clinical Study  Protocol).
The amendment is to be approved b y the relevant EC and if applicable, the national regulatory 
authority , before implementation. L ocal requirements are to be followed for revised protocols.
AstraZeneca or designee will distribute any  subsequent amendments and new versions of the 
protocol to each PI . For distribution to the ECs, see Section 10.3.
If a protocol amendment requires a change to a centre’s ICF, AstraZeneca or designee and the 
centre’s EC are to approve the revised ICF before the revised form is used. 
If local regulations require, an y administrative change will be communicated to or approved 
by each EC.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
119(125)10.6 Audits and inspections
Authorised representatives of AstraZeneca, a regulatory  authority , or an EC may  perform 
audits or inspections at the centre, including source data verification. The purpose of a n audit 
or inspection is to sy stematically  and independently  examine all study -related activities and 
documents, to determine whether these activities were conducted, and data were recorded, 
analysed, and accuratel y reported according to the protocol, GCP, guidelines of the ICH, and 
any applicable regulatory requirements. The Investigator will contact AstraZeneca or designee 
immediately  if contacted by  a regulatory  agency  about an inspection at the centre.
11. LIST OF REFERENCES
ACR ad hoc committee, September 1999
ACR ad hoc committee. Guidelines for Referral and Management of s ystemic L upus 
Erythematosus in Adults. Arthritis & Rheumatism Vol. 42, No. 9, September 1999, pp 1785 –
1796).
American College of Rheumatology, 2013
American College of Rheumatology . Vasc ulitis, https://www.rheumatology .org/ 
Practice/Clinical/Patients/Diseases_And_Conditions/Vasculitis, updated February  2013.
American Psychiatric Association, 1994
American Ps ychiatric Association, 1994. Diagnostic and Statistical Manual of Mental 
Disorders , 4th Edition. American Ps ychiatric Association, Washington, DC.
Baechler et al, 2003
Baechler EC, Batliwalla FM, Kary pis G, Gaffney  PM, Ortmann WA, Espe KJ, et al. 
Interferon
-inducible gene expression signature in peripheral blood cells of patients with severe 
lupus. Proc Natl Acad Sci USA. 2003;100(5):2610-5.
Banchereau et al, 2004
Banchereau J, Pascual V, Palucka AC. Autoimmunity  through cy tokine -induced dendritic cell 
activation. I mmunit y. 2004;20:539–50.
Bengtsson et al, 2000
Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of 
type I interferon s ystem in sy stemic lupus ery thematosus correlates with disease activity  but 
not with antiretroviral antibodies. Lupus. 2000;9:664-71.
Bennett et al, 2003
Bennett L, Palucka AK , Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and 
granulopoiesis signatures in sy stemic lupus ery thmatosus blood. Journal of Experimental 
Medicine. 2003;197(6):711-23.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
120(125)Bernatsky et al, 2006
Bernatsk y S, Boivin JF, Joseph L , Manzi S, Ginzl
er E, Gladman DD, et al. Mortality  in 
systemic lupus ery thematosus. Arthritis Rheum. 2006;54(8):2550 -7.
Bertsias et al, 2008
Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR 
recommendations for the management of systemic lupus ery thematosus. Report of a Task 
Force of the EULAR Standing Committee for International Clinical Studies I ncluding 
Therapeutics, Ann Rheum Dis 2008;67:195 –205).
Blomberg S et al, 2001
Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Rönnblom L. Presence of 
cutaneous interferon
-alpha producing cells in patients with sy stemic lupus ery thematosus. 
Lupus. 2001;10(7):484 -90.
Brunner et al, 2012
Brunner HI, Bennett MR, Mina R, Suzuki M, Petri M, Kiani AN, et al. Association of 
noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. 
Arthritis Rheum. 2012 Aug;64(8):2687 -97.
Burman, 2009
Burman CF, Sonesson C, Guilbaud O, 2009. A recy cling framework for the construction of 
Bonferroni -based multiple tests. Stats in Med. 2009;28:739–761.
Cella et al, 2002
Cella DF, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution -
based methods to derive minimal clinically  important differences on the functional assessment 
of cancer therap y (FACT) ana emia and fatigue scales. J Pain Sy mptom Manage. 2002;24:547 -
61.
Cellestis, 2005
Clinicians Guide to QuantiFERON®-TB Gold.
Cervera et al, 2006 
Cervera R, Abarca -Costalago M, Abramovicz D, Allegri F, Annunziata P, Aydintug AO, et al. 
Systemic lupus ery thema tosus in Europe at the change of the millennium: lessons from the 
"Euro -Lupus Project". Autoimmun Rev. 2006;5(3):180 -6.
CHMP, February 2015
CHMP Guideline on clinical investigation of medicinal products for the treatment of sy stemic 
lupus ery thematosus and lupus nephritis ( 26 February  2015; EMA/CHMP/51230/2013).
Cochran, 1954
Cochran, W. G. 1954. Some Methods for Strengthening the Common χ2 Tests. Biometrics 
10:417 -
451.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
121(125)Cooper et al, 1998
Cooper GS, Dooley  MA, Treadwell EL, St Clair EW, Parks CG, Gilkeson G S. Hormonal, 
environmental, and infectious risk factors for developing s ystemic lupus ery thematosus. 
Arthritis Rheum. 1998;41(10):1714-24.
Criswell, 2008
Criswell L A. The genetic contribution to sy stemic lupus ery thematosus. Bull NYU Hosp Jt 
Dis. 2008;66(3):176-83.
Crow and Wohlgemuth, 2003
Crow MK, Wohlgemuth J. Microarray  anal ysis of gene expression in lupus. Arthritis Res 
Ther. 2003;5:279 -
87.
Dall’era et al, 2005
Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis Jr, JC. Ty pe I Interferon correlates 
with clinical and serologic manifestations of s ystemic lupus ery thematosus. Ann Rheum Dis. 
2005; 64:1692-7.
Dobkin et al, 1999
Dobkin PL , Da Costa D, Dritsa M, Fortin PR, Senécal J L, Goulet JR, et al. Quality  of life in 
systemic lupus ery thematosus patient s during more and less active disease states: differential 
contributors to mental and phy sical health. Arthritis Care Res. 1999;12(6):401 -10.
Doria et al, 2006
Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi -Puttini P, et al. L ong-term 
prognosis and causes of death in sy stemic lupus ery thematosus. Am J Med. 2006;119:700 -6.
Doria and Briani, 2008
Doria A, Briani C. Lupus: improving long- term prognosis. Lupus. 2008;17(3):166-70.
European Centre for Disease Prevention and Control, 2015
Europe an Centre for Disease Prevention and Control. I nfluenza Case Definitions. 
http://ecdc.europa.eu/en/activities/surveillance/eisn/surveillance/pages/influenza case 
definitions.aspx, accessed January  2015
EuroQoL Group, 1990
EuroQoL Group. EuroQoL -a new facilit y for the measurement of health -related quality  of 
life. Health Policy . 1990;16(3):199-208.
Farkas et al, 2001
Farkas L, Beiske K, Lund- Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacy toid dendritic cells 
(natural interferon -alpha/beta -producing cells ) accumulate in cutaneous lupus ery thematosus 
lesions. Am J Pathol. 2001;159(1):237 -43.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
122(125)Feng X et al, 2006
Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association 
of increased interferon -inducible gene expression with disea se activit y and lupus nephritis in 
patients with sy stemic lupus ery thematosus. Arthritis Rheum. 2006;54(9):2951 -
62.
Furie et al, 2009
Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence -
based s ystemic lupus erythematosus responder index. Arthritis Care & Research. 
2009;61(9):1143 -51.
Furie et al, 2011
Furie RA, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, 
randomised, placebo -controlled, study  of belimumab, a monoclonal antibody  that inhibits B 
lymphocy te stimulator, in patients with sy stemic lupus ery thematosus. Arthritis Rheum. 
2011;63:3918-3930.
Huang et al, 2008
Huang X, Yang N, Ou X, L i D, Wang Z, Xie Q, et al. Sequential activation of protein kinase 
C delta and JNK is required for interferon -alpha -induced expression of IFIT4. Cell Signal. 
2008 Jan;20(1):112-9.
Hylton et al, 1986
Hylton W, Cay ley J, Dore C, Denman AM. 2',5' -oligoaden ylate synthetase induction in 
lymphocy tes of patients with connective tissue diseases. Ann Rheum Dis. 1986 
Mar;4 5(3):220-4.
Jolly et al, 2010
Jolly  M, Pickard AS, Wilke C, Mikolaitis RA, Teh L -S, McElhone K, et al. Lupus-specific 
health outcomes measure for US patients: the LupusQoL -US version. Ann Rheum Dis. 
2010;69:29-33.
Kirou et al, 2004
Kirou KA, Lee C, George S, Louca K, Papagiannis I G, Peterson MG, et al. Coordinate 
overexpression of interferon- alpha -induced genes in sy stemic lupus ery thematosus. Arthritis 
Rheum. 2004;50(12):3958
-67.
Kirou et al, 2005
Kirou KA, Lee C, George S, L ouca K, Peterson MG, Crow MK. Activation of the 
interferonalpha pathway  identifies a subgroup of sy stemic lupus ery thematosus patients with 
distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491 -503.
Lahita, 1999
Lahita RG. The role of sex hormones in sy stemic lupus ery thematosus. Curr Opin Rheumatol. 
1999;11(5):352 -6.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
123(125)McElhone et al, 2007
McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon, C, et al. Development 
and validation of a disease -specific health -related quality  of life measure, the L upusQo L, for 
adults with sy stemic lupus ery thematosus. Arthritis Care Res. 2007;57:972 -
9.
Merrill, 2014
Merrill, J.M. Guidelines for use of the SLEDAI- 2K to assess disease activity  (modified for 
assessment over one month). L upus Foundation of America. Accessed 08 December 2014 at: 
http://www.lupus.org/
Navarra et al, 2011
Navarra S, Guzman RM, Gallacher AE, Hall S, L evy RA, Jimenez RE, et al. Efficacy  and 
safet y of belimumab in patients with active s ystemic lupus ery thematosus: a randomised, 
placebo- controlled, p hase 3 trial. Lancet. 2011;377:721 -31.
Okamoto et al, 2004
Okamoto H, Katsumata Y, Nishimura K, Kamatani N. I nterferon -inducible protein 
10/CXCL 10 is increased in cerebrospinal fluid of patients with central nervous sy stem lupus. 
Arthritis Rheum. 2004;50:3729-32.
Pascual et al, 2006
Pascual V, Farkas L, Banchereau J. Sy stemic lupus ery thematosus: all roads lead to ty pe I 
interferons. Curr Opin Immunol. 2006;18(6):676 -82.
Petri, 2001 
Petri M. L ong-term outcomes in lupus. Am J Managed Care. 2001;7(16) S uppl: S480-5.
Posner et al, 2007
Posner K, Oquendo MA, Gould M, Stanley  B, Davies M. Columbia Classification Algorithm 
of Suicide Assessment (C -CASA): Classification of Suicidal Events in the FDA’s Pediatric 
Suicidal Risk Analy sis of Antidepressants Am J P sychiatry  2007; 164(7):1035-1043
Ramsey -Goldman and Manzi, 2000
Ramsey -Goldman R, Manzi S. Sy stemic lupus erythematosus. Women and health. Academic 
Press 2000:704.
Reilly et al, 1993
Reilly  MC, Zbrozek AS, Dukes EM. The validit y and reproducibility  of a work productivity  
and activity  impairment instrument. PharmacoEconomics 1993; 4(5):353 -65.
Rönnblom and Alm, 2003
Rönnblom L , Alm GV. Sy stemic lupus ery thematosus and the ty pe I interferon s ystem. 
Arthritis Res Ther. 2003;5:68-75.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
124(125)Rönnblom and Pascual, 2008
Rönnblom L , Pascual V. The innate immune s ystem in SL E: type I interferons and dendritic 
cells. L upus. 2008;17(5):394 -
9.
Sampson et al, 2006
Sampson HA, Munoz- Furlong A, Campbell RL , Adkinson NF, Bock SA, Branum A, et al. 
Second sy mposium on the definition and management of anaph ylaxis: summary  report- second 
National Institute of Allergy  and Infectious Diseases/Food Allergy  and Anaphy laxis Network 
symposium. J Allergy  Clin I mmunol. 2006;117(2):391 -7.
Schwartz et al, 2009
Schwartz N, Rubinstein T, Burkl y LC,Collins CE, Blanco I, Su L , et al. Urinary  TWEAK as a 
biomarker of lupus nephritis: a multicenter cohort study . Arthritis Res Ther. 2009;11(5):R143.
Sigurdsson, Göring et al, 2008
Sigurdsson S, Göring HH, Kristjansdottir G, Milani L , Nordmark G, Sandling 
JK, et al. 
Comprehensive evaluation of the genetic variants of interferon regulatory  factor 5 (IRF5) 
reveals a novel 5 bp length poly morphism as strong risk factor for s ystemic lupus 
erythematosus. Hum Mol Genet. 2008;17(6):872 -81.
Sigurdsson, Nordmark et al, 2008
Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, et al. A risk 
haploty pe of STAT4 for systemic lupus ery thematosus is over -expressed, correlates with anti-
dsDNA and shows additive effects with two risk alleles of I RF5. Hum Mol Genet. 
2008;17(18):2868 -76.
Stoll et al, 2004
Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Anal ysis of the relationship between 
disease activity  and damage in patients with sy stemic lupus erythematosus -a 5-yr prospective 
study . Rheumatology  (Oxford). 2004;43(8):1039-44.
Tan et al, 1982
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of sy stemic 
lupus ery thematosus. Arthritis and Rheum 1982; 25:1271-1277. 
Touma et al, 2010
Touma Z, Urowitz MB, Gladmann DD. SLEDAI -2K for a 30- day window. L upus. 
2010;19:49-50.
Urowitz et al, 1976
Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smy th HA, Ogry zlo MA. The bimodal 
mortality  pattern of s ystemic lupus ery thematosus. Am J Med. 1976 Feb;60(2):221 -5.
Von Feldt, 1995
Von Feldt JM. Sy stemic lupus ery thematosus: recognizing its various presentations. Postgrad 
Med. 1995;97(4):79-94.
Revised Clinical Study Protocol
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
125(125)Wallace et al, 2009
Wallace DJ, Stohl W, Furie RA, L isse JR, McKay JD, Merrill JT, et al. A phase II, 
randomised, double -blind, placebo -controll ed, dose -ranging stud y of belimumab in patients 
with active sy stemic lupus ery thematosus. Arthritis and Rheumatism. 2009;61:1168
-1178.
World Health Organization, 2014
World Health Organization. Definitions and reporting framework for tuberculosis – 2013 
revision (updated December 2014) http://apps.who.int/iris/bitstream/10665/79199/1/ 
9789241505345 eng.pdf 
Yao et al, 2009
Yao Y, Richman L, Higgs BW, Morehouse CA, de los Rey es M, Brohawn P, et al. 
Neutralization of interferon -alpha/beta -inducible genes and downstream effect in a phase I 
trial of an anti -interferon -alpha monoclonal antibody in s ystemic lupus ery thematosus. 
Arthritis Rheum. 2009 Jun;60(6):1785-96.
Yao et al, 2010
Yao Y, Higgs BW, Richman L , White B, Jallal B. Use of t ype I interferon- inducible mRNAs 
as pharmacod ynamic markers and potential diagnostic markers in trials with sifalimumab, an 
anti-IFNalpha antibod y, in sy stemic lupus ery thematosus. Arthritis Res Ther. 2010 Apr 14;12 
Suppl 1:S6.
Yellen et al, 1997
Yellen SB, Cella DF, Webster K, Ble ndowski C, Kaplan E. Measuring fatigue and other 
anaemia -related s ymptoms with the Functional Assessment of Cancer Therapy  (FACT) 
measurement s ystem. J Pain Sy mptom Manage. 1997;13:63 -74.
Zhang et al, 2009
Zhang X, Nagaraja HN, Nadasd y T, Song H, McKinley A, Prosek J. A composite urine 
biomarker reflects interstitial inflammation in lupus nephritis kidney  biopsies. Kidney  Int. 
2012 Feb;81(4):401 -6.
Zonana- Nanach et al, 2000
Zonana -Nanach A, Barr SG, Magder LS, Petri M. Damage in s ystemic lupus ery thematosus
and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801 -8.
Clinical Study Protocol Appendix B
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix B
Additional Safety Information
Clinical Study Protocol Appendix B
Drug Subst ance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(3)FURTHER GUIDANCE ON T HE DEFINITION OF A SERIOUS 
ADVERSE EVENT (SAE)
Life threatening
‘Life-threatening’ means that the subject was at immediate risk of death from the AEas it 
occurred or it is suspected that use or continued use of the product would result in the 
subject ’s de
ath.‘Life -threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatitis that resolved without hepatic failure).
Hospitalisation
Outpatient treatment in an emergency  room is not in itself a serious AE, a lthough the reasons 
for it may  be (eg, bronchospasm, lary ngeal oedema). Hospital admissions and/or surgical 
operations planned before or during a stud y are not considered AEs if the illness or disease 
existed before the subject was enrolled in the study , provided that it did not deteriorate in an 
unexpected way  during the study .
Important medical event or medical intervention
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical even ts may  not be immediately  life threatening or result in 
death, hospitalisation, disability  or incapacit y but may  jeopardize the subject or may  require 
medical intervention to prevent one or more outcomes listed in the definition of serious. These 
should us ually  be considered as serious.
Simply  stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used.
Examples of such events are:
 Angioedema not severe enough to require intubation but requiring iv hy drocort isone 
treatment
 Hepatotoxicity  caused b y paracetamol (acetaminophen) overdose requiring 
treatment with N -acetylcysteine
 Intensive treatment in an emergency  room or at home for allergic bronchospasm
 Blood d yscrasias (eg, neutropenia or anaemia requiring blo od transfusion, etc) or 
convulsions that do not result in hospitalisation
 Development of drug dependency  or drug abuse.
Clinical Study Protocol Appendix B
Drug Subst ance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
3(3)A GUIDE TO INTERPRETING THE CAUSALITY QUESTION
The following factors should be considered when deciding if there is a “reasonable 
possib ility” that an AE may  have been caused by  the drug.
 Time Course. Exposure to suspect drug. Has the 
subject actuall y received the 
suspect drug? Did the AE occur in a reasonable temporal relationship to the 
administration of the suspect drug?
 Consistency  with known drug profile. Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology  and toxicology ) or drugs of the same 
pharmacological class? OR could the AE be anticipated from its pharmacological 
properties?
 Dechallenge experience .Did the AE resolve or improve on stopping or reducing the 
dose of the suspect drug?
 No alternative cause. The AE cannot be reasonably  explained by  another aetiology  
such as the underly ing disease, other drugs, other host or environmental factors.
 Rechall enge experience. Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? AstraZeneca would not normally  recommend or support 
a rechallenge.
 Laboratory  tests. A specific laboratory  investigation (if performed) has confirmed 
the relationship?
A “reasonable possibility” could be considered to exist for an AE where one or more of these 
factors exist.
In contrast, there would not be a “reasonable possibility ” of causality  if none of the above 
criteria apply  or where there is evidence of exposure and a reasonable time course but any  
dechallenge (if performed) is negative or ambiguous or there is another more likely cause of 
the AE.
In difficult cases, other factors could be considered such as:
 Is this a recognised feature of overdose o f the drug?
 Is there a known mechanism?
Ambiguous cases should be considered as being a “reasonable possibility ” of a causal 
relationship unless further evidence becomes available to refute this. Causal relationship in 
cases where the disease under study  has deteriorated due to lack of effect should be classified 
as no reasonable possibility .
Clinical Study Protocol Appendix C
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix C
Actions Required in Cases of Combined Increase of Aminot ransferase and 
Total Bilirubin -Hy’s Law
Clinical Study Protocol Appendix C
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(6)TABLE OF CONTENTS PAGE
TABLE OF CONTENTS ......................................................................................... 2
1. INTRODUCTION ................................................................................................... 3
2. DEFIN IT
IONS......................................................................................................... 3
3. IDENTIFICATION OF PO TENTIAL HY’S LAW CAS ES................................... 3
4. FOLLOW -UP.......................................................................................................... 4
4.1 Potential Hy ’s Law Criteria not met ........................................................................ 4
4.2 Potential Hy ’s Law Criteria met .............................................................................. 4
5. REVI EW AND ASSESSMEN T OF POTENT IAL HY’S LAW CASES ...............
5
6. REFERENCES ........................................................................................................ 6
Clinical Study Protocol Appendix C
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
3(6)1. INTRODUCTION
During the course of the study  the Investigator will remain vigi lant for increases in liver 
biochemistry .The investigator is responsible for determining whether a subject meets 
potential Hy ’s Law (PHL) criteria at an y point during the stud y.
The Investigator participates, together with  clinical project representat ives, in review and 
assessment of cases meeting PHL criteria to agree whether Hy ’s Law (HL) criteria are met.
HL criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry  other than Drug Induced Liver Injury  (DILI) ca used by  the Investigational 
Medicinal Product (IMP). 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Adverse Events (AE) and Serious Adverse Events (SAE) according to the outcome 
of the review and assessment in line with standard safet y reporting processes.
2. DEFINITIONS
Potential Hy’s Law (PHL)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3x upper limit of 
normal (ULN) and total b ilirubin (TBL) ≥2xUL N irrespective of an increase in alkaline 
phosphatase (ALP), at any  point during the study  following the start of study  medication. The 
elevations do not have to occur at the same time or within a specified time frame.
Hy’s Law (HL)
AST or ALT 
≥3x UL N and TBL ≥2xULN, where no other reason, other than the IMP, can be 
found to explain the combination of increases, eg, elevated ALP indicating cholestasis, viral 
hepatitis, anot
her drug. The elevations do not have to occur at the same time or within a 
specified time frame.
For PHL and HL the elevation in transaminases must precede or be coincident with (ie ,on the 
same day ) the elevation in TBL, but there is no specified timefram e within which the 
elevations in transaminases and TBL must occur.
3. IDENTIFICATION OF PO TENTIAL HY’S LAW CAS ES
In order to identify  cases of PHL  it is important to perform a comprehensive review of 
laboratory  data for any  subject who meets an y of the follow ing identification criteria in 
isolation or in combination:
 ALT ≥3xULN

Clinical Study Protocol Appendix C
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
4(6) AST 
≥3xUL N
 TBL ≥2xUL N
When a subject meets any of the identification criteria, in isolation or in combination, the 
central laboratory  will immediately  send an alert to the I nvestigator (also sent to  
representative). 
The Investigator will also remain vigilant for an y local laboratory  reports where the 
identification criteria are met, where this is the case the Investigator will:
 Request a repeat of the test (new blood draw) by  the ce ntral laboratory
 Complete the appropriate unscheduled laboratory  CRF module(s) with the original 
local laboratory  test result
When the identification criteria are met from central or local laboratory  results the I nvestigator 
will without delay :
 Determine w hether the subject meets PHL criteria (see Section 2of this a ppendix 
for definition) b y reviewing laboratory  reports from all previous visits (including 
both central and local laboratory  results)
The Investigat or will without delay  review each new laboratory  report and if the identification 
criteria are met will:
 Determine whether the subject meets PHL criteria (see Section 2of this a ppendix 
for definition) b y reviewing laboratory  reports from all previous visits
 Promptly  enter the laboratory  data into the laboratory  CRF
4. FOLLOW-UP
4.1 Potential Hy’s Law Criteria not met
If the subject does not meet PHL  criteria the Investigator will:
 Perform follow -up on subsequent labora tory results according to the guidance 
provided in the Clinical Study  Protocol.
4.2 Potential Hy’s Law Criteria met
If the subject does meet PHL  criteria the Investigator will:
 Immediately  notify  the  Medical Monitor representative who will then inform 
the 
AstraZeneca Medical and Safet yStudy  Team within 1 business day .

Clinical Study Protocol Appendix C
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
5(6)Within 1 business day , the  Medical Monitor contacts the Investigator, to provide 
guidance, discuss and agree an approach for the study  subject ’s follow -up and the continuous 
review of dat a.Subsequent to this 
initial contact the Investigator will:
 Monitor the subject until liver biochemistry  parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically  
indicated 
 Investigate the etiolog y of the event and perform diagnostic investigations as 
discussed with the Medical Monitor
 Complete the three Liver CRF Modules as information becomes available 
 If at an y time (in consultation with the Medical Monitor ) the PHL case meets 
serious c riteria, report it as an SAE using standard reporting procedures
5. REVIEW AND ASSESSMEN T OF POTENTIAL HY’S LAW 
CASES
The instructions in this Section should be followed for all cases where PHL criteria are met.
The 
Medical Monitor will contact the Invest igator to carry  out actions as described in 
Section 4. The Medical Monitor should contact the Investigator within 1 business day  of 
seeing the PHL laboratory  criteria in order to review available data and agree on whether t here 
is an alternative explanation for meeting PHL  criteria other than DILI caused by  the IMP. The 
AstraZeneca Medical Science Director and Global Safety  Physician will also be involved in 
this review together with other subject matter experts as appropria teand should be notified 
within 1 business day  of the  Medical Monitor having discussed data with the 
Investigator .
According to the outcome of the review and assessment, the I nvestigator will follow the 
instructions below.
If there isan agreed alter native explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequentl y 
whether the AE meets the criteria for a SAE:
 If the alternative explanation is notan AE, record the alt ernative explanation on the 
appropriate CRF
 If the alternative explanation is an AE/SAE, record the AE /SAE in the CRF 
accordingl y and follow the AZ standard processes
If it is agreed that there is no explanation that would explain the AL T or AST and TBL 
elevations other than the IMP:

Clinical Study Protocol Appendix C
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
6(6) Report an SAE (report term ‘Hy ’s Law’) according to AstraZeneca standard 
processes. 
The ‘Medically  Important’ serious criterion should be used if no other serious 
criteria apply
As there is no alternative explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If the 
medical monitor cannot contact the site within 2 weeks of the PHL  laboratory  
values being available to clarify  details of the case, then it is assumed that there is no 
alternative explanation until such time as an informed decision can be made:
 Report an SAE (report term ‘Potential Hy ’s Law’) apply ing serious criteria and 
causality  assessment as per above
 Continue follow -up and review according to agreed plan. Once the necessary  
supplementary  information is obtained, repeat the review and assessment to 
determine whether HL criteria are met. Update the SAE report according to the 
outcome of the review
6. REFERENCES
FDA Guidance for Industry  (issued July  2009) ‘Drug- induced liver injury : Premarketing 
clinical evaluation’:
http://www fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf

Clinical Study Protocol Appendix D
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix D
American College of Rheumatology Criteria for Systemic Lupus
Erythematosus Classification
Clinical Study Protocol Appendix D
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(3)1997 Update of the 1982 American College of Rheum atology Revised Criteria for Classification of 
Systemic Lupus Erythematosus
Item Definition
Malar rash Fixed erythema, flat or raised, over the malar eminences, sparing the nasolabial 
folds
Discoid rash Erythematous, raised patches with adherent keratotic scaling and follicular 
plugging: atrophic scarring may occur in older lesions
Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient his tory or physician 
observation
Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a physician
Nonerosive arthritis Involving 2 or more peripheral joints, characterized by tenderness, swelling, or 
effusion
Pleuritis or per icarditis   a. Pleuritis --convincing history of pleuritic pain or rub heard by a physician or 
evidence of pleural effusion
OR
b. Pericarditis –documented by electrocardiogram or rub or evidence of 
pericardial effusion
Renal disorder a. Persistent pr oteinuria > 0.5 gm per day or > 3+ if quantitation not performed
OR
b. Cellular casts --may be red cell, hemoglobin, granular, tubular, or mixed
Neurologic disorder a. Seizures --in the absence of offending drugs or known metabolic derangement, 
eg, uremia, ketoacidosis, or electrolyte imbalance
OR
b. Psychosis --in the absence of offending drugs or known metabolic derangement, 
eg, uremia, ketoacidosis, or electrolyte imbalance
Hem atologic disorder a. Hemolytic anemia with reticulocytosis
OR
b. Leukopeni a--< 4,000/mm3on ≥ 2 occasions
OR
c. Lymphopenia --< 1,500/mm3on ≥ 2 occasions
OR
d. Thrombocytopenia --< 100,000/mm3in the absence of offending drugs
Immunologic disorder a. Anti -DNA: antibody to native DNA in abnormal titer
OR
b. Anti -Sm:presence of antibody to Sm nuclear antigen
OR
c. Positive finding of antiphospholipid antibodies based on: 1) an abnormal serum 
level of IgG or IgM anticardiolipin antibodies; 2) a positive test result for lupus 
anticoagulant using a standard method; or 3) a false -positive t est result for at 
least 6 months and confirmed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absorption test.
Clinical Study Protocol Appendix D
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
3(3)1997 Update of the 1982 American College of Rheum atology Revised Criteria for Classification of 
Systemic Lupus Erythematosus
Item Definition
Positive antinuclear 
antibody  An abnormal titer of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time in the absence of drug.
Clinical Study Protocol Appendix E
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix E
Systemic Lupus Erythematosus Disease Activity Index 2000
Clinical Study Protocol Appendix E
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)

Clinical Study Protocol Appendix F
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix F
Briti sh Isles Lupus Assessment Group -2004
Clinical Study Protocol Appendix F
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)

Revised Clinical Study Protocol Appendix G
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 3
Date 01 February  2016
Protocol Dated 01 February  2016
Appendix G
Physician Global Assessment
Revised Clinical Study Protocol Appendix G
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 3
Date 01 February 2016
2(2)

Revised Clinical Study Protocol Appendix H
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 3
Date 01 February  2016
Protocol Dated 01 February  2016
Appendix H
System Lupus International Collaborating Clinics/A merican College of 
Rheumatology Damage Index
Clinical Study Protocol Appendix I
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix I
Cutaneous Lupus Erythematosus Disease Area and Severity Index
Clinical Study Protocol Appendix I
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)

Clinical Study Protocol Appendix J
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix J
Columbia Suicide Severity Rating Scale
Clinical Study Protocol Appendix J
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
3(7)

Clinical Study Protocol Appendix J
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
4(7)

Clinical Study Protocol Appendix J
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
6(7)

Clinical Study Protocol Appendix J
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
7(7)

Clinical Study Protocol Appendix K
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix K
Personal Health Questionnaire Depression Scale -8
Clinical Study Protocol Appendix K
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(3)

Clinical Study Protocol Appendix K
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
3(3)

Clinical Study Protocol Appendix L
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix L
Short Form 36 Version 2 (Acute Recall)
Clinical Study Protocol Appendix L
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(5)

Clinical Study Protocol Appendix L
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
3(5)

Clinical Study Protocol Appendix L
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
4(5)

Clinical Study Protocol Appendix L
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
5(5)

Clinical Study Protocol Appendix M
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix M
Functional Assessment of Chronic Illness Therapy -FATIGUE
Clinical Study Protocol Appendix M
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)

Clinical Study Protocol Appendix N
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix N
EuroQoL 5 Dimensions
Clinical Study Protocol Appendix N
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)

Clinical Study Protocol Appendix O
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix O
LupusQo L Questionnaire
Clinical Study Protocol Appendix P
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix P
Patient Global Assessment
Clinical Study Protocol Appendix P
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)

Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix Q
Work  Productivity a nd Activity Impairment
Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
2(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifro lumab (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
3(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
4(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
5(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifroluma b (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
6(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
7(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
8(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (M EDI-546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
9(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
10(11)

Clinical Study Protocol Appendix Q
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Num ber 2
Date 09 April 2015
11(11)

Clinical Study Protocol Appendix R
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix R
Pain Numerical Rating Scale
Clinical Study Protocol Appendix R
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)

Revised Clinical Study Protocol Appendix S
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 3
Date 01 February  2016
Protocol Dated 01 February  2016
Appendix S
Medical Resource Use Questionnaire
Revised Clinical Study Protocol Appendix S
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 3
Date 01 February 2016
2(4)

Revised Clinical Study Protocol Appendix S
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 3
Date 01 Febr uary 2016
3(4)

Revised Clinical Study Protocol Appendix S
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 3
Date 01 February 2016
4(4)

Clinical Study Protocol Appendix T
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix T
Vasculitic Syndromes Excluded from the Study
Clinical Study Protocol Appendix T
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)Subjects wit h a history  or current diagnosis of the following vasculitis sy ndromes are 
excluded from participating in the stud y. Vasculitis due to SL E is allowed in the study .
 Behçet’s Disease
 Buerger’s Disease
 Central Nervous S ystem Vasculitis
 Churg Strauss S yndrome
 Cryoglobulinemia
 Giant Cell Arteritis
 Henoch -Schönlein Purpura
 Kawasaki Disease
 Microscopic Poly angiitis
 Polyarteritis Nodosa
 Polymyalgia Rheumatica
 Takay asu’s Arteritis
 Wegener’s Granulomatosis
Revised Clinical Study Protocol Appendix U
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
Protocol Dated 18May 2016
Appendix U
Restricted Medications
Revised Clinical Study Protocol Appendix U
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 5
Date 18 May 2016
2(2)Medications 
to be D iscontinu edPrior to signing ICF
Restricted medication Disco ntinuation 
prior to signing 
ICFRestricted medication Disco ntinuation 
prior to signing 
ICF
Abatacept (CTLA 4 Ig) 24 weeks Intravenous Globulin 4 weeks
Acthar®gel 6 weeks Leflunomide 36 weeks
Adali mumab 12 weeks Lenalidomide 8 weeks
Alefacept 12 weeks Lupuzor (IPP -201101) 12 weeks
Anakinra 12 weeks Memantine 4 weeks
Apremilast 4 weeks Natalizumab 24 weeks
Atacicept (TACI -Ig)* 40 weeks Obinutuzumab* 26 weeks
Bcell depleter * 26weeks Ocrelizumab * 26 weeks
Belimumab 12weeks Ofatumumab * 26 weeks
Blisibimod ( AMG 623 ) 8 weeks Plasmapheresis 24 weeks
Certolizumab pegol 24 weeks Retinoids 4 weeks
Cyclophosphamide 24 weeks Rituximab * 26 weeks
Cyclosporine ** 4 weeks Sifalimumab (MEDI -545) 26 weeks
Cytokines (eg, IFN) Washout Time Similar to Study drug 26 weeks
Danazol 4 weeks Sirolimus 4 weeks
Dapsone 4 weeks Sulfasalazine 4 weeks
Eculizumab 12 weeks Tabalumab 26 weeks
Efalizumab 12 weeks Tacrolimus *** 4 weeks
Epratuzumab 26weeks Thalidomide 8 weeks
Etanercept 4 weeks Tocilizumab 12 weeks
Golimumab 12 weeks Tofacitinib 4 weeks
Immunosuppressants Washout Time Topical Pimecrolimus 4 weeks
Infliximab 12 weeks
*     provided B cell count is normal at screening
**   cyclosporine eye dr ops are acceptable for use in the study
*** oral tacrolimus has a 4 w eek washout period and topical tacrolimus has a 2 w eek washout period
Clinical Study Protocol Appendix V
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix V
Oral Corticosteroid Guidance
Clinical Study Protocol Appendix V
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)Examples of Equival ent Doses of Oral Prednisone
Oral Prednisone and 
EquivalentsEquivalent Dose
Oral Prednisone 7.5 mg 10 mg 20 mg 30 mg 40 mg
Cortisone 37.5 mg 50 mg 100 mg 150 mg 200 mg
Hydrocortisone 30 mg 40 mg 80 mg 120 mg 160 mg
Methylprednisolone 6 mg 8 mg 16 mg 24 mg 32 mg
Prednisolone 7.5 mg 10 mg 20 mg 30 mg 40 mg
Triamcinolone 6mg 8 mg 16 mg 24 mg 32 mg
Example of OCS Tapering Schedule
Time pointInitial Dose of Oral Prednisone or Equivalent
40 mg 30 mg 20 mg 10 mg *
Week 8 35 mg 27.5 mg 17.5 mg 10 mg
Week 12 30 mg 25 mg 15 mg 10 mg
Week 16 25 mg 20 mg 10 mg 10 mg
Week 20 15 mg 15 mg 10 mg 7.5 mg
Week 24 10 mg 10 mg 7.5 mg ≤7.5 mg
Week 28 7.5 mg 7.5 mg ≤7.5 mg ≤7.5 mg
* Note: subjects on OCS doses equivalent to 10 mg prednisone/day may tolerate tapering by 1 mg/day per 
visit rather than an abrupt drop from 10 mg/day to 7.5 mg/day. The stepw ise tapering of OCS dose should 
be performed at the discretion of the I nvestigator.
Clinical Study Protocol Appendix W
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix W
General Guidance for Determination of Major Surgery
Clinical Study Protocol Appendix W
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)The goal of this guidance is to maximize the benefit/risk for each subject entering this study . 
An important aspect to this goal is taking into account all relevant history , including recent 
surgeries and/or injuries thatcould influence the safety  of th e subject potentially  being 
exposed to an additional immunomodulatory  medication or could bias the efficacy  endpoints 
of the trial.
Given the advancement and availability  of surgical techniques, major sur gery is in the 
judgment of the Investigator and his/
her evaluation of the following criteria, regardless of the 
specific surgical procedure:
1. Has the subject completely  recovered (mentally , emotionally , and phy sically ) from 
the surgery  and is not receiving additional medications related to the prior surgery  
(ie, antibiotics)?
2. Has the subject completed all follow -up visits related to the surgery , including 
ancillary  services such as phy sical and/or occupational therapy ?
3. Has the subject resumed all of their prior activities?
4. Has the subject returned to his/her baseline medications for SL E and non -SLE 
indications?
Clinical Study Protocol Appendix X
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix X
Guidance for Abnormal Pap Smear Results
Clinical Study Protocol Appendix X
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(2)Pap Smear Result Abbreviation Also Known As Suggested Action
Atypical squamous cells –
undetermined 
significanceASC–US — Permitted to enter study
Atypical squamous cells –
cannot exclude HSILASC–H — Permitted to enter study
Atypical glandular cells AGC — Permitted to enter study
Low-grade squamous 
intraepithelial lesionLSILMild dysplasia
Cervical intraepithelial 
neoplasia –1 (CIN –1)Permitted to enter study
High -grade squamous 
intraepithelial lesionHSIL Moderate dysplasia
CIN-2 / CIN IIPermitted to enter stud y
High -grade squamous 
intraepithelial lesionHSIL CIN–3 / CIN III
Carcinoma in situ (CIS)Exclude/discontinue subject
Endocervical 
adenocarcinoma in situAIS — Exclude/discontinue subject
Clinical Study Protocol Appendix Y
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 2
Date 09April 2015
Protocol Dated 09April 2015
Appendix Y
Anaphylaxis
Clinical Study Protocol Appendix Y
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
2(6)In adults, anaph ylaxis is highl y likely when an y 1 of the following 3 criteria is fulfilled:
1.
Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (eg, generalised hives, pruritus or flushing, swollen lips, 
tongue and/or uvula) 
AND AT LEAST ONE OF THE FOLLOWING:
 Respiratory  compromise (eg, dy spnoea, wheeze-bronchospasm, stridor, reduced 
peak expiratory  flow, h ypoxaemia)
 Reduced BP (see number 3 below for definition) or associated s ymptoms of end-
organ d ysfunction (eg, hy potonia [collapse], sy ncope, incontinence)
2. Two or more of the following that occur rapidly  after exposure to a likel y allergen 
for that subject (minutes to several hours): 
 Involvement of the skin -mucosal tissue (eg, generalised hives, itch, flush, swollen 
lips, tongue and/or u vula)
 Respiratory  compromise (eg, dy spnoea, wheeze-bronchospasm, stridor, reduced 
peak expiratory  flow, h ypoxaemia)
 Reduced BP (see number 3 below for definition) or associated s ymptoms (eg, 
hypotonia [collapse], sy ncope, incontinence)
 Persistent gastroint estinal sy mptoms (eg, crampy  abdominal pain, vomiting)
3. Reduced BP after exposure to known allergen for that subject (minutes to several 
hours); for adults a s ystolic BP of less than 90 mm Hg or greater than 30% decrease 
from that person’s baseline BP (take n at or immediately  prior to start of the 
infusion), whichever BP is lower.
The following definitions are provided for the purposes of this study :
Hypersensitivity reaction : an acute onset of an illness with involvement of the skin, mucosal 
tissue, or both during infusion of investigational product (but does not meet the definition of 
anaph ylaxis described above).
Infusion -related reaction :any other reaction occurring during infusion of investigational 
product or felt to be temporally  related to the infusi on within 24 hours of investigational 
product administration.
To assist with the mitigation of these AEs, see Table 1, which categorizes reactions by  
severit y of s ymptoms, proposes severit y
-specific treatment and offers guidance on 
management of investigational product. Final treatment is at the discretion of the Investigator 
and should reflect local SOC.
Clinical Study Protocol Appendix Y
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C000 05
Edition Number 2
Date 09 April 2015
3(6)Table 1
An approach to management of anaphylactic, hypersensitivity, and infusion -related reactions
Severity of symptoms Treatment Investigational product
Mild reactions (infusion and 
hypersensitivity)
Mild infusion -related reactions such 
as headache, nausea, non- pruritic 
rash, or mild hypersensitivity 
reactions including local ised 
cutaneous reactions such as mild 
pruritus, flushin g, rash, dizziness, 
headache, ≤20mmHg change in 
systolic BP from pre -infusion 
measurementEvaluate subject , including close monitoring of vital 
signs 
At the discretion of the Investigator, treat subject , for 
example, with:
-Normal saline (~500 to 1000 mL/hour IV) 
and/or
-Diphenhydramine 50 mg IV or equivalent and/or
-Acetaminophen 500 to 650 mg or equivalent 
dose of paracetamol and/or
-Topical antihistamines and/or low -potency 
topical corticosteroid preparations and/or
- Anti- nausea medication, as neededStop i nvestigational product infusion 
immediately
Option 1: do not resume investigational product 
infusion; OR at the discretion of the 
Investigator, resume current investigational 
product infusion under observation and 
complete investigational product infusion at no 
more than half the planned infusion rate
Option 2: discontinue any further 
administration of investigational product; OR at 
the discretion of the Investigator, continue 
future investigational product administrations 
and consider slowing infusion rate and 
pretreating subject 1.5 to 0.5 hours prior to 
investigational product administration, for 
example with:
-Diphenhydramine 50 mg IV or equivalent
-Acetaminophen 500 to 650 mg or 
equivalent dose of paracetamol
Moderate reactions (infusion)
Infusion- relate d reaction such as 
those listed above under mild 
reactions but excluding moderate 
hypersensitivity reactions (see 
below)Evaluate subject , including close monitoring of vital 
signs 
Treat subject , for example, with:
-Normal saline (~500 to 1000 mL/hour IV) 
and/or
-Diphenhydramine 50 mg IV or equivalent and/or
-Acetaminophen 500 to 650 mg or equivalent 
dose of paracetamol and/or
- Anti- nausea and/or antiemetic intramuscular, as 
neededStop investigational product infusion 
immediately
Option 1: do not resume inves tigational product 
infusion; OR based on risk/benefit evaluation, 
at the discretion of the Investigator, resume 
current investigational product infusion under 
observation and at no more than half the 
planned infusion rate after treatment of current 
signs a nd symptoms as suggested (eg, normal 
saline and/or Tylenol and/or topical 
antihistamines)
Clinical Study Protocol Appendix Y
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
4(6)Sev
erity of symptoms Treatment Investigational product
Additional Options for Future Administration 
of investigational product
Discontinue any further administrations of 
investigational product; OR
Further investigatio nal product infusions, at the 
discretion of the Investigator, continue 
investigational product administration and 
consider slowing infusion rate and pretreating 
subject 0.5 to 1.5 hours prior to investigational 
product administration, for example with:
- Diphenhydramine 50 mg IV or equivalent
-Acetaminophen 500 to 650 mg or 
equivalent dose of paracetamol
- Anti- nausea and/or antiemetic by mouth
Prior to next administration of investigational 
product administration, consider initiating at a 
slower infusion rate a nd pretreating subject 0.5 
to 1.5 hours prior to next administration of 
investigational product, for example, with
-Diphenhydramine 50 mg IV or equivalent
-Acetaminophen 500 to 650 mg or 
equivalent dose of paracetamol
If moderate event recurs in the same subject, 
discontinue further investigational product 
administration
Clinical Study Protocol Appendix Y
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 April 2015
5(6)Sev
erity of symptoms Treatment Investigational product
Moderate hypersensitivity 
reactions
Infusion related reactions which 
may include general ised rash or 
urticaria, palpitations, chest 
discomfort, shortness of breath, 
hypo -or hypertension wit h 
>20mmHg change in systolic BP 
from pre -infusion measurementEvaluate subject , including close monitoring of vital 
signs 
Treat subject , for example, with:
-Normal saline (~500 to 1000 mL/hour IV) 
and/or
-Diphenhydramine 50 mg IV or equivalent and/or
-Aceta minophen 500 to 650 mg or equivalent 
dose of paracetamol and/or
-IV corticosteroids, such as hydrocortisone 
100mg or methylprednisolone 20 to 40 mgStop investigational product infusion 
immediately
DO NOT resume current infusion
Discontinue any further adm inistrations of 
investigational product
Consider need for additional oral antihistamine 
administration or oral corticosteroid 
administration to prevent reoccurrence of 
symptoms over subsequent 2 to 3 days
Clinical Study Protocol Appendix Y
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Edition Number 2
Date 09 A pril 2015
6(6)Sev
erity of symptoms Treatment Investigational product
Severe
Above plus fever with rigors, hypo-
or hyp ertension with ≥40 mmHg 
change in systolic BP, signs of end 
organ dysfunction (eg, symptomatic 
hypotension such as hypotonia, 
syncope, incontinence, seizure) from 
pre-infusion measurement, or 
wheezing, angioedema, or stridor
OR
Life-threatening
Defined as a reaction that is 
life-threatening and requires pressor 
and/or ventilator support or shock 
associated with acidemia and 
impairing vital organ function due to 
tissue hypoperfusionEvaluate subject , including close monitoring of vital 
signs
Maintain airway , oxygen if available
Treat subject immediately, for example with:
-Normal saline (~500 to 1000 mL/hour IV)
-Epinephrine for bronchospasm, hypotension 
unresponsive to IV fluids, or angioedema. Dose 
and route as per local SOC, example, 
epinephrine 1:1000, 0.5 to 1.0 mL administered 
SC for mild cases and intramuscular for more 
severe cases
-IV corticosteroids, such as hydrocortisone 
100mg or methylprednisolone 20 to 40 mg
-Diphenhydramine 50 mg IV or equivalent
-Acetaminophen 500 to 650 mg or equivalent 
dose of paracetamol
Call emergency medical transport for transport to 
emergency hospital based on judgment of the 
Investigator
Grade 3 wheezing, hypotension or angioedema is 
unresponsive to single dose of epinephrine
Grade 4 event
At the discretion of the Investiga torStop investigational product infusion 
immediately
Do not resume current infusion 
Permanently discontinue investigational 
product administration
Consider need for additional oral antihistamine 
administration or oral corticosteroid 
administration to pre vent reoccurrence of 
symptoms over subsequent 2 to 3 days
Revised Clinical Study Protocol Appendix Z
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
Protocol Dated 18May 2016
Appendix Z
Modified Flare Index
Clinical Study Protocol Am endment
Amendment Number 04
Drug Substance Anifrolumab (MEDI
-546)
Study Code D3461C00005
Date 18May 2016
Protocol Dated 18May 2016
A Multicentre, Randomised, Double -blind, Placebo -controlled, Phase 3 
Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in 
Adult Subjects with Active Systemic Lupus Erythematosus
This submission /document contains trade secrets and confidential commercial information, disclosure of which 
is prohibited w ithout providing advance notice to AstraZeneca and opportunity to object.
Sponsor:
AstraZeneca AB, 151 85 Södertälje, Sweden
Centres affected by the Amendment:
All sites participatin g in the study .
Note: in addition to the changes listed below, minor text/style changes were made.
Section sof protocol affected:
3.1 Inclusion criteria ; 3.3.2 Concomitant medications for Sy stemic Lupus Erythematosus 
standard of care during the study
Previous text:
3.1 Inclusion criteria
7. Currently  receiving at least 1 of the following*:
(a) A dose of oral prednisone ( ≤40mg/day ) or prednisone equivalent dose 
for a minimum of 2 weeks prior to signing of the ICF. The dose of oral 
prednisone or prednisone equivalent the subject is taking must be stable 
for a minimum of 2 weeks prior to Week 0 (Day  1)
(b) Any of the following medications administered for a minimum of 
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
2(17)12
weeks prior to signing the informed consent, and at a stable dose for 
a minimum of 8 weeks p rior to signing the informed consent and 
until Day 1:
(i) Azathioprine ≤200 mg/day
(ii) Antimalarial (eg, chloroquine, hy droxy chloroquine, 
quinacrine)
(iii) Mycophenolate mofetil ≤2 g/day  or my cophenolic acid 
≤1.44 g/day
(iv) Oral, subcutaneous (SC), or intramuscular methotrexate 
≤25mg/week
(v) Mizoribine ≤150 mg/day
*If receiving oral prednisone (or equivalent) and another agent, the dose duration for 
both (a) and (b) must be met
15. Meets all of the following TB criteria:
(a) No history  of latent or active TB prior to Screening, with the exception 
of latent TB with documented completion of appropriate treatment
(b) No signs or s ymptoms suggestive of active TB from medical history  or 
physical examination
(c) No recent contact with a person with active TB OR if there has been 
such contact, referral to a phy sician specialising in TB to undergo 
additional evaluation prior to randomisation (documented appropriatel y 
in source), and, if warranted, receipt of appropriate treatment for latent 
TB at or before the first administration of investigational product
(d) Must meet 1 of the following criteria:
(i) Negative QuantiFERON -TB Gold [QFT- G] test result for 
TB obtained from the study  Central Laboratory  within 
3 months prior to randomisation OR
(ii) Positive QFT -G test result for TB obtained during the 
Screening Period from the study  Central Laboratory  for 
which active TB has been ruled out and appropriate 
treatment for latent TB has been initiated prior to the first 
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
3(17)investigational product administra tion OR
(iii) Indeterminate (confirmed on retest) QFT
-G test result for 
TB obtained during the Screening Period from the study  
Central Laboratory  with ongoing QFT -G testing for TB 
according to the Stud y Plan 
(e) A chest radiograph with no evidence of current act ive infection (eg, TB) 
or old active TB, malignancy , or clinically  significant abnormalities 
(unless due to SL E) obtained during the Screening Period or any time 
within 12 weeks prior to signing of the informed consent
17. OCS dose stable for at least 2 weeks at Randomisation (Day  1)
18. Stable SL E SOC treatment at Randomisation (Day 1) (see Section 3.3.2)
3.3.2 Concomitant medications for Sy stemic Lupus Ery thematosus standard of care during the 
study
Permitted SOC SLE Limitations of Use
OCS-Oral prednisone or eq uivalent up to ≤40mg/day is permitted 
from at least 2 weeks prior to signing of the informed 
consent . The dose of oral prednisone must remain stable at least 
2 weeks prior to Day 1
-Subjects with increased SLE disease activity may receive 1 
permitted burst and taper of OCS between Day 1 and Week 12. 
Additional details on burst and taper for SLE and non -SLE (eg, 
asthma or COPD exacerbation) disease activity are provided in 
Sections 3.3.2.1 to 3.3.2.4
Revised text:
3.1 Inclusion criteria
7. Currently  receiving at least 1 of the following*:
(a) Where prednisone is the single standard of care medication (ie, the 
subject is not concurrently receiving any medication listed in 
inclusion criterion 7(c)), a dose of oral prednisone ≥7.5 mg/day but 
≤40 mg/day (or prednisone equivalent**) for a minimum of 8 weeks 
prior to Day 1. In addition, the dose of oral prednisone or 
predni sone equivalent the subject is taking must be stable for a 
minimum of 2 weeks prior to r andomisation
(b) Where prednisone is not the single standard of care medication (ie, 
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
4(17)the subject is concurrently receiving at least one medication listed in 
inclusion crit erion 7(c)), a dose of oral prednisone ≤40mg/day  (or 
prednisone equivalent**) for a minimum of 2 weeks prior to signing of 
the ICF. In addition, the dose of oral prednisone or prednisone 
equivalent the subject is taking must be stable for a minimum of 2 w eeks 
prior to randomisation
(c) Any of the following medications administered for a minimum of 
12
weeks prior to signing the informed consent, and at a stable dose for 
a minimum of 8 weeks prior to signing the informed consent 
through Day 1:
(i) Azathioprine ≤200 mg/day
(ii) Antimalarial (eg, chloroquine, hy droxy chloroquine, 
quinacrine)
(iii) Mycophenolate mofetil ≤2 g/day  or mycophenolic acid 
≤1.44 g/day
(iv) Oral, subcutaneous (SC), or intramuscular methotrexate 
≤25mg/week
(v) Mizoribine ≤150 mg/day
*If receiving oral prednisone (or equivalent) and an additional agent, the dose 
duration and maximum allowable dosages for both ( b) and ( c) must be met
**See Appendix V for examples of prednisone equivalency
15. Meets all of the following TB criteria:
(a) No history  of active TB prior to any Screening visit
(b) No history of latent TB prior to initial Screening visit, with the 
exception of latent TB with documented completion of appropriate 
treatment
Note: Subject s with no history of latent TB prior to the initial 
Screening visit, but who are diagnosed with latent TB during 
screening, may be considered eligible if appropriate treatment is 
initiated prior to randomi sation. Such subject s may be re -screened 
if necessary to allow for local guidelines on latent TB treatment 
initiation.
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
5(17)(c) No signs or s ymptoms suggestive of active TB from medical history  or 
physical examination
(d) No recent contact with a person with active TB OR if there has been 
such contact, referral to a phy sician specialising in TB to undergo 
additi onal evaluation prior to randomisation (documented appropriatel y 
in source), and, if warranted, receipt of appropriate treatment for latent 
TB at or before the first administration of investigational product
(e) Must meet 1 of the following criteria:
(i) Negati ve QuantiFERON -TB Gold [QFT
-G] test result for 
TB obtained from the study  Central Laboratory  within 
3 months prior to randomisation OR
(ii) Positive QFT -G test result for TB obtained during the 
Screening Period from the study  Central Laboratory  for 
which active TB has been ruled out and appropriate 
treatment for latent TB has been initiated prior to the first 
investigational product administra tion OR
(iii) Indeterminate (confirmed on retest) QFT- G test result for 
TB obtained during the Screening Period from the study  
Central Laboratory  with ongoing QFT -G testing for TB 
according to the Stud y Plan 
(f) A chest radiograph with no evidence of current act ive infection (eg, TB) 
or old active TB, malignancy , or clinically  significant abnormalities 
(unless due to SL E) obtained during the Screening Period or any time 
within 12 weeks prior to signing of the informed consent
17. OCS dose stable for at least 2 weeks prior to randomisation
18. Stable SL E SOC treatment (see Section 3.3.2) at the time of randomisation
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
6(17)3.3.2 Concomitant medications for Sy stemic Lupus Ery thematosus standard of care during the 
study
Permitted SOC SLE Limitat ions of Use
OCS-Oral prednisone or equivalent up to ≤40mg/day is permitted 
from at least 2 weeks prior to signing the informed consent . 
The dose of oral prednisone must remain stable at least 2 weeks 
prior to randomisation
-Where prednisone is the single standard of care medication 
(ie, the subject is not concurrently receiving any medication 
listed in inclusion criterion 7(c)), a dose of oral prednisone 
≥7.5 mg/day but ≤40 mg /day (or prednisone equivalent ) for a 
minimum of 8 weeks prior to Day 1 is required
-Subjects with increased SLE disease activity may receive 1 
permitted burst and taper of OCS between Day 1 and Week 12. 
Additional details on burst and taper for SLE and non -SLE (eg, 
asthma or COPD exacerbation) disease activity are provided in 
Sections 3.3.2.1 to 3.3.2.4
Reason for Amendment: 
The criteria for inclusion based on concomitant medication and tuberculosis status were 
clarified. These change s weremade to provide further guidance to the Investigator.
Persons who initiated the Amendment:
AstraZeneca
Section of protocol affected:
3.2.2 Exclusion criteria related to concomitant medications ; 3.3.1.2 Restricted medications; 4 
Study  plan and timing of procedures, Table 2 Study  plan detailing the procedures at screening
Previous text:
3.2.2 Exc lusion criteria related to concomitant medications
9. Receipt of an y of the following:
(a) Any new oral prednisone therapy  (or equivalent) any time from 2 weeks 
prior to signing of the ICF through Day  1 or any  change in current oral 
prednisone dose (or equivalent) any time from 2 weeks prior to Day 1 
(see Appendix V for examples of prednisone equivalency ) 
(b) Any new dose of the following any time in the 12 weeks prior to signing 
the ICF or change in the current dose any time in the 8 weeks prior to 
signing the ICF through Day  1: azathioprine; an y antimalarial (eg, 
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
7(17)chloroquine, h ydrox ychloroquine, quinacrine); my cophenolate 
mofetil/my cophenolic acid; oral, SC, or intramuscular methotrexate
13. Receipt of B cell -depleting therapy  (including but not limited to, ocrelizumab, 
ofatumumab, atacicept, obinutuzumab, or rituximab) 
≤
26 weeks prior to signing the ICF ; ≤40 week s for atacicept
(see Appendix U)
or if therap y was administered >26 weeks ago (40 weeks for atacicept), 
absolute B cell less than the lower limit of normal or baseline value prior to 
receipt of B cell -depleting therapy  (whichever is lower) 
14. Receipt of epra tuzumab, belimumab, or tabalumab ≤12 weeks prior to signing the 
ICF
3.3.1.2 Restricted medications
(o) Other immunosuppressants including but not limited to calcineurin inhibitors (eg, 
cyclosporine, tacrolimus [including topical]) or leflunomide. 
4 Study plan and timing of procedures, Table 2 Study  plan detailing the procedures at 
screening
Footnote ‘c’:
Receipt of B cell -depleting therapy  (including but not limited to, ocrelizumab, ofatumumab, 
atacicept, obinutuzumab, or rituximab) ≤26 weeks prior to sig ning the ICF ( ≤40 weeks for 
atacicept [see Appendix U]) and if therap y was administered >26 weeks ago (40 weeks for 
atacicept), absolute B cell less than the lower limit of normal or baseline value prior to receipt 
of B cell -depleting therapy  (whichever is lower).
Revised text:
3.2.2 Exclusion criteria related to concomitant medications
9. Receipt of an y of the following:
(a) Where prednisone is the single standard of care medication (ie, the 
subject is not concurrently receiving any medication listed in 
inclusion criterion 7(c)), any addition of a new oral prednisone 
therapy (or equivalent) any time in the 8 weeks prior to Day 1, OR 
any change in/ discontinuation of current oral prednisone dose (or 
equivalent) anytime within the 2 weeks prior to randomisation (see 
Appendix V for examples of prednisone equivalency )
(b) Where prednisone is not the single standard of care medication (ie, 
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
8(17)the subject is concurrently receiving at least one medication listed i n 
inclusion criterion 7(c)): 
(i) Any addition of a new oral prednisone therapy (or 
equivalent) any time from 2 weeks prior to signing of the 
informed consent form through Day 1, OR any change 
in/ discontinuation of current oral prednisone dose (or 
equivalen t) anytime within the 2 weeks prior to 
randomisation (see Appendix V for examples of 
prednisone equivalency)
(ii) Any 
addition of a new dose of any of the following 
anytime in the 12 weeks prior to signing of the informed 
consent through Day 1, or change in/ discontinuation of 
current dose anytime in the 8 weeks prior to signing of 
the informed consent through Day 1: az athioprine; any 
antimalarial (e g,chloroquine, hydroxychloroquine, 
quinacrine); mycophenolate mofetil/mycophenolic acid; 
oral,SC, or intramusc ular methotrexate ; mizoribine
10. Receipt of any of the following:
(a) Azathioprine >200 mg/day
(b) Mycophenolate mofetil >2 g/day or mycophenolic acid >1.44 g/day
(c) Oral, SC, or intramuscular methotrexate >25 mg/week
(d) Mizoribine >150 mg/day
(e) Any change in route of administration of oral, SC, or intramuscular 
methotrexate anytime within 
the 8 weeks prior to signing of the 
informed consent through Day 1
14. Receipt of B cell -depleting therapy  (including but not limited to, ocrelizumab, 
ofatumumab, atacicept, obinutuzumab, or rituximab) 
<26weeks prior to signing the ICF ; <40weeks for atacicept
(see Appendix U)
or if therap y was administered ≥26weeks ago (40 weeks for atacicept), 
absolute B cell less than the lower limit of normal or baseline valu e prior to 
receipt of B cell -depleting therapy  (whichever is lower) 
15. Receipt of epratuzumab or tabalumab <26 weeks prior to signing the ICF, or 
belimumab <12 weeks prior to signing the ICF
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
9(17)3.3.1.2 Restricted medications
(o) Other immunosuppressants including but not limited to calcineurin inhibitors (eg, 
cyclosporine, tacrolimus [including topical]) or leflunomide. 
Note: Cyclosporine eye drops are acceptable for use in the study.
4 Study  plan and timing of procedures, Table 2 Study  plan detailing the procedures at 
screening
Footnote ‘c’:
Receipt of B cell -depleting therapy  (including but not limited to, ocrelizumab, ofatumumab, 
atacicept, obinutuzumab, or rituximab) <26weeks prior to signing the ICF (<40 weeks for 
atacicept [see Appendix U]) and if therap y was administered ≥26weeks ago (40 weeks for 
atacicept), absolute B cell less than the lower limit of normal or baseline value prior to receipt 
of B cell -depleting therapy  (whichever is lower).
Reason for Amendment: 
The criteria for exclusion based on concomitant medications were clarified, and a minor 
addition was made allowing the concomitant use of cy closporine ey e drops (to match with 
Appendix U) . These changes were made to provide further guidance to the Investigator .
Persons who initiated the Amendment:
AstraZeneca
Sections of protocol affected:
List of abbreviations and definition of terms; 3.2.4 Exclusion criteria related to infection and 
malignancy  risk factors; 4 Study  plan and timing of procedures, Table 2 Stud y plan detail ing 
the procedures at screening; 4 Study  plan and timing of procedures, Table 3 Study  plan 
detailing the procedures during the Treatment Period (double -blind period) ; 5.3.10 Clinical 
laboratory  tests, Table 5 Clinical laboratory  tests
Previous text:
3.2.4 Exclusion criteria related to infection and malignancy  risk factors
26. Known history  of a primary  immunodeficiency , splenectom y, or an y underly ing 
condition that predisposes the subject to infection, or a positive result for human 
immunodeficienc y virus (HIV) infection confirmed by  central laboratory  at 
screening
27. Confirmed positive test for hepatitis B serology  for:
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
10(17)(a) Hepatitis B surface antigen, OR 
(b) Hepatitis B core antibody  (HBcAb) AND hepatitis B virus (HBV) DNA 
detected b y reflex testing by  thecentral laboratory at screening 
Note: Subjects with HBcAb positivity  at screening will be tested every  3months for HBV 
DNA. To remain eligible in the study , subject HBV DNA levels must remain below the lower 
limit of quantitation (LLOQ) as per the cent ral laboratory .
31.
Opportunistic infection requiring hospitalisation or parenteral antimicrobial 
treatment within 3 y ears of randomisation 
4 Study  plan and timing of procedures, Table 2 Study  plan detailing the procedures at 
screening
Footnote ‘b’:
Redraw for ANA/anti -dsDNA, or IFN test can be done within the 30 -day screening window, 
however, results must be available within the 30 -day screening window for subjects to be 
randomised.
4 Study  plan and timing of procedures, Table 3 Study  plan detailing the procedures during the 
Treatment Period (double-blind period)
Footnote ‘f’:
Subjects with HBcAb positivity at screening will be tested every  3 months for HBV DNA. To 
remain eligible in the study , subject HBV DNA levels must remain below the LLOQ as per 
the central laboratory .
Revised text:
List of abbreviations and definition of terms
A new abbreviation was added:
HBsAg Hepatitis B surface antigen
3.2.4 Exclusion criteria related to infection and malignancy  risk factors
27. Known history  of a primary  immunodeficien cy, splenectom y, or an y underly ing 
condition that predisposes the subject to infection, or a positive result for human 
immunodeficiency  virus (HIV) infection confirmed by  central laboratory  at 
screening . Subjects refusing HIV testing during the screening p eriod will not be 
eligible for study participation
28. Confirmed positive test for hepatitis B serology  for:
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
11(17)(a) Hepatitis B surface antigen (HBsAg) , OR 
(b) Hepatitis B core antibody  (HBcAb) AND hepatitis B virus (HBV) DNA 
detected 
above the lower limit of quantitat ion (LLOQ) by reflex 
testing b y the central laboratory at screening 
Note: Subjects who are HBcAb positive at screening will be tested every  3months for HBV 
DNA. To remain eligible forthe study , the subject’s HBV DNA levels must remain below 
the 
LLOQ as per the central laboratory.
32. Opportunistic infection requiring hospitalisation or intravenous antimicrobial 
treatment within 3 y ears of randomisation
4 Study  plan and timing of procedures, Table 2 Study  plan detailing the procedures at 
screening
Footnote ‘b’:
Redraw for ANA/anti -dsDNA, or IFN test can be done within the 30 -day screening window, 
however, results needed to determine eligibility and stratification must be available within 
the 30- day screening window for subjects to be randomised.
4 Study plan and timing of procedures, Table 2 Study  plan detail ing the procedures at 
screening
A new footnote ‘g’ was added:
g Subjects within the treatment or follow- up period at the time of amendment 4 
approval will undergo HIV testing at the time of amend ment 4 ICF signature.
4 Study  plan and timing of procedures, Table 3 Study  plan detailing the procedures during the 
Treatment Period (double-blind period)
Footnote ‘f’:
Subjects who are HBcAb positive at screening will be tested every  3 months for HBV DNA.
To remain eligible forthe study , the subject’s HBV DNA levels must remain below the 
LLOQ as per the central laboratory .
5.3.10 Clinical laboratory  tests, Table 5 Clinical laboratory  tests
A new footnote ‘**’ was added:
** Subjects within the treatment or follow -up period at the time of amendment 4 
approval will undergo HIV testing at the time of amendment 4 ICF signature.
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
12(17)Reason for Amendment: 
The criteria for performing HIV testing at screening were clarified, along with exclusion 
based on antimicrobial treatment and hepatitis B serology . It was also further clarified that 
ANA/anti -dsDNA, or IFN test results 
needed to determine eligibility  and stratification must be 
available within the 30 -day screening window for subjects to be randomised. These changes
were made to provide further guidance to the Investigator.
Persons who initiated the Amendment:
AstraZeneca
Section of protocol affected:
4.4 Follow -up Period
Previous text:
Procedures will be performed according to the Follow -up Period Study  Plan (Table 4). 
Subjects who complete the Week 52 visit may  be eligible to participate in a L TE study . 
Subjects who complete the double -
blind treatment period will have follow- up visits at Week 
56 and Week 60, unless they  enrol in the LTE study . Subjects who are withdrawn from the 
study , and do not agree to complete the 52- week study  period, should complete the early  
discontinuation visit (Week 52 procedures), and be followed 8 and 12 weeks after the last 
administration of investigational product b y completing the Follow up Visit 1 and 2 
assessments (see Section 3.7).
Revised text:
Procedures will be performed according to the Follow -up Period Study  Plan (Table 4). 
Subjects who complete the Week 52 visit may  be eligible to participate in a L TE study . 
Subjects who complete the double -blind treatment period will have follow- up visits at Week 
56 and Week 60, unless they  enrol in the LTE study . Subjects who are withdrawn from the 
study , and do not agree to complete the 52- week study  period, should complete the early  
discontinuation visit (Week 52 procedures) within 4 weeks of the last dose of investigational 
product , and be followed 8 and 12 weeks after the EDV visit by completing the Follow up 
Visit 1 and 2 assessments (see Section 3.7).
Reason for Amendment: 
The tim ing of the earl y discontinuation visit was clarified. This change was made to provide 
further guidance to the Investigator.
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
13(17)Persons who initiated the Amendment:
AstraZeneca
Section of protocol affected:
5.3.8.2 Tuberculosis results from screening evaluations
Previous text:
 If the screening QFT -
G test is positive at screening but the subject is not newly 
positive , the subject must have been diagnosed with latent TB and must have 
documentation confirming completion of appropriate treatment.
Revised text:
 If the screening QFT -G test is positive at the initial Screening visit ,but the subject 
is not newly positive as of the initial Screening visit , the subject must have been 
diagnosed with latent TB and must have documentation confirming completion of 
appropriate treatment. Subject s with no history of latent TB prior to the initial 
Screening visit, but who are diagnosed with latent TB during screening, may 
be considered eligible if appropriate treatment is initiated prior to 
randomi sation. Such subject smay be re -screened if necessary to allow for local 
guidelines on latent TB treatment initiation.
Reason for Amendment: 
The screening requirements for a positive QFT -G test at screening were clarified. This change 
was made to provide further guidance to t he Investigator.
Persons who initiated the Amendment:
AstraZeneca
Section of protocol affected:
7.7 Post study  access to study  treatment
Previous text:
Following evaluation at Week 52, subjects will either be followed for a 12 -week Follow -up 
Period or continue in a LTE study  that will continue until anifrolumab has been approved for 
use on the market or until development has been discontinued by  the Sponsor.
Revised text:
Upon evaluation at Week 52, subjects will either be followed for a 12 -week Follow -up 
Period, or transition to an LTE study (if eligible) that will continue for approximately 3 
years after the completion of the Week 52 visit.
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
14(17)Reason for Amendment: 
The duration of 
the long -term extension (L TE) study  was clarified. This change was made to
provide 
further guidance to the I nvestigator.
Persons who initiated the Amendment:
AstraZeneca
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
15(17)Section of protocol affected:
Appendix U Restricted Medications
Previous Text:
Medications to be Discontinued Prior to signing ICF
Restricted medication Discontinuation 
prior to signing 
ICFRestricted medication Discontinuation 
prior to signing 
ICF
Abatacept (CTLA 4 Ig) 24 weeks Intravenous Globulin 4 weeks
Acthar®gel 6 weeks Leflunomide 36 weeks
Adalimumab 12 weeks Lenalidomide 8 weeks
Alefacept 12 weeks Lupuzor (IPP -201101) 12 weeks
Anakinra 12 weeks Memantine 4 weeks
Apremilast 4 weeks Natalizumab 24 weeks
Atacicept (TACI -Ig)* 40 weeks Obinutuzumab* 26 weeks
B cell depleter* 26 weeks Ocrelizumab* 26 weeks
Belimumab 12 weeks Ofatumumab* 26 weeks
Blisibimod (AMG 623) 8 weeks Plasmapheresis 24 weeks
Certolizumab pegol 24 weeks Retinoids 4 weeks
Cyclophosphamide 24 weeks Rituximab* 26 weeks
Cyclosporine** 4 weeks Sifalimumab (MEDI -545) 26 weeks
Cytokines (eg, IFN) Washout Time Similar to Study drug 26 weeks
Danazol 4 weeks Sirolimus 4 weeks
Dapsone 4 weeks Sulfasalazine 4 weeks
Eculizumab 12 weeks Tabalumab 12 weeks
Efalizumab 12 weeks Tacrolimus*** 4 weeks
Epratuzumab 12 weeks Thalidomide 8 weeks
Etanercept 4 weeks Tocilizumab 12 weeks
Golimumab 12 weeks Tofacitinib 4 weeks
Immunosuppressants Washout Time Topical Pimecrolimus 4 weeks
Infliximab 12 weeks
*     provided B cell count is normal at screening
**   cyclosporine eye drops are acceptable for use in the study
***oral tacrolimus has a 4 w eek washout period and topical tacrolimus has a 2 w eek washout period
Clinical St udy Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
16(17)Revised text:
Medications to be Discontinued Prior to signing ICF
Restricted medication Discontinuation 
prior to signing 
ICFRestricted medication Discontinuat ion 
prior to signing 
ICF
Abatacept (CTLA 4 Ig) 24 weeks Intravenous Globulin 4 weeks
Acthar®gel 6 weeks Leflunomide 36 weeks
Adalimumab 12 weeks Lenalidomide 8 weeks
Alefacept 12 weeks Lupuzor (IPP -201101) 12 weeks
Anakinra 12 weeks Memantine 4 weeks
Apremilast 4 weeks Natalizumab 24 weeks
Atacicept (TACI -Ig)* 40 weeks Obinutuzumab* 26 weeks
B cell depleter* 26 weeks Ocrelizumab* 26 weeks
Belimumab 12 weeks Ofatumumab* 26 weeks
Blisibimod (AMG 623) 8 weeks Plasmapheresis 24 weeks
Certolizumab pegol 24 weeks Retinoids 4 weeks
Cyclophosphamide 24 weeks Rituximab* 26 weeks
Cyclosporine** 4 weeks Sifalimumab (MEDI -545) 26 weeks
Cytokines (eg, IFN) Washout Time Similar to Study drug 26 weeks
Danazol 4 weeks Sirolimus 4 weeks
Dapsone 4 weeks Sulfasalazine 4 weeks
Eculizumab 12 weeks Tabalumab 26 weeks
Efalizumab 12 weeks Tacrolimus*** 4 weeks
Epratuzumab 26 weeks Thalidomide 8 weeks
Etanercept 4 weeks Tocilizumab 12 weeks
Golimumab 12 weeks Tofacitinib 4 weeks
Immunosuppressants Washout Time Topical Pimecrolimus 4 weeks
Infliximab 12 weeks
*     provided B cell count is normal at screening
**   cyclosporine eye drops are acceptable for use in the study
*** oral tacrolimus has a 4 w eek washout period and topical tacrolimus has a 2 week washout period
Clinical Study Protocol Amendment 04
Drug Substance Anifrolumab (MEDI -546)
Study Code D3461C00005
Date 18 May 2016
17(17)Reason for Amendment: 
Appendix U was 
modified to provide further guidance to the Investigator. The washout 
periods for Epratuzumab and Tabalumab were corrected.
Persons who initiated the Amendment:
AstraZeneca
Section of protocol affected:
Appendix ZModified Flare Index
Previous Text:
Hemoly tic anemia: Hb <70g/L or decrease in Hb >30 g/L with positive Coombs AND at least 
one of the following: decreased haptoglobin, increased total bilirubin due not due to Gilbert’s 
disease, increa sed reticulocy te count.
Revised text:
Hemoly tic anemia: Hb <70g/L or decrease in Hb >30 g/L with positive Coombs AND at least 
one of the following: decreased haptoglobin, increased total bilirubin not due to Gilbert’s 
disease, increased reticulocy te count.
Reason for Amendment: 
Incorrect text was amended.
Persons who initiated the Amendment:
AstraZeneca
Clinical Study Protocol Am endment 04Appendix A
Drug Substance Anifrolumab (MEDI- 546)
Study Code D3461C00005
Edition Number 5
Date 18May 2016
Protocol Dated 18May 2016
Appendix A
Signatures